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Abstract 
Conventional adult dosage forms such as tablets and capsules are often not suitable 
for the paediatric and geriatric population due to either swallowing difficulties or a 
requirement for tailored dosing to meet individual needs. Alternative oral 
formulations such as orally disintegrating tablets (ODTs) are available; however these 
usually require the incorporation of taste masking techniques. One approach to taste 
masking is to reduce contact between the bitter active pharmaceutical ingredient 
(API) and taste buds. This may be achieved by hindering release in the oral cavity 
using reverse enteric polymeric coatings.  
 
In vitro dissolution testing can be employed to elucidate taste masking capability by 
quantifying release of the API in simulated oral cavity conditions. This provides a 
robust analytical approach circumventing the expense and ethical challenges 
associated with human taste testing panels or animal testing. To achieve taste 
masking, drug release should be below the bitterness threshold concentration of the 
API. A vast array of dissolution methodologies has been employed in the evaluation 
of taste masked formulation performance in literature, with little agreement 
between approaches, and a lack of biorelevance.  
 
For optimal predictability, the dissolution test should be biorelevant and the 
dissolution media should mimic human saliva as closely as possible. Human saliva is 
thus a biological fluid of great importance in the field of dissolution testing. However, 
until now, no consensus has been reached on its key characteristics relevant to 
dissolution testing.  As a result, it is difficult to select or develop an in vitro dissolution 
medium to best represent human saliva.  
 
In this thesis, for the first time, the pH, buffer capacity, surface tension, viscosity and 
flow rate of both unstimulated (US) and stimulated (SS) human saliva were 
investigated with a sufficient number of participants to generate statistically 
meaningful results (Chapter 3). This provides a platform of reference for future 
dissolution studies using simulated salivary fluids (SSFs).  
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Additionally, the conversion between US and SS was investigated using mechanical 
stimulation, and for the first time using an ODT dosage form as a stimulant (Chapter 
4). This was in order to ascertain if dissolution testing is necessary in media 
representing both stimulation states. Furthermore, the characteristics of human 
saliva were directly compared experimentally to examples of the main types of SSF 
currently available (Chapter 3). Since the current SSFs were not found to be suitable 
to represent human saliva according to key characteristics, novel SSFs are proposed 
in this work (Chapter 5), accompanied by early stage dissolution testing to determine 
their suitability (Chapter 6).  
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Chapter 1: Introduction 
1.1 Background 
N.B. The content of this Chapter of the thesis is modified from the publication by 
Gittings et al., 2014 [1] in which I was the leading author.  
The oral route is by far the most popular route of drug administration due to 
convenience and thus compliance [2]. However, standard oral tablets or capsules are 
not suitable for everyone. The paediatric and geriatric population have complex 
additional needs compared to the adult population. In these groups, swallowing 
difficulties are common. This results in the insufficiency of oral tablets and capsules 
for use in these populations and an increased prevalence of alternative oral dosage 
forms usage [3, 4]. Pharmacokinetic parameters such as volume of distribution, 
metabolism and clearance may change rapidly in these populations [5, 6], leading to 
a requirement for more tailored oral dosage forms which can undergo manipulation 
to meet individual needs [7].  Additionally, in the standard adult population, 
alternative dosage forms are becoming more popular. For example, orally 
disintegrating tablets can be taken “on the move” without the requirement for co-
administration of water.  
There are many alternative oral formulations in existence. In a review written in 
2007, there were at least 17 oral formulations listed [8]. These included liquid 
formulations such as solutions, suspensions, and syrups, as well as tablets and 
powders for reconstitution into a liquid formulation. Tablet formulations included 
orally disintegrating tablets, chewable tablets, scored dividable tablets and 
effervescent tablets. Other formulations such as films, drops, mini-tabs, bulk granules 
or powders and sprinkle capsules were also detailed.  
In the present research, we focus on microparticulates as an alternative dosage form 
for oral delivery. These are particularly advantageous since they can be formulated 
into various other dosage forms such as sprinkle formulations, suspensions or more 
commonly, orally disintegrating tablets (ODTs).  
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Unlike tablets and capsules, alternative oral formulations tend to be more complex 
and require advanced taste masking techniques. Many drugs have undesirable 
organoleptic properties such as a bitter or metallic taste or burning sensation which 
reduces compliance, resulting in therapeutic failure. In the case of microparticulates, 
residence time in the oral cavity may be prolonged for a small proportion of particles 
(particularly after “dry” delivery of an ODT) compared to standard tablets or 
capsules. This leads to more likelihood of non-compliance due to adverse taste. Taste 
masking, therefore, could be critical for the therapeutic and commercial success of 
these microparticulate or alternative oral formulations.  
1.2 Taste Masking Techniques  
Broadly, approaches to taste masking aim to use strong flavours and sweeteners to 
overpower the bitter Active Pharmaceutical Ingredient (API), reduce contact between 
the API and the taste buds, or to reduce release of the API in the oral cavity [9]. 
Specifically, methods of taste masking include use of flavours and sweeteners [10-
14], lipophilic vehicles [15-19], coating with polymers [20-32], carbohydrates [33-36], 
lipids [37-39] or proteins [9], complexation with cyclodextrins [40-46] or ion- 
exchange resins [47-60], formation of salts [9], and solid dispersions [61-66]. In 
practice, combinations of these techniques are often employed. For example in one 
case, ibuprofen orally disintegrating tablets were manufactured using a lipid matrix, 
coated with a film forming agent and formulated with a sweetener in order to 
achieve taste masking [11]. 
Whilst flavours and sweeteners are straight forward techniques, many excipients are 
subject to regulatory restrictions which limit their use, particularly in the paediatric 
population. For example, sucrose is a common sweetener but can cause dental 
caries, whilst certain flavours have been associated with hypersensitivity, toxicity or 
allergy and should also be kept to a minimum [8]. 
When the alternative method of inhibiting contact between API and taste buds by 
reducing release in the mouth is used, the manufacturing processes become more 
complex compared to the simple addition of a flavour or sweetener. These require 
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sophisticated and advanced technologies and are subsequently more costly to 
develop and manufacture [7].  
In addition, flavours and sweeteners, although simple, may not sufficiently mask the 
taste of extremely bitter compounds. Lipophilic vehicles increase the viscosity in the 
mouth and coat the taste buds with the oil, surfactant or lipid. On the other hand 
polymeric, carbohydrate or protein coatings act as a physical barrier surrounding the 
drug particle. Coatings are commonly used as an initial approach to taste masking 
and thus are widely used, whereas complexation with cyclodextrins or ion exchange 
resins is less common. Formation of salts or use of ion exchange resins is particularly 
suitable for highly soluble, ionisable drugs which form less soluble complexes at 
salivary pH. However, cyclodextrin complexation is generally reserved for low dose 
drugs which are shielded from taste buds in the central pore of the cyclodextrin 
molecule. A detailed review of taste masking technologies for oral pharmaceuticals 
was carried out by Sohi et al. in 2004 which describes these methods in greater depth 
[9]. More recently, in 2010, Douroumis [67] investigated taste masking technologies 
specifically for orally disintegrating tablets and thin oral film formulations whereby 
the merits and drawbacks of such technologies are described. Additionally in 2016, 
Afriyie, Batchelor and De Matas [68] undertook a critical evaluation of 24 taste 
masking technologies which were compared based on quality attributes. Despite 
emerging approaches in the pharmaceutical industry, the authors found that more 
established techniques such as polymeric coatings showed best results.  
In the present research, we use microparticulates intended for oral drug delivery with 
a view to coating individual particulates using a reverse enteric coating for taste 
masking purposes. Such reverse enteric coatings are designed to hinder release of 
the bitter API in the oral cavity, but allow complete and rapid drug release in the 
acidic environment of the stomach.  
Different taste masking techniques and manufacturing parameters can have a great 
impact on the physicochemical characteristics and performance of the taste masked 
formulation. Taste evaluation of the masked formulation must be assessed to 
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guarantee the capability of the taste masking technique. Additionally, one must 
ensure that the taste masking technique does not affect API bioavailability.  
1.3 Taste Evaluation 
The most common method of taste evaluation is human taste panels. These are 
typically small groups (< 20 people) of healthy volunteers who swill the formulation 
in their mouth for a set time before spitting it out. They then rate the formulation for 
different attributes based on an intensity scale. Taste panels are usually composed of 
lay members rather than trained, professional taste testers thus results are subjective 
with high inter-individual variability [69]. It may be questionable whether results can 
be translated into the paediatric and geriatric population whose preferences and 
perceptions of taste may differ. However, due to ethical reasons, paediatric testing is 
minimal and generally limited to controlled needed clinical studies.  
Other in vivo tests include animal preference tests, or brief access taste aversion 
(BATA) tests, where the animal avoids bitter tasting compounds. These are generally 
based on a “lickometer” model whereby the animal is placed in a chamber with a 
number of sipper tubes containing the drug in different concentrations. Only one 
sipper tube is exposed at a time. The number of licks from each sipper tube is 
counted, and the animal should avoid sipper tubes containing the drug above the 
bitterness threshold for that API [70, 71]. 
An additional in vivo taste evaluation method is electrophysiological models, where 
electrodes measure the nerve response to stimuli in an anaesthetised animal. 
However, these are very rarely used and not documented widely [69]. In vivo testing 
is expensive and subject to ethical considerations and inter-subject variability, 
therefore in vitro taste assessments are becoming increasingly popular.  
Recently, there have been several reports of the use of electronic tongues (e-tongues 
or taste sensors) for taste assessment [12, 19, 23, 29, 37, 41, 52, 72, 73]. These 
models contain electrochemical sensors which can detect various substances of 
different tastes and intensities, which generates electrical signals that are interpreted 
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by the accompanying chemometrics software. One example is the Insent Taste 
Sensing System TS-5000Z as shown in Figure 1.1. 
 
Figure 1.1: Insent Taste Sensing System TS-5000Z (Insent Intelligent Sensor 
Technology Inc., Atsugi-Shi, Japan). Outlined by Woertz et al. [72]. 
 
There are several types of e-tongue in existence, differing by their receptor type and 
selectivity, required sample properties and handling requirements [69]. An 
alternative to e-tongues is in vitro assay methods which involve measurement of 
activation of G-proteins found in taste buds based on activation of receptors in an in 
vitro membrane. This method has many limitations outlined elsewhere and is not 
widely used [69].  
Finally, in vitro drug release studies (dissolution tests) are employed to evaluate taste 
masking properties of a formulation. This approach removes the subjectivity 
associated with in vivo taste testing, replacing it with robust analytical data. The 
amount of drug released in a simulated oral environment is assessed. However, this 
leads to a requirement for biorelevant dissolution to mimic the oral cavity for 
accurate predictions. In our case, reverse enteric coatings should completely hinder 
release of the API in the oral cavity. Therefore the amount of drug released in the 
dissolution test should be close to zero.  
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1.4 Dissolution Testing Purpose 
With the exception of using flavours or sweetening agents, the aim of taste masking 
is to reduce or inhibit the interaction between the API and the taste buds [9]. Where 
hindered release of API in the oral cavity is critical for taste masking, dissolution 
testing should be carried out to confirm this. Acceptable amounts of drug release in 
the oral cavity will depend on the bitterness of the API. Highly bitter molecules have 
lower acceptable limits of release and vice versa, thus there is no set limit of 
acceptable drug release for all drug candidates. There is also no set Pharmacopoeial 
dissolution test for taste masked particles. However, the Federation International 
Pharmaceutique (FIP) and American Association of Pharmaceutical Scientists (AAPS) 
published joint guidance for the dissolution testing of taste masked polymer coated 
particles in orally disintegrating tablets (ODT). This guidance recommends the use of 
a neutral medium where the drug should have less than or equal to 10 % drug 
dissolved in 5 minutes to achieve taste masking.  
It is recommended by the authors that this test is performed by following the same 
principles of solid oral dosage forms, using a compendial paddle apparatus (usual 
volume 900 mL and temperature 37 °C) with a suggested agitation rate of 50 rpm. 
They add that this apparatus may be used to determine the dissolution of either the 
ODT formulation or the bulk coated granules/powder; however higher agitation 
speeds may be required for bulk granules due to mounding. No medium specification 
is detailed other than that it should be neutral, assumingly for biorelevant 
representation of the oral cavity. It is also not discussed whether the amount of bulk 
granules or formulation should be increased in line with the non-physiological 
volume employed in this test.  
The acceptance criteria of less than 10 % release largely depends on the bitterness 
intensity of the API [74]. Taste masking is realistically achieved when API release is 
minimal and below the bitterness threshold of the API in the oral cavity. This requires 
an assay for detection of the API from the dissolution media at concentrations below 
its bitterness threshold, thus the lower limit of quantification of the assay should be 
considered carefully.  
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Where hindered release in the oral cavity is desired for taste masking, it is imperative 
to ensure that the taste masking technique, such as polymer coating, does not inhibit 
release of the API elsewhere in the gastrointestinal (GI) tract. If dissolution in the GI 
tract is sub optimal or incomplete, the amount of API absorbed could decrease and 
its bioavailability or bioequivalence may also be altered. This would result in an 
altered pharmacokinetic profile for the taste masked formulation which is not well 
correlated with the profile of the API alone or non-taste masked formulations.  
An example of this is the application of coatings as a method of taste masking. These 
could adversely affect the pharmacokinetic profile of the API by reducing or delaying 
overall absorption into the systemic circulation. Coatings should ideally hinder 
release in the oral cavity but allow complete and rapid release and dissolution before 
the drug reaches the site of absorption.  
In the case of reverse enteric coatings of microparticulates, drug release should occur 
in the acidic environment of the stomach. However, this may be highly dependent on 
gastric residence time and the prandial state of the individual. In the fed stomach, pH 
may be raised which may inhibit the release of API from the coated particulate. Thus, 
the coating material should be selected carefully to avoid this as the choice of 
polymer is pivotal in obtaining the desired plasma concentration-time profile.  
Reverse enteric polymers such as Eudragits® are often employed for taste masking 
purposes [25, 32, 64, 75-77]. These can selectively swell or dissolve in certain 
conditions, releasing the drug in specific areas of the GI tract for absorption whilst 
masking the bitter taste of the drug in the mouth. Eudragit E® is insoluble above pH 5 
and does not release the API until reaching the stomach, thus is suitable for taste 
masking purposes. However, consideration should be given to whether the drug is 
degraded in the stomach, such as cefuroxime. This undergoes microbial degradation 
in the stomach, so the system can be combined with other pH sensitive polymers 
such as Eudragit L® [78]. This is an enteric polymer which does not release the drug 
until above pH 6, thus protecting the API from degradation in the stomach and 
allowing release in the early intestine. However, enteric polymers which delay 
release until the small intestine may not be suitable for drugs with a narrow 
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absorption window in the upper GI tract [78]. Potential rapid gastric expulsion of 
dosage forms must also be considered when using pH sensitive coatings in isolation 
or in combination. Resultantly, polymers should be chosen very carefully and the 
formulation should be evaluated in vitro for dissolution and absorption using 
biorelevant models to ensure the pharmacokinetic profile of the API is not altered by 
the coating. 
Hoang Thi et al. [37] also found the composition of the coating layer to have an 
impact on the dissolution profile. In this study, acetaminophen particles were coated 
with sodium caseinate and lecithin in different ratios for taste masking. Both ratios 
hindered drug dissolution in phosphate buffer pH 7.4 compared to pure drug as 
shown in Figure 1.2. Whilst this may be suitable for taste masking purposes, it may 
also reduce the bioavailability and efficacy of the formulation. 
 
Figure 1.2: Hindered dissolution of acetaminophen from taste masked powders 
coated with different ratios of sodium caseinate: lecithin. Data obtained using flow-
through mini-column apparatus, phosphate buffered saline pH 7.4, 1 mL min-1. Taken 
from Hoang Thi et al. [37].  
 
The very presence of a coating layer, and the composition of the coating and core 
particles can have a substantial effect on the dissolution and thus absorption and 
bioavailability of taste masked particles compared to other formulations. This was 
demonstrated by Shirai et al. [33, 35] as shown in Figure 1.3.  
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Figure 1.3: The effect of polymer coating on the dissolution of granules of 
sparfloxacin using paddle apparatus, 50 rpm, 900 mL distilled water. Taken from 
Shirai et al. [35]. Reproduced with permission from Biol. Pharm. Bull. Vol. 16, No. 2. 
Copyright (1993) The Pharmaceutical Society of Japan.  
 
More recently, it has been demonstrated that the thickness of the coating [21, 22] 
(Figure 1.4) and the molecular weight of the polymers [36] can also affect dissolution 
and thus the pharmacokinetic profile. 
  
Figure 1.4: Dissolution rate of ibuprofen from core particles with different amounts 
of film coatings using paddle apparatus, 50 rpm, Japanese pharmacopoeia XV 
dissolution medium No. 2 pH 6.8, 900 mL. Taken from Hamashita et al. [22] 
Reproduced with permission from Chem. Pharm. Bull. Vol. 56, No. 7. Copyright (2008) 
The Pharmaceutical Society of Japan. 
   
10 
 
Of equal importance in coated formulations is the composition of the core material. 
For example, ibuprofen particles were made using four core components and coated 
with the same film material [21]. However, dissolution profiles of the four 
formulations differed as shown in Figure 1.5. The authors found that when 
dissolution rate was rapid, taste masking was compromised; however, when 
dissolution rate was slow, bioavailability was compromised. This highlights the 
importance of developing formulations which efficiently mask the taste sensation of 
the API without affecting the pharmacokinetic profile.  
 
Figure 1.5: Dissolution of ibuprofen from coated particles containing different core 
materials using paddle apparatus, 50 rpm, Japanese pharmacopoeia XV dissolution 
medium No. 2 pH 6.8, 900 mL. Taken from Hamashita et al. [21]. Reproduced with 
permission from Chem. Pharm. Bull. Vol. 17, No. 3. Copyright (2007) The 
Pharmaceutical Society of Japan. 
 
Particles in which alternative methods of taste masking were employed have also 
been shown to have an impaired or altered dissolution profile as a result of taste 
masking. Formulations using ion-exchange resins demonstrated dissolution to be 
dependent on the choice of resin [60], particle size of complexes [59], and ratio of API 
to resin [57]. In taste masked lipid formulations, the choice of lipid binder and 
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solubilising agent was shown to affect the dissolution profile of a poorly soluble drug 
in lipid pellets [15]. In lipid microspheres, the size of the microspheres affected both 
the rate and extent of dissolution. The composition of fatty acids within the 
microspheres also effected in vitro release rate [17]. Furthermore, the rate and 
extent of cetirizine release from cross-linked chitosan microparticles was shown to be 
dependent on chitosan concentration [79].  
In our case, taste masked microparticles are often incorporated into ODT 
formulations. These disintegrate in saliva and are subsequently swallowed, avoiding 
the requirement to swallow large solid dosage forms. However, this generates 
potential for administration without water. Such “dry delivery” could affect oro-
pharyngeal and oesophageal transit time as particles may be retained within these 
regions for extended periods of time. Thus the pharmaceutical industry aims to 
generate formulations with extended taste masking time. However, this has the 
potential to affect the dissolution and hence pharmacokinetic (PK) profile and 
bioequivalence of the formulation. Wilson et al. [80] investigated the distribution of a 
rapidly dissolving formulation of benzodiazepine with a radiolabelled ion-exchange 
resin. Using dry delivery and normal swallowing, they found that after the 9 minute 
experiment, 8 % of the resin remained in the glottal area, confirming that taste 
masking for extended periods of time (perhaps up to 30 minutes to completely avoid 
adverse taste) is an important consideration for the pharmaceutical industry.  
In summary, taste masking techniques have been shown to delay, alter or hinder the 
dissolution of the API in vitro. This may adversely affect the absorption of the API and 
the PK profile compared to pure drug or non-taste masked formulations. It is 
therefore important to assess the dissolution of the taste masked formulation for 
two reasons. Firstly, one can predict the taste masking capability of the formulation 
by estimating the likely release in the oral cavity. This requires biorelevant models of 
the oral cavity for accurate prediction of whether drug release is above or below the 
bitterness threshold of the API.  Secondly, one should assess the effect of taste 
masking on the PK profile using dissolution testing models representing the 
remainder of the gastrointestinal tract, or crudely, the stomach and small intestine. 
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The dissolution methodology employed in the evaluation of taste masked 
formulation is discussed later in this Chapter.  
1.5 Anatomy and Physiology of the Oral Cavity 
To predict the likely release of API in the oral cavity, dissolution testing should mimic 
the oral environment as closely as possible. Therefore, one must firstly consider the 
anatomy and physiology of the oral cavity.  
The main anatomical features of the oral region are shown in Figure 1.6 and include 
the teeth, gingivae, tongue, lips and palate. Many other important anatomical 
features contribute to this region including a complicated arrangement of muscles, 
nerves, blood vessels and lymphatic drainage [81-84].  
 
Figure 1.6: The main anatomical features of the oral region [82].  
 
The oral cavity can be further divided into two sections. Firstly, the oral vestibule, 
situated between the lips or cheeks on one side and teeth and gums on the other and 
secondly, the oral cavity proper, which is behind the teeth and confined by the 
palate, tongue and oropharynx.  
The oral cavity is covered by a lining known as the oral mucosa. This comprises poorly 
permeable, keratinized hard palatal and gingival mucosa. It also comprises the more 
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permeable, non-keratinized sublingual, soft palatal and buccal mucosa. The degree of 
keratinization affects drug absorption from these sites, along with the thickness of 
the mucosa, blood flow and saliva flow. For example, the sublingual mucosa is only 
100 - 200 µm thick compared to the buccal mucosa which is 500 - 600 µm, so has 
greater permeability than buccal mucosa, which in turn has greater permeability than 
keratinised palatal mucosa. However, drugs are quickly removed from the sublingual 
mucosa in saliva, thus only rapid acting, highly permeable drugs would be absorbed 
at this site [85-87].  
Saliva is generated by three major salivary glands, shown in Figure 1.7, and several 
minor salivary glands. The major salivary glands, in order of size are the parotid, 
submandibular and sublingual glands, which together contribute approximately 90 % 
of total saliva. The remainder comes from minor glands which are located all over the 
oral cavity with the exception of the anterior hard palate. Salivary glands have a 
secretory acinus in which isotonic saliva is released. As the saliva travels through the 
duct of the gland, electrolyte exchange takes place resulting in a hypotonic solution 
which is released [81, 88]. The excretion process is discussed in more detail in 
Chapter 3.   
 
Figure 1.7: Location of the three main salivary glands. Adapted from Moore et al. 
[84]. 
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Unstimulated saliva flow rate has been shown to range between 0.05 - 2.87 mL min-1 
with mean values between 0.37 and 0.56 mL min-1 across several studies [89-92]. The 
volume of saliva present has been stated to range from 0.09 - 1.86 mL, with mean or 
median values in the range 0.37 - 0.70 mL and only approximately 30 % of saliva 
being swallowed in each unforced swallow [91, 93, 94]. Additionally, the pH of saliva 
has been shown to range from 5.45 - 7.8 [89, 90, 92, 95, 96]. The characteristics of 
saliva, including the pH and flow rate are discussed in more detail in Chapter 3.  
Saliva is produced for lubrication of the oral cavity, protection of dentition and soft 
tissues, digestion of food, anti-microbial purposes and to deliver molecules to the 
taste buds [97]. Natural saliva is a complex aqueous solution containing 99 % water 
and a diverse spectrum of inorganic ions, small organic molecules and proteins. The 
inorganic ions present are bicarbonate and phosphate, which contribute to the buffer 
capacity of saliva, and electrolytes such as sodium, potassium, magnesium, zinc, 
calcium, chloride, fluoride, iodide, thiocyanate and nitrates. The small molecules 
present include steroid hormones, amino acids, glucose, creatinine, and urea. The 
proteins present include immunoglobulins, mucins (which contribute to the viscosity 
of saliva), enzymes including lingual lipase and amylase, growth factors and anti-
microbial factors such as lactoferrin and lysozyme [97]. As for any biological fluid, the 
complexity of natural saliva renders it extremely challenging to recreate the exact 
composition.  
1.6 Physiology of Taste and Bitterness Reception  
Taste buds are located in circumvallate, foliate and fungiform papillae, shown in 
Figure 1.8 observed on the tongue and palate. They are comprised of an assembly of 
taste receptor cells, which have taste receptors for the five taste sensations: sweet, 
salt, sour, bitter and umami. Umami is a relatively recent discovery and represents 
tastes associated with the savoury flavours of monosodium glutamate and aspartate. 
These receptors vary in nature from G-Protein coupled receptors to ion channels, 
which innervate a series of afferent neurons before reaching higher order brain 
centres [81, 98].  
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Figure 1.8: The location of taste buds on the tongue and schematical representation 
of a taste bud. Taken from Chandrashekar et al. [98]. (TRC = taste receptor cell).  
 
Each taste sensation aids us in making decisions about the quality of food we ingest. 
This develops from a very early age since a human baby just a few days old can 
distinguish between favourable sweet sensations and unfavourable bitter sensations 
[99]. Substances possessing sweet and umami tastes encourage their own 
consumption, whilst sour tastes warn us that food may be spoiled or rancid, and salty 
tastes help to regulate our electrolyte consumption. The bitter taste sensation, 
associated with numerous APIs, was developed to prevent the ingestion of toxic 
bitter compounds. Thus it is natural for the patient to reject bitter tasting drugs and 
imperative that bitter taste is masked.  
For many years, it was believed that taste mapping existed on the tongue, whereby 
each region of the tongue was receptive to only one taste sensation, meaning bitter 
taste could only be sensed by a certain part of the tongue. However, this theory is 
now outdated and reception of all five basic tastes is now demonstrated to occur 
across all areas of the tongue [98]. Therefore, each taste bud contains the receptors 
for all five taste sensations. However, it is not presently clear how different taste 
sensations are decoded.  
One theory proposes that taste is decoded in the periphery. In this proposal, each 
taste receptor cell within the taste bud is tuned to detect just one taste sensation 
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and possesses receptors for that one taste only. Multiple taste receptor cells make up 
each taste bud, allowing all tastes to be recepted by a single taste bud.  
Another theory proposes that decoding occurs centrally rather than peripherally. This 
theory is thought to be the prevailing model for nearly three decades [98]. In this 
theory, a single taste receptor cell expresses receptors for many taste sensations, 
thus recognising all taste modalities. This combined information is then decoded 
centrally and interpreted.  
The salt and sour tastes are the least well understood in terms of their reception. It is 
understood that salt reception is mediated via amiloride-sensitive sodium channels. 
The sour taste is thought to be associated with a member of the transient receptor 
potential (TRP) ion channel family, PKD2L1, which has been found to be expressed in 
sour sensitive taste receptor cells not responsive to sweet, umami or bitter tastes 
[98]. The sweet, umami and bitter tastes are far better understood and are 
associated with certain G-protein coupled receptors (GPCRs).  
The favourable taste sensations are mediated by three GPCRs: T1R1, T1R2 and T1R3. 
The T1R1+3 receptors form a heterodimer capable of detecting umami tastes, whilst 
the T1R2+3 receptors form a heterodimer for the detection of sweet tastes. In mice, 
if either the T1R2 or 3 part of the receptor is knocked out, leaving a homozygous 
receptor for the remaining part, the mouse suffers a drastic loss of sweet taste 
sensation [100]. It is interesting to note that the substance itself is not sweet, but the 
way that the substance is recepted makes us decide it is sweet. For example, cats 
possess mutations in the T1R2 receptor gene, causing inactivation of the receptor, 
resulting in their inability to detect sweet sensations. Similarly, polymorphisms can 
occur in bitterness receptor genes in humans affecting our perception of bitterness. 
The bitter taste is also mediated by GPCRs, T2Rs. The number of T2Rs in the family 
varies depending on the literature cited. Reviews in 2001 and 2002 describe 24 and 
26 T2Rs respectively [99, 100]. A review in 2006 stated there were approximately 30 
T2Rs [98], whilst a 2014 review detailed that the number of T2Rs varies from 3 to 49 
depending on the species [101]. The large number of receptors allows humans to 
detect a vast range of potentially toxic substances. However, not all humans would 
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perceive the same substance to be bitter. Two typical examples are the sensitivity to 
phenylthiocarbamide (PTC) and 6-n-propyl-2-thiouracil (PROP). In some people, these 
evoke an intense bitter taste sensation; however, other people fail to detect them as 
bitter and perceive them as tasteless. These two molecules are detected by T2R38, 
which has two alleles – one which codes for a PTC/PROP sensitive receptor, and one 
coding for an insensitive receptor [101]. Polymorphisms have also been found to exist 
in T2R16, 31 and 43 in humans which no doubt also cause differences in perception 
of bitterness between individuals [102]. In addition, olfactory and visual information, 
hunger or satiety, previous exposure and conditioned responses to certain 
substances may influence individuals’ perception of bitterness  [98].  
Interestingly, bitter taste receptors, T2Rs, have been found in extra-oral locations, 
including the respiratory system [103, 104] and gastrointestinal tract [102]. These 
may have some involvement in regulation of digestion and metabolic processes. 
However, it is not thought that taste buds occur in these locations. The effect of 
bitter APIs on these taste receptors remains unclear.  
1.7 Effect of Age and Gender on Taste Perception and Reception 
Weiffenbach, Cowart and Baum [105] stated that early taste threshold studies 
reported substantial and significant sensitivity decreases with age. They asked 170 
participants between the ages of 23 and 88 years old to scale the intensity of four 
tastant solutions – sweet, sour, salty and bitter. They measured the intra class 
correlation coefficient, which represents the consistency of participants’ responses to 
each taste. They found that older individuals obtained lower correlation coefficients 
than younger individuals, indicating a less consistent response to a particular tastant, 
and a lower ability to detect tastants reliably with increased age.  
Similarly, Kennedy et al. [106] investigated sweetness detection and recognition 
thresholds in a young adult population (18 – 33 years) and older adult population (63 
– 85 years) and found significant differences in detection and recognition thresholds 
between the two age groups, with older adults less likely to identify the taste. This 
may result in pharmaceutical preparations requiring more sweeteners or flavours in 
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the older population to make them palatable, however, they did not consider bitter 
taste.  
One article by Ng et al. [107] investigated the response of different age groups to the 
savoury flavours of pork and beef and found that taste threshold in the elderly group 
was significantly higher than middle aged or young adults, and that taste threshold 
increased with age. Again, this article did not investigate the bitter taste.  
Age related changes in perceived sour intensity have been reported [108], as well as 
a generic taste loss in response to all five basic tastes associated with increased age 
in one study [109]. Another study agrees with these conclusions and found that 
increased age resulted in increased recognition thresholds for the four main taste 
sensations (not considering umami) with significantly higher recognition thresholds in 
the older group compared to younger adults [110].  
Further supporting the phenomenon of age related decline in taste perception of 
bitter substances is research by Cowart, Yokomukai and Beauchamp [111] who 
observed an age related decline in the threshold and suprathreshold sensitivity to the 
extremely bitter molecule quinine, but interestingly not for urea, when younger 
adults (aged 18 – 38) were compared to elderly adults (aged 65 – 86). This indicates 
that sensitivity may not be lost to the same degree to all tastant types.  
Moreover, Schiffman et al. [112] also observed increased detection and recognition 
thresholds in older adults, compared to younger adults for bitter compounds. 
Interestingly, they also observed a strong correlation between bitter threshold and 
the log P of the compound, however, this was not noted at suprathreshold 
concentrations and may require further investigation.  
All of the above studies investigated age related changes in the perception of tastants 
in elderly adults compared to younger adults. However, these researchers did not 
consider how taste is perceived by children. There appears to be far fewer studies 
investigating this in the literature, perhaps due to the ethical issues associated with 
clinical testing of compounds in children in past years.  
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To address this issue, research by James et al. [113] evaluated the response to 
different tastants, namely aqueous solutions of sucrose, and three foods: orange 
juice, custard and shortbread biscuits. Each type of stimulus had five different levels, 
representing five different levels of sweetness. They compared the different tastants 
and were asked to estimate the magnitude of each taste sensation. The study 
comprised of two groups: healthy adults with a mean age of 20.7 years, and healthy 
children with a mean age of 8.9 years. The results showed a similar response for 
adults and children to all stimuli with the excpetion of orange juice, where children 
showed a reduced response across all concentrations compared to adults. Gender 
was found to have no effect in the response for the children’s response to any of the 
stimuli. This research indicates that at mid-childhood (8 – 9 years of age), children 
have a similar response to sweetness magnitude as adults. However, unfortunately, 
bitter compounds were not evaluated in this research.  
Another study [114] conducted a post hoc analysis to investigate the response of 
children to different types of oral medication. They found that children possessing 
the bitter sensitive alleles of taste receptor genes were more likely to have taken 
solid medication rather than a liquid formulation, and preferred higher 
concentrations of sucrose in their beverages. These findings do not come as a 
surprise, but do indicate that personalising medicine to reflect children’s genotype 
and thus inherent ability to detect bitter compounds may be an avenue for future 
paediatric formulation development. However, unfortunately in this study, children’s 
perception of the same bitter compound was not compared to that of adults.  
An additional study [115] investigated how children aged from “kindergarten” to 
“third grade” and adults responded to different spices and found no significant 
difference between children of any age and adults in response to detection of spices 
at different concentrations.  
In general, literature reveals that the elderly population have a poorer perception of 
taste compared to younger adults, however, this may not affect all taste sensations 
equally within the same individual. To the best of our knowledge, no research groups 
compare changes in taste perception over age within the same individual due to 
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difficulties in experimental design, which would result in very long studies across 
multiple researchers and years of participant compliance with the trial. Nevertheless, 
one should compare within subject differences in taste with respect to age in order 
to take into account genetic polymorphisms. In most of this research, it is not clear if 
poor taste perception in the elderly group is due to genetic polymorphisms of the 
taste receptor genes as discussed in Chapter 1, or due to loss of taste perception. 
Study design should be carefully considered to account for this. In children, fewer 
studies have been conducted, however response to sweetness in children aged 8 – 9 
years, and response to spices in children of a broad age range is comparable to 
adults. Bitter taste perception requires further assessment in children in comparison 
to adults. It is also noteworthy that although perception of sweetness or bitterness in 
children may be comparable to humans, willingness to eat bitter substances may be 
less in children due to a lack of environmental exposure. As stated previously, tastes 
allow us to make decisions about the nutrients we intake, with sweet taste 
encouraging consumption and bitter taste warning of potential toxic compounds. 
Over time and environmental exposure, adults learn to tell which bitter substances 
are safe, and to regulate their sweet intake for health reasons. However, children 
may lack this understanding. Less evidence is available on the effect of gender on 
taste perception, however, in general, no differences are observed in either the adult 
or child population.  
1.8 Existing Dissolution Testing Methods 
Sequential dissolution testing, using more than one medium to simulate the 
compartments of the GI tract is of high importance for taste masked formulations. 
One should use a biorelevant oral model to assess taste masking efficiency, followed 
by a biorelevant model of the stomach and intestine to assess the effect of taste 
masking on bioavailability of the API. However, very few research groups have 
employed a sequential dissolution process in the in vitro assessment of their taste 
masked dosage forms [19, 24, 60, 63], and to our knowledge none have employed a 
suitable sequential process in which the entire GI tract is modelled including the oral 
cavity. 
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The British Pharmacopoeia (BP) has recommended dissolution tests for delayed 
release dosage forms. However, these are not appropriate for taste masked particles 
as they aim to mimic the stomach and the small intestine with the use of an acid 
stage followed by a buffer stage, with no consideration of the oral cavity. For coated 
granules, the reader is directed to dissolution tests for solid dosage forms within the 
BP, as above [116]. The lack of appropriate pharmacopoeial standard dissolution test 
for taste masked particles has led to wide variety in the dissolution methods 
adopted. This project aims to work towards development of an appropriate 
biorelevant dissolution model for the evaluation of taste masked or alternative oral 
formulations such as microparticulates. However, we firstly evaluate the existing 
dissolution methods used in the evaluation of taste masked particles.  
1.8.1 Single Dissolution Medium 
Some research groups used a single dissolution medium in the in vitro release assay 
for evaluating taste masked particles. Most commonly, phosphate buffer was the 
medium of choice at pH 6.8 [10, 11, 41, 75, 117-122]. However, phosphate buffers 
with other pH values in the range 5.6 - 8.0 have also been employed [15, 17, 36, 79]. 
Water has also been used in some studies [29, 33, 43, 62] and the addition of 
surfactants to water or phosphate buffer has also been demonstrated. Mizumoto et 
al. added 0.1 % v/v Tween 80®, a non-ionic surfactant to phosphate buffer in order to 
improve the wettability of the taste masked famotidine particles [123, 124] whilst 
Hamashita et al. used 0.01 % v/v polysorbate 80 in phosphate buffer pH 6.8 [21] and 
Lee et al. used 0.1 % w/v sodium dodecyl sulphate in water [40].  
In some of those cases [33, 36, 41, 43, 62, 117, 121], the single medium was used to 
represent dissolution performance in the small intestine. This was coupled with a 
different method of taste masking evaluation in most examples such as human taste 
testing panels. The remaining examples detailed above evaluate the in vitro drug 
release under conditions similar to those observed in the oral cavity, where pH has 
been shown to be 5.4 – 7.8 [95].   
Use of a single medium may enable the researcher to predict taste masking 
performance by investigating release under simulated oral cavity conditions. 
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However, in these studies, physiologically relevant volumes were not used. The 
medium volume in the above examples varied between 100 - 900 mL which may 
cause an over-estimation of drug release as the volume of saliva in the mouth is 
typically less than 2 mL [93]. The dose used for in vitro dissolution testing was not 
increased to compensate for the greater than physiological volumes employed in any 
of these cases. However, if the formulation is designed to be ingested with a glass of 
water then dissolution testing to reflect intake conditions may be appropriate using 
volumes of 200 - 300 mL. Additionally, sole use of an oral cavity model does not 
inform the researcher if the formulation has sufficient dissolution further along the 
GI tract, and whether the coating, or other taste masking technique allows release of 
the API for absorption.  
It should also be noted that some researchers used a single dissolution test based on 
gastric conditions. Commonly, 0.1 M hydrochloric acid (HCl) has been employed [13, 
56, 57, 64], however 0.07 M HCl [30], simulated gastric fluid (SGF) [59] and  HCl with 
addition of surfactant [16] have also been used. A single dissolution test in a gastric 
or intestinal medium may inform the researchers about the dissolution of the 
formulation in that particular location, but is not useful in the evaluation of taste 
masking.  
1.8.2 Dual Dissolution Media 
There are numerous examples in the literature where two media have been used to 
evaluate taste masked particles. In most cases, parallel dissolution tests were 
undertaken using the paddle apparatus with different media. In such cases, the 
media was commonly HCl pH 1.2 and phosphate buffer pH 6.8. This can be further 
divided into cases where the phosphate buffer stage was used to describe the fate of 
the formulation in the oral cavity [27, 28, 32, 44, 45, 65] or in the small intestine [46, 
52, 54, 55]. Oral pH has been demonstrated to be 5.4 - 7.8 and intestinal pH varies 
between pH 5 - 8 depending on the location and pre- or post-prandial state [95, 125, 
126]. Where prolonged periods of time were used for the phosphate buffer stage, 
results are usually translated to the fate of the formulation in the small intestine. 
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Water has been used as an alternative to phosphate buffer to represent the oral 
cavity conditions in some cases [48, 77].  
Parallel dissolution testing using acetate buffer pH 4 and phosphate buffer pH 6.8 is 
also observed within the literature [18, 61, 127]. In these cases the acidic pH can be 
considered a compromise between fasted pH which has been stated to be between 1 
- 3 and fed pH which can reach values of up to 7 [95, 125, 128]. Where parallel tests 
are undertaken, the possibility of the API dissolving in acidic medium then 
precipitating out in the higher pH of the intestine is not considered.  
In some cases, in vitro testing took place in a single dissolution bath with changing 
media [19, 24, 60, 63]. Sequential dissolution testing was performed using an acid 
stage (0.1 M HCl) followed by a buffer stage (phosphate buffer pH 6.8) as described in 
the BP [116] for delayed release oral dosage forms. Such sequential methodologies 
could be considered superior to alternatives as they are more physiologically 
representative. Importantly, the above cases do not model the oral cavity and cannot 
be used to predict taste masking efficacy.  
1.8.3 Multiple Dissolution Media 
Multiple in vitro dissolution tests have been performed on certain taste masked 
formulations. Ishikawa et al. compared taste masked granules at pH 1.2, 5 and 6.8. 
pH 5 was used to simulate cases in which gastric pH is elevated by drugs or food [76]. 
Granules were coated with Eudragit® E, a reverse enteric polymer, and dissolution 
was assessed using basket apparatus containing 900 mL media, 100 rpm.  The results 
showed complete and rapid release of API in the pH 1.2 medium. At pH 5, release 
was complete but dissolution rate was slower. Finally, at pH 6.8, incomplete release 
was observed with less than 10 % of API dissolving over 480 minutes.  
Similarly, Ostrowski et al. compared taste masked enteric coated pellets to a 
suspension formulation and evaluated them at pH 1.2, 4.5 and 6.8 [20]. Chun and 
Choi [49] investigated release from an ion exchange complex at pH 2, 4 and 6, 
whereas Robson et al. [38] investigated in vitro drug release from fatty acid 
microspheres at pH 5.9, 6.8, 7 and 8 and Agresti et al. [53] used pH 3, 5.5 and 7 to 
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evaluate release from a drug-peptide complex. Ogata et al. [129] used buffers of pH 
1.2, 5, 6.8 and water to evaluate their taste masked granules. Chiappetta et al. [66] 
also used water as a dissolution media in the evaluation of their polymeric 
microparticles, which were analysed in pH 1.5 and 6.8 as well as tap water to 
simulate intake conditions. Dissolution tests were carried out in parallel in all the 
above mentioned examples using 500 - 1000 mL media where specified and generally 
either paddle or basket apparatus. Thus none of these methodologies are 
biorelevant, particularly when considering the oral cavity dissolution.  
1.8.4 Methods Modelling the Oral Cavity 
In literature highlighted thus far, several in vitro dissolution tests have been 
performed at oral pH. However, previously discussed examples are not an accurate 
representation of the oral cavity in terms of volume and agitation. Our attention is 
now drawn to in vitro dissolution testing where the researchers aimed to model the 
oral cavity in more depth in order to accurately predict taste masking performance.  
Lee et al. [51] evaluated polymer coated nanohybrid particles of sildenafil at neutral 
pH in deionised water for two minutes as a model of the oral cavity in addition to 
testing at pH 1.2 as a gastric model. However, both tests were carried out using 900 
mL media and the paddle dissolution apparatus. Such a large volume is not 
representative of the oral cavity. The dose of the formulation assessed was not 
increased to compensate for the greater dilution effect. Smaller volumes were used 
by Guhmann et al. [23] who evaluated polymer coated diclofenac particles in 50 mL 
of simulated salivary fluid (SSF) pH 7.4 which were stirred at 50 rpm over a maximum 
of 5 minutes and sampled. The composition of SSF used is shown in Table 1.1. 
Hamashita et al. [22] evaluated polymer coated particles in 20 mL Japanese 
Pharmacopoeia 2nd fluid of pH 6.8 for ten seconds. This contains a 1:1 mixture of 
phosphate buffer pH 6.8 and water [130]. A sample was placed into a 50 mL beaker 
and stirred with medium. These models incorporated representative residence times 
and media for the oral cavity, however, volumes were still excessive.  
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Table 1.1: Composition of Simulated Salivary Fluid (SSF) used by Guhmann et al. [23].  
Component Concentration 
Potassium dihydrogen phosphate 12 mM 
Sodium chloride 40 mM 
Calcium chloride 1.5 mM 
Sodium hydroxide To pH 7.4 
Demineralized water To 1 L 
 
Shukla et al. [58] and Sheshala et al. [31] assessed taste masked particles in 5 mL of 
phosphate buffer pH 6.8 by placing the sample into a 25 mL vessel with 5 mL medium 
and leaving to stand for either 60 or 120 seconds to model the oral cavity. Both 
groups also assessed the dissolution in HCl, with Sheshala et al. additionally testing in 
900 mL acetate buffer pH 4.5 and phosphate buffer pH 6.8. Five mL is closer to 
physiological volumes of saliva, but still excessive. Additionally, no agitation was 
employed in these examples.  
Numerous researchers assessed taste masked particles in 10 mL SSF where samples 
were placed into the media and shaken for 60 seconds. “Average salivary fluid” at pH 
6.8 of unknown origin or composition was used by Patra et al. [50] who also 
performed dissolution testing on etoricoxib ion-exchange complexes in 900 mL 0.1 M 
HCl. pH 6.8 buffer was used as SSF by Randale et al. [25] who additionally used 500 
mL SGF without enzymes for evaluation of polymeric metoclopramide microparticles. 
“SSF” of pH 6.2 was used by Yan et al. [26] who also tested polymer coated donepezil 
particles in 900 mL “SSF”. In this case “SSF” referred to the use of distilled water. 
Additionally, Khan et al. [131] performed dissolution tests on polymeric ondansetron 
microparticles in SSF pH 6.2 of unknown composition and 500 mL SGF without 
enzymes. In these cases, shaking the dissolution vessel may not be a reproducible 
method of agitation and may not accurately simulate the hydrodynamics of the oral 
cavity.   
Simulations of the oral cavity using novel methods of agitation have been developed. 
Shirai et al. [34, 35] performed in vitro dissolution testing on taste masked granules 
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of sparfloxacin by placing a sample of the formulation into a 10 mL syringe and 
adding 10 mL water. Agitation was provided by revolving the syringe five times in 30 
seconds. This method was developed based on the fact that in vivo taste tests 
involved volunteers holding 10 mL of an aqueous solution of the drug in water in the 
mouth. Similarly, Kondo et al. [132] placed a sample of coated paracetamol granules 
into a 10 mL syringe with 10 mL water. Agitation was provided by ten repeat syringe 
inversions over 30 seconds.  
Perhaps one of the more reproducible and physiologically representative methods 
adopted for in vitro modelling of the oral cavity in the assessment of taste masked 
particles is that outlined by Thia et al. [37]. The authors used a syringe pump 
connected by tubing to a mini column. The sample was placed in the column with 
further tubing connecting the distal end of the column to a vessel for sample 
collection as shown in Figure 1.9.  The column was heated to 37 0C with a column 
heater and phosphate buffer of pH 7.4 was passed through the system at a flow rate 
of 1 mL min-1. The 1 mL min-1 flow rate has been widely used in saliva flow modelling 
[133].  
Figure 1.9: Mini column apparatus used by Thia et al. [37]. (PBS = phosphate buffered 
saline).  
 
A similar mini column method, shown in Figure 1.10 was also adopted by Yajima et al. 
[134] for evaluation of the bitterness of clarithromycin dry syrup. Here, phosphate 
buffer, pH 6.5 filled the column and was then pumped through the column at flow 
rates of 0.3, 0.5 and 0.7 mL min-1. Better correlation between in vitro release and 
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sensory analysis results was seen for the mini column method than for shaking, 
inversion or paddle methods suggesting the superiority of this approach in modelling 
the oral cavity.  
 
Figure 1.10: Mini column apparatus used by Yajima et al. [134]. Reproduced with 
permission from Chem. Pharm. Bull. Vol. 50, No. 2. Copyright (2002) The 
Pharmaceutical Society of Japan. (CAM = clarithromycin).  
 
With respect to modelling the oral cavity, no pharmacopoeial recommendations are 
provided. There is a lack of consensus on the volume, apparatus, media and duration 
of the dissolution test that should be used, thus a variety of approaches have been 
adopted. The media representing saliva used in the evaluation of taste masked 
formulations by in vitro dissolution testing have been described in this section. 
However, it is worthy to note that other artificial salivas are described in the 
literature or available commercially. These are discussed in more detail in Chapter 3 
as they have not yet been used to represent saliva in dissolution testing of taste 
masked formulations, and many were developed for other applications.  
1.9 Limitations of Current Approaches and Future Directions 
A vast array of dissolution tests has been executed aiming to predict taste masking 
capability and/or evaluate subsequent dissolution of taste masked formulations in 
the GI tract. Little agreement between researchers was observed. A single medium 
may represent the oral cavity to predict taste masking capability. However this 
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should mimic the oral environment as closely as possible, which has been achieved in 
very few of the described examples. It is also apparent that several different media 
have been used in these dissolution experiments to simulate saliva. Multiple media 
have been employed in some cases, although these are commonly performed in 
parallel, providing snapshot information about dissolution in certain conditions but 
failing to reflect the transit between compartments of the GI tract. Where a 
sequential dissolution process was carried out, only gastric and intestinal conditions 
were considered. Importantly, the oral cavity was not considered in these cases.  
This introduction has highlighted the need for development of a sequential in vitro 
dissolution model for the evaluation of taste masked formulations. Ideally, this 
should include a physiologically representative sequential model of the oral cavity, 
stomach and small intestine. This could be used to evaluate not only the capability of 
the formulation to mask the taste sensation of the API by hindering release in the 
oral cavity, but to ensure release is sufficient elsewhere in the GI tract such that the 
overall pharmacokinetic profile of taste masked formulations is not altered compared 
to existing formulations. The model should also ensure that no precipitation occurs 
on transition between compartments. Ideally, the model should have the capability 
of discriminating between unstimulated and stimulated salivary states and the fed 
and fasted states.  This is particularly pertinent in the case of reverse enteric 
polymeric coatings for taste masking purposes since the different prandial and 
stimulatory states may significantly affect drug release from the formulation.  
For optimal accuracy of the model in predicting in vivo behaviour, physiological 
conditions should be modelled as closely as possible. Thus consideration should be 
given towards the relevant environments within the GI tract including the changing 
pH, agitation and hydrodynamics, volumes and media composition. 
An accurate in vitro model should also consider the absorption in each compartment 
as this may reduce the amount of API transferred to the next stage of the sequential 
dissolution model. Estimating absorption also allows the user to predict the effect of 
the taste masking technique e.g. coating on the bioavailability and the plasma API 
concentration-time relationship after dosing. 
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Taste masked particles are nominally evaluated for in vitro dissolution, surface 
characteristics and in vitro or in vivo taste testing. Where taste masked formulations 
have been assessed in vivo, in terms of assessment of the effect of taste masking on 
the pharmacokinetic profile and bioavailability, this has generally been in 
bioequivalence studies where the formulation is compared to a marketed 
formulation in the species of choice, as shown in Figure 1.11 [13, 26, 29, 31-33, 35, 
43, 48, 51].  
 
Figure 1.11: Plasma concentration-time graph demonstrating bioequivalence 
between an orally disintegrating tablet (ODT) comprised of microspheres of 
donepezil, taste masked by coating with Eudragit EPO®, and marketed product after 
oral administration to rats [26]. Reproduced with permission from Biol. Pharm. Bull. 
Vol. 33, No. 8. Copyright (2010) The Pharmaceutical Society of Japan.  
 
Most published reports achieved bioequivalence with the optimised formulation, 
reflecting the fact that absorption of the optimised taste masked formulation was 
comparable to the commercial formulation, and the taste masking technique did not 
affect the pharmacokinetic profile. The authors of Figure 1.11 assessed the 
dissolution of the taste masked product in a simulated stomach environment and 
found that the product had similar dissolution to the non-taste masked, commercial 
product. Similar dissolution performance in vitro suggests that comparable results 
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are likely to be seen in vivo for the two formulations. This was then confirmed using 
bioequivalence testing, as shown in the Figure. Although in vivo bioequivalence 
testing provides the most accurate assessment of the effect of formulation changes 
on bioavailability, appropriate sequential dissolution methodology should be able to 
predict these effects.  
Permeability testing is occasionally carried out in vitro using cell culture, artificial 
membranes or ex-vivo tissue diffusion in diffusion cells or Ussing chambers [2, 135]. 
Specific models for estimating permeability in the oral cavity have also been 
developed and are described elsewhere [133, 136, 137]. However, these are not 
generally routinely applied to the in vitro evaluation of taste masked formulations. 
Alternatively, in silico modelling can be employed to estimate absorption based on 
the characteristics of the API and dissolution data using computational models [138-
142].   
The development of dynamic dissolution models, with or without absorption phases 
is described in detail by McAllister [143]. An example of a model which considers 
dissolution only is the artificial stomach duodenal model (ASD) [144]. This system 
comprises two compartments, the stomach and the duodenum, as shown in Figure 
1.12. Fluid is pumped into each compartment to mimic flow of secretions. Fluid also 
flows from the stomach to the duodenum, and exits the duodenum to mimic 
physiological transfer between compartments. The system is relatively simple and 
computer controlled, requiring little operator input. It can be used in conjunction 
with biorelevant media and/or in silico predictions of the pharmacokinetic profile 
[145]. Media composition and volume may be altered to reflect different species, 
ages and disease states [146]. The ASD model has been used successfully to predict 
the performance of different crystalline or amorphous forms of an API [146, 147] and 
the effect of gastric pH variations [145]. Prediction of precipitation on transfer 
between the two compartments can also be studied using this model [144]. However, 
the model alone does not incorporate an oral cavity for the consideration of taste 
masking, nor does it model absorption in any way. Thus the assumption is made that 
the amount of API dissolved in the duodenal compartment is equal to the overall 
bioavailability. This is not the case for drugs where permeability and metabolism limit 
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systemic exposure. It also only models the upper GI tract, whereas many taste 
masked formulations exhibit delayed release for example due to pH sensitive 
coatings. This may result in an inaccurate prediction of formulation performance 
using this system. Thus it is best suited to comparison of immediate release 
formulations during pharmaceutical development. 
 
Figure 1.12: Schematic representation of the artificial stomach – duodenum (ASD) 
model. Taken from Bhattachar and Burns [144].  
 
The most sophisticated and biorelevant model currently in existence is known as TNO 
Intestinal Model (TIM). This is a dynamic, computer controlled, multi-compartmental, 
sequential model considering both dissolution and permeability. TIM-1 models the 
stomach, duodenum, jejunum and ileum, shown in Figure 1.13, whilst TIM-2 models 
the colon only [148-151]. The two systems can be used together [152]. Both systems 
incorporate a predetermined pH profile maintained by computer controlled addition 
of acid or bicarbonate and flexible water filled walls to maintain physiological 
temperature with alternating water pressure to simulate peristaltic contractions. 
Valves between compartments can be programmed to mimic the gradual passage of 
chyme observed in vivo. Semi permeable lipid or dialysis membranes are used to 
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estimate the amount of drug available for absorption. TIM-1 also has computer 
controlled secretion of enzymes into each compartment. The TIM-2 system has an 
anaerobic environment maintained by nitrogen flow, where microflora can be 
cultured and grown prior to the experiment. It is also possible to introduce a solid 
meal to these models [150, 151].  
 
Figure 1.13: Schematic representation of the TNO intestinal model (TIM-1) system. 
Taken from Dickinson et al. [149].  
 
However, these models are not optimal for evaluation of taste masked formulations 
as, crucially, they do not consider the oral cavity. TIM models are a tool of the 
pharmaceutical industry, resulting in limited access to them and consequently limited 
reports of their use. Existing literature generally details the application of these 
models to Biopharmaceutics Classification System (BCS) [153] class 1 drugs, which are 
highly soluble, highly permeable drugs. Investigations of the effect of prandial state 
and formulation have been employed [143, 149, 150, 154-156]. TIM-1 has been used 
in the successful evaluation of poorly soluble drugs in one report.  This report also 
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describes internal projects in which TIM-1 did not distinguish between tested 
products, however differences were observed in clinical trials. The authors proposed 
that this was due to non-biorelevant stomach hydrodynamics and suggested the use 
of TIM is not appropriate where performance of the formulation is highly dependent 
on gastric emptying and agitation [149].  
Another major limitation of the TIM models is that the semi permeable membranes 
are non-biological and rely entirely on passive diffusion to predict the amount of drug 
available for absorption. They cannot claim to predict absorption as they do not 
account for efflux, active transport or cellular metabolism. The membranes are only 
present in the jejunal and ileal sections, whereas absorption may occur from any of 
the compartments in vivo. This is particularly important for drugs which are absorbed 
in the upper small intestine. TIM-1 has been shown to overestimate maximal plasma 
concentrations in one study based on maximal jejunal dialysis concentrations due to 
a lack of first pass metabolism and distribution of the drug - factors which are not 
considered by the TIM-1 system [155].  
There have also been reports of extensive plastic binding for some drugs, lowering 
their recovery. For example, mean recovery of BCS class 1 drug paroxetine was only 
75 % [150]. Additionally, the number of replicates of experiments using these models 
are generally less than 3 due to the lengthy set up time [149]. The complexity of this 
model suggests that its application is not likely to be in quality control, but may lie in 
formulation development where differences in predicted pharmacokinetic profiles 
between formulations can be evaluated [150].  Despite their limitations, the TIM 
models are very prestigiously designed tools and can be considered highly 
biorelevant.  
Thus a model which employs both a sequential, biorelevant dissolution process and 
estimation of absorption is needed in order to accurately predict the effect of taste 
masking on the pharmacokinetic profile of the API. A suitable model, incorporating 
an oral cavity and remainder of the GI tract with proven in vitro-in vivo correlation 
could reduce variation in the in vitro assessment of drugs or taste masked dosage 
forms, enabling comparison between research and reducing in vivo testing. Such a 
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model could be derived as an extension of an existing model. For example with BP 
dissolution apparatus 2, a mini paddle apparatus containing SSF could be used to 
represent the oral cavity with contents subsequently transferred to a larger vessel 
representing the stomach, followed by a third vessel representing the small intestine. 
BP dissolution apparatus 3 uses reciprocating cylinders whereby the sample is 
immersed in a dipping motion into fluids of different composition. An additional 
cylinder in this apparatus could be filled with a small volume of SSF. BP dissolution 
apparatus 4 uses a flow through cell whereby different media are passed over the 
sample within the cell. SSF could be used as the first of a sequence of biorelevant 
media. The ASD system could be extended by the addition of an oral compartment 
which flows into the stomach compartment. Alternatively, TIM-1 system could be 
coupled to a mini column apparatus for more biorelevant conditions than achievable 
using standard compendial apparatus. In order to also incorporate an absorption 
phase, dissolution vessels may be combined with cell layers or Ussing chambers. 
Additionally, dissolution data could be coupled with in silico modelling to predict the 
overall PK profile.  
There are numerous opportunities in the development of novel biorelevant 
technologies for the assessment of taste masked oral formulations. It is perhaps most 
efficient to begin with a simple approach such as modified compendial apparatus and 
evaluate the most promising formulations in a more complex model such as the TIM-
1 system coupled to an oral model. Whichever approach is adopted should be as 
biorelevant as practicable to allow for accurate prediction of taste masking efficiency 
and the effect of taste masking on the PK profile.  
In addition to the numerous biorelevant gastrointestinal models in existence as 
discussed, biorelevant media have also been receiving attention in the 
biopharmaceutics arena. A vast array of media have been developed representing 
various biological fluids [157]. Examples of this include simulated gastric fluid, 
intestinal fluid and colonic fluid (SGF, SIF and SCF respectively), and the prestigiously 
developed fed and fasted state media representing the gastric and intestinal 
compartments – fasted / fed  state simulated gastric fluids (FaSSGF and FeSSGF), 
fasted / fed state simulated intestinal fluids (FaSSIF and FeSSIF) and fasted / fed state 
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simulated colonic fluids (FaSSCoF and FeSSCoF). The FeSSGF and FeSSIF media have 
also been updated providing snapshot media reflecting the early, mid and late stages 
after feeding, during which digestion is beginning to take place and composition of 
fluids alters [128, 158-160]. Such biorelevant simulated gastric and intestinal fluids 
are widely used in dissolution testing [95, 161-163]. However, simulated salivary 
fluids have received less attention. This introductory review has demonstrated that 
no consensus on the choice of model representing the oral cavity, or dissolution 
media representing human saliva has been reached. This is perhaps because the 
characteristics of the oral cavity and of human saliva are not well understood. 
Therefore, the aim of this PhD is to develop a biorelevant dissolution methodology 
for drugs and dosage forms in the oral cavity. Our focus begins with the selection or 
development of a suitable biorelevant media representing human saliva. This media 
could be used in the assessment of taste masked dosage forms to evaluate taste 
masking efficiency, and coupled with an existing gastrointestinal tract model to 
predict the effect of taste masking (e.g. polymer coating) on API bioavailability and 
pharmacokinetics. 
Taste masked formulations are most commonly evaluated in vivo by taste testing 
panels. This is subject to inter-individual variation and cannot be extrapolated to the 
paediatric population. Alternatively, in vitro dissolution testing is used to evaluate 
taste masking capability, by quantifying release in simulated oral cavity conditions.  
However, little agreement between the in vitro dissolution methodologies adopted is 
observed and most current methodologies are not biorelevant. Additionally, taste 
masking may affect the absorption and pharmacokinetic profile of the API by 
hindering dissolution and absorption in the GI tract. Thus dissolution testing should 
also mimic the rest of the GI tract to ensure the pharmacokinetic profile is not altered 
by the taste masking technique. Dissolution tests aiming to mimic one or more 
environment within the remaining GI tract were found to be highly variable, and not 
physiologically representative. We have identified the requirement for a model which 
considers both the oral cavity and the rest of the GI tract, ideally considering 
dissolution and permeability. To our knowledge, there is no such model currently in 
existence.  The stomach and intestine have been extensively modelled, and 
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prestigiously designed biorelevant media representing these compartments are 
widely used. However, the oral cavity is less well modelled and there is no consensus 
on the composition of a media to represent human saliva. The aim of this PhD is 
therefore to develop a biorelevant dissolution methodology for drugs and dosage 
forms in the oral cavity. Our focus begins with the selection or development of a 
suitable biorelevant media representing human saliva. 
1.10 Aims and Objectives of the PhD 
Aims 
1. The selection or development of biorelevant simulated salivary fluid(s) for use as 
dissolution media.  
2. The development of a biorelevant dissolution methodology representing the oral 
cavity for the in vitro assessment of taste masking efficiency.  
Objectives 
 Investigate the properties of human saliva based on literature 
 Characterise human saliva experimentally where literature is inconclusive 
regarding properties relevant to dissolution 
 Evaluate the biorelevance of existing simulated salivary fluids available 
commercially or outlined in literature 
 Select or develop the most biorelevant simulated salivary fluid(s) to be used in 
dissolution testing 
 Confirm the suitability of the chosen media by direct comparison with human 
saliva for specified parameters, and by comparative dissolution experiments 
 Evaluate potential dissolution models and apparatus 
 Select and/or develop, and validate, a biorelevant dissolution methodology 
representing the oral cavity. 
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Chapter 2: Materials and Methods  
2.1 Materials  
Glandosane® (Cell Pharm GmBH, Hannover, Germany) was purchased from a local 
pharmacy. Saliva Orthana® spray and gel were kindly donated by CCMed® (Picket 
Piece, UK). Note that Saliva Orthana® gel is not currently a marketed product and its 
composition is confidential information. The full composition of these can be found in 
Tables 2.1 – 2.3 below. 
VitaMelts™ vitamin C orally disintegrating tablets (Bioglan®, UK) were purchased 
from a local Holland and Barrett store. Xanthan gum, from xanthanomas campestris, 
and Tween 20® were purchased from Sigma-Aldrich® (Gllingham, UK). All other 
chemicals and solvents were obtained from Fischer Scientific (Loughborough, UK).  
Table 2.1: Composition of Simulated Salivary Fluids: Phosphate Buffered Saline  
Ingredient Quantity (per 1000 mL) 
Potassium Dihydrogen Orthophosphate 1 g 
Dipotassium Hydrogen Orthophosphate 2 g 
Sodium Chloride 8.5 g 
Deionised Water To 1000 mL 
Sodium Hydroxide or Hydrochloric Acid Adjust the pH if necessary to pH 6.8 
 
Table 2.2: Composition of Simulated Salivary Fluids: Glandosane® [164] 
Ingredient Quantity (per 50 g aqueous solution) 
Carboxymethylcellulose Sodium 0.5 g 
Sorbitol 1.5 g 
Potassium Chloride 0.06 g 
Sodium Chloride 0.0422 g 
Magnesium Chloride (6 H2O) 0.0026 g 
Calcium Chloride (2 H2O) 0.0073 g 
Potassium Monohydrogen Phosphate 0.0171 g 
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Table 2.3: Composition of Simulated Salivary Fluids: Saliva Orthana® Products  
Ingredient Amount (per 100 mL aqueous solution) 
Porcine Gastric Mucin 3500 mg 
Methyl-4-hydroxybenzoate 100 mg 
Benzalkonium Chloride 2 mg 
EDTA Disodium Salt.H2O (E386) 50 mg 
H2O2 250 ppm 
Xylitol 2000 mg 
Peppermint Oil 5 mg 
Spearmint Oil 5 mg 
NaCl 45 mg 
KCl 63 mg 
CaCl2 30 mg 
K2HPO4 10 mg 
KOH 76 mg 
Xanthan Gum (in Saliva Orthana® gel) 500 mg 
 
2.2 Ethical Approval 
All saliva samples were collected in accordance with ethical approval number 
R12122013 SoP TTTFS, Faculty of Medicine and Health Sciences Research Ethics 
Committee, Queens Medical Centre, Nottingham University Hospitals. Participation 
was voluntary and informed written consent was obtained. All data was held in 
accordance with the Data Protection Act. This included data storage on password 
protected spreadsheets for all personal information, identification of participants 
using numbers where possible and back up of all documents on secure servers from 
the University of Nottingham.   
2.3 Human Volunteers 
Participants were recruited from the University of Nottingham by email for ease of 
recruitment and were healthy adult volunteers. Exclusion criteria included chronic or 
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acute illness in the past 3 months, cold or flu symptoms, oral health concerns and any 
medication, with the exception of contraception. Participants were asked not to eat, 
drink, smoke or use oral hygiene for 2 hours prior to donation. In a preliminary 
literature search, these exclusion factors were reported to affect saliva flow or 
composition [165]. In addition, other researchers used similar exclusion criteria when 
collecting human saliva for characterisation, and a period of one hour [90, 96, 166] or 
two hours [89] after exposure to stimulants was required before human saliva 
collection. Donations took place at approximately 15:00 hours to avoid diurnal 
salivary changes. It is thought that saliva flow is lowest during hours of sleep, and has 
a natural peak flow in the afternoon [165] or during times of stimulation [165, 167]. 
The time 15:00 hours was chosen for practical reasons to allow sufficient time after 
exposure to potential stimulants. It has also been reported that circannual cycles of 
saliva secretion may be present [167], therefore donations all took place within a 
short period of a few weeks. Participation was voluntary and informed written 
consent was obtained.  
2.3.1 Trial 1 
The study group demographics are shown in Table 2.4. The study group was mostly 
Caucasian (26 of 30 participants). The number of participants required was 
determined using a power calculation, which is detailed further in section 2.8: 
Statistical Analysis. The narrow age group recruited was due to recruitment largely 
from the postgraduate community at the University of Nottingham and is a limitation 
of this work. However, it is difficult to recruit a “paediatric sample” or “geriatric 
sample” encompassing all ages within these populations. For example, paediatrics 
range from pre-term neonates to teenagers, therefore a much larger trial would be 
required to generate meaningful data for these diverse populations. Nevertheless, 
future collaborations with Dr. Catherine Tuleu have been discussed and there may be 
an opportunity for future studies.  
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Table 2.4: Trial 1 study group demographic data 
Total number of participants 30 
Age (mean +/- S.D. (range)) 26.13 +/- 3.55 (20 - 35) 
Age 20 – 27 22 
Age 28 – 35 8 
Male 13 
Female 17 
 
2.3.2 Trials 2 and 3 
The study group demographics are shown in Table 2.5. The same participants were 
used for both Parafilm® and ODT stimulation trials (Trials 2 and 3) to allow for 
comparison. A smaller group of participants was recruited for this trial according to 
power calculations.  
Table 2.5: Trial 2 and 3 study group demographic data 
Total number of participants 10 
Age (mean +/- S.D. (range)) 26.7 +/- 5.14 (20 - 36) 
Age 20 – 27 7 
Age 28 – 36 3 
Male 4 
Female 6 
Caucasian ethnicity 5 
Oriental ethnicity 5 
 
2.4 Saliva Collection and Characterisation of Flow Rate  
2.4.1 Trial 1: Human Saliva Trial 
The rationale for collecting human saliva and for selecting the particular parameters 
to characterise is discussed in Chapter 3. A preliminary literature search indicated 
that there may be differences in the characteristics of unstimulated and stimulated 
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saliva. In a review paper of saliva composition and function [165], flow rate was 
indicated to vary depending on stimulation state. In another review [167], differences 
in the composition of unstimulated and stimulated saliva were documented. 
Furthermore, some literature focussed on the characteristics of only unstimulated 
saliva [89, 92] whilst another review documented the electrolyte composition of 
unstimulated and chewing stimulated saliva [168]. Therefore, both unstimulated and 
chewing stimulated saliva were collected.   
Participants were asked firstly to donate an unstimulated saliva sample by draining 
their saliva via a sterile disposable funnel into two 15 mL polypropylene sterile 
graduated centrifuge tubes (Grenier Bio-One, UK) and one 1.5 mL polypropylene 
graduated micro centrifuge tube (Sarstedt, UK). Samples were collected in 3 different 
vessels to allow for separate defrosting for each characterisation. For each type of 
saliva (US and SS), the following was collected: 10 mL for buffer capacity, 6 mL for 
viscosity and 1.5 mL for surface tension measurement. This allowed for a slight excess 
for each measurement.  The time taken to donate each volume was recorded using a 
stopwatch and the exact volume was used to calculate flow rate for each sample.  
The methods used for saliva collection in other literature varied slightly. In some 
cases, saliva was simply expectorated into a vessel such as a cup [92, 169] or wide 
mouthed test tube [96, 166]. However, these methods do not allow collection into a 
graduated vessel, which is preferable to accommodate flow rate analysis. Other 
groups used more invasive techniques such as drawing saliva from under the tongue 
using a polyethylene catheter attached to a syringe, [170] or instructing the 
participant to lean forward whilst saliva was drawn into a syringe from under the 
tongue [171]. These methods collect saliva primarily produced by the sublingual 
salivary glands and not whole mixed saliva. In addition, the presence of the syringe or 
catheter in the oral cavity may stimulate salivary flow, and a less invasive procedure 
would probably be more acceptable to participants. Therefore, the method we 
employed was in line with other research groups who asked subjects to lean forward 
and drain their saliva via funnels into graduated centrifuge tubes [89, 172]. This 
technique benefits from being non-invasive and allowing easy flow rate calculation. 
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Participants then donated a stimulated saliva sample. For this, they were asked to 
continually chew a 5 cm x 5 cm piece of Parafilm® and repeat the donations following 
this stimulation. Stimulation was controlled by regulating the size of the piece of 
Parafilm®, and the same volume of saliva was collected each time. There are three 
possible mechanisms of saliva stimulation: mechanical, gustatory and olfactory, with 
olfactory being the weakest stimulus [167]. Unlike gustatory stimuli, mechanical 
stimuli can allow reproducible stimulation without tastant molecules remaining in the 
mouth and activating taste receptors for unknown periods of time or affecting 
salivary composition and biochemistry. Parafilm® is widely used in literature [173-
176] for mechanical stimulation due to its lack of flavour and inert composition. 
Some research groups have used citric acid as a gustatory stimulant [177-179] 
however, this affects the pH and buffer capacity of saliva. Additionally, some 
researchers have used flavoured chewing gums [180, 181], however, this provides 
both gustatory and mechanical stimulation which is less reproducible than 
mechanical stimulation alone due to differences in reception and perception of taste 
amongst individuals [98, 99].  
Samples were immediately tested for pH, flash frozen in liquid nitrogen and 
temporarily placed on dry ice until being transferred to a -80 °C freezer for storage. 
Samples were labelled as biohazards and stored in the freezer until being defrosted 
for characterisation. No significant difference in pH was observed between fresh and 
defrosted samples (paired t-test, N = 60). During storage, samples were required to 
comply with the Human Tissue Act, thus all samples were logged onto a spreadsheet 
when they entered storage and when they were removed or destroyed.  
It is reported that in untreated human saliva, proteolytic enzymes from white blood 
cells, oral bacteria and salivary glands can degrade salivary proteins, which reduces 
saliva viscosity. Thus some researchers choose to centrifuge samples before storage 
[182]. However, centrifugation may remove some proteins which contribute to 
salivary viscosity such as mucins. Therefore it is recommended to add protease 
inhibitors, store samples in the cold and/or reduce the time between collection and 
measurement instead of centrifugation [182]. Collection of samples on ice and 
storage at -20 °C or -80 °C can minimise proteolysis. In a review paper evaluating 
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saliva storage options and their influence on its biochemical and physiochemical 
properties, storage at -80 °C was found to be preferable to storage at -20 °C as the 
protein profile of saliva was not altered at the lower temperature. At only -20 °C, the 
protein composition altered, and this outcome was not improved by adding protease 
inhibitors. Therefore, our samples were stored at -80 °C. In the same review [182], it 
was identified that slow freezing and freeze-thaw cycles contributed to protein 
precipitation, therefore rapid freezing in liquid nitrogen was recommended followed 
by storage at -80 °C.  
Disposal of all saliva samples after analysis was carried out by diluting saliva with 
disinfectant, sealing and autoclaving according to local procedures.  
2.4.2 Trial 2: US to SS Conversion using Parafilm® Stimulation 
Participants were asked firstly to donate an unstimulated saliva sample by draining 
their saliva via a sterile disposable funnel into three pre-weighed 1.5 mL 
polypropylene graduated micro centrifuge tubes (Sarstedt, UK), each time 
expectorating their saliva after a 30 s period into a new centrifuge tube for a total of 
1.5 minutes. This allowed for three separate samples for analysis and 
characterisation.  
Participants then donated a stimulated saliva sample into pre-weighed 15 mL 
polypropylene sterile graduated centrifuge tubes (Grenier Bio-One, UK). Larger 
centrifuge tubes were used as stimulated saliva was expected to have a greater flow 
rate, and thus a greater volume collected in each time period. For this, they were 
asked to continually chew a 5 cm x 5 cm piece of Parafilm® [173-176] and repeat the 
donations during this stimulation. Stimulation was controlled by regulating the size of 
the piece of Parafilm® as before. Participants expectorated their saliva at 30 s 
intervals for 30 minutes. The timer was started at the point when Parafilm® was 
placed into the mouth for chewing, time zero. From zero to 10 minutes, participants 
advanced onto the next centrifuge tube every 30 s. From 10 to 30 minutes, 
participants advanced onto the next tube every 2 minutes (whilst still expectorating 
saliva every 30 s so that flow rate was unaffected).  
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The experiment was allowed to continue for 30 minutes as this reflects the duration 
of dissolution testing to be carried out representing the oral cavity. Ultimately, once 
methodology has been fully established, dissolution testing will be performed with 
the oral dosage form – multiparticulates (with or without taste masking coating) 
made into an orally disintegrating tablet (ODT). Although the majority of an ODT is 
swallowed quickly after disintegration, evidence suggests that some particles remain 
in the oral cavity for prolonged periods of time. Research by Wilson et al. [80] 
showed that nearly 10 % of an ODT radiolabelled with technetium-99m remained in 
the oral cavity after 9 minutes. In agreement with Pfizer®, the dissolution test was set 
to 30 minutes to ensure all ODT particles would be swallowed from the oral cavity 
and to test the efficiency of taste masking coatings after prolonged oral exposure.  
Samples were immediately tested for pH, weighed to determine flow rate (see 
section 2.4.3 below), then flash frozen in liquid nitrogen and stored at -80 °C until 
being defrosted for characterisation of buffer capacity. Samples were stored, labelled 
and disposed of as per section 2.4.1.  
2.4.3 Trial 3: US to SS Conversion using ODT Stimulation 
Participants donated unstimulated saliva as above. VitaMelts™ vitamin C orally 
disintegrating tablets (Bioglan®, UK) were divided into quarters using a tablet splitter. 
Participants placed a quarter ODT on their tongue and allowed to disintegrate. The 
timer was started when the ODT was placed on the tongue, time zero. Disintegration 
time was noted and found to have a mean value +/- S.D. of 59.1 s +/- 11.3 s. 
Participants were asked to swallow three times after disintegration to ensure ODT 
particles were swallowed. From 1.5 minutes until 30 minutes, participants 
expectorated saliva every 30 s and donations proceeded as above. Samples were 
characterised and stored as above. 
Vitamin C was chosen as a model ODT since ascorbic acid and citric acid are 
commonly used as saliva stimulating agents in ODTs, providing gustatory stimulation 
for enhanced disintegration. Therefore, the active ingredient in the VitaMelts™ ODT 
(ascorbic acid) is also used as an excipient, making these tablets similar to a placebo. 
This was a favourable property for gaining ethical approval to use these in our human 
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clinical trials. In addition, using a specific API may affect the stimulation of saliva, and 
we wished to investigate only the effect of an ODT in general, not individual APIs, on 
saliva characteristics. A number of vitamin C ODTs can be sourced online, however, 
many are only available to order from other countries, or contain more than 100 % of 
the recommended daily allowance (RDA) of vitamin C, which may affect ethical 
approval. VitaMelts™ ODTs were readily available and were purchased from a local 
Holland and Barrett store. These are UK marketed and contain 100 % of the RDA of 
vitamin C.  
The VitaMelts™ ODTs are classified as vitamins, minerals and supplements and do not 
have to conform to the same regulatory requirements as pharmaceuticals. FDA 
guidance for Industry suggests ODTs for pharmaceutical use should disintegrate 
within 30 s [183], however, other authors recommend disintegration should be 
within less than a minute [184], whilst FIP/AAPS guidance states the more lenient 
value of less than 3 minutes [74].  
However, disintegration time of VitaMelts™ ODTs was towards the longer end of 
these recommendations according to preliminary experiments in 10 volunteers, with 
tablet disintegration being between 2 - 3 minutes. The ODTs were therefore divided 
into quarters yielding mean disintegration time +/- S.D. of 59.1 s +/- 11.3 s, which is 
more in line with pharmaceutical products.  
Participants were asked to swallow their saliva three times after they felt that 
disintegration was complete. This was to ensure, as best as possible, that ODT 
particles had been swallowed and did not remain in the oral cavity. The presence of 
ascorbic acid in saliva may dramatically affect the pH and buffer capacity of saliva. 
Preliminary trials were carried out in which a VitaMelts™ ODT was placed in 
deionised water, and our simulated salivary fluids (SSFs), developed as part of the 
PhD (see Chapter 5). In each media, the pH was reduced by greater than 3 units 
within the first minute after addition of a whole ODT. Therefore, saliva was 
swallowed after disintegration to reduce the presence of ascorbic acid in saliva as 
much as possible.  
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In a preliminary trial of five participants, the density of US and SS was assessed. A 
paired t-test showed no significant difference between US and SS, confirming that 
weight of saliva could be used to calculate flow rate. Density was found to have a 
mean value of 976.8 mg/mL. All centrifuge tubes were weighed using CPA225D 
balances (Sartorius, UK). For trials 2 and 3, all centrifuge tubes were weighed before 
and after the donations. Flow rate was calculated from the weight and density of 
saliva, and the time period for each sample, measured using a stopwatch.   
It was favourable to use weight and density instead of using graduated test tubes (as 
per the first trial) since samples were collected every 30 s for trials 2 and 3, meaning 
much smaller volumes were obtained. Although some micro centrifuge tubes are 
graduated, this is not very accurate as saliva samples contain a liquid phase plus 
some bubbles as a top layer, which is highly irregular. Therefore, analysing the flow 
rate by weight and density was considered more accurate.  
2.5 Characterisation of pH and Buffer Capacity 
2.5.1 Trial 1 
2.5.1.1 pH 
An S220 seven compact pH/ion meter was used with InLab Science Pro electrode (SI 
343 071, Mettler Toledo, Switzerland). The pH meter was accurate to +/- 0.002 pH 
units and a 3 point calibration was used at pH 4, 7 and 10. The pH of human saliva 
was measured immediately after collection prior to freezing the samples in liquid 
nitrogen and storing at -80 °C. The pH was measured in triplicate for each participant 
for both US and SS.  
2.5.1.2 Buffer Capacity 
A 4 mL saliva sample was allowed to warm to 37 °C in the test tube. Temperature was 
maintained using a water bath (beaker) in which the test tube for titration was 
placed. The beaker was placed on an RCT basic hotplate stirrer (IKA Works GmbH, 
Germany) with temperature probe. Initial pH was tested using the above electrode. 
The sample was then titrated with 0.01 M HCl at 37 °C until a decrease in pH of 1 unit 
was observed. Buffer capacity in mmol H+/L saliva was calculated from the volume of 
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acid added. Stirring speed was set such that the added HCl was adequately mixed 
throughout the bulk of the sample without forming a vortex. A 100 mm x 23 mm 
B19/26 glass test tube was used (supplied by Scientific Glassware Supplies, UK). 
Human saliva was analysed in duplicate for each participant for each type of saliva.  
This size test tube was selected for titration because it was the smallest test tube 
with sufficient diameter to enable the pH electrode to reach the bottom of the tube, 
whilst larger diameter tubes required a larger sample of saliva for the electrode to be 
properly submerged in the sample. We aimed to use the smallest amount of saliva 
possible for the benefit of the trial subjects.   
A number of studies have been performed in the literature assessing the buffer 
capacity of human saliva, with various methodologies. In most cases, the 
experimental design employed does not allow one to reach quantitative 
conclusions/comparisons about the actual buffer capacity value or range. Literature 
values are reported in different ways.  
Some research groups have simply quoted the buffer capacity to be high, medium or 
low, without providing any actual value [185, 186]. In these cases, buffer capacity 
was determined by measuring the initial pH, adding a known amount of acid and 
measuring the final pH. The change in pH was measured and based on this buffer 
capacity was stated as high, medium or low. However, since neither the initial and 
final pH, nor pH change was quoted one cannot draw direct quantitative comparisons 
between studies.  
Some researchers simply state the bicarbonate concentration of saliva samples to 
infer buffer capacity [89]. However, since multiple buffers contribute to the buffer 
capacity of saliva, and the prevalence of each buffer can change depending on the 
stimulation state [165, 167], this is not entirely appropriate.  
Furthermore, in some cases, buffer capacity is quoted in mmol H+ L-1 pH-1 [173, 187] 
assessed by measuring the initial pH and adding acid such that pH decreases by a 
single unit or known amount. This does allow for quantitative comparison between 
studies. In addition, this approach has been adopted in the evaluation of buffer 
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capacity of other gastrointestinal fluids [95, 159, 162, 188-190], allowing for further 
comparison between the properties of saliva and other fluids. Therefore, this 
approach was adopted for our research.  
Since the bicarbonate buffering system contributes to the buffer capacity of saliva, it 
is possible that some carbon dioxide escapes the system during the titration as no 
measures were put into place to seal or close the system during analysis. This could 
be considered a limitation of the methodology. However, the sampling time was 
minimal, in the range of a couple of minutes, and samples were defrosted 
immediately prior to analysis to reduce the effect of CO2 and loss from the system 
and resultant pH change.  
2.5.2 Trials 2 and 3 
2.5.2.1 pH 
The pH was measured immediately after sample donation. No water bath was used 
since samples were freshly donated. An S220 seven compact pH/ion meter was used 
with an InLab® Ultra-Micro electrode (Mettler Toledo, Switzerland). The pH meter 
was calibrated as above with the same accuracy. The micro-electrode was selected 
for trials 2 and 3 since sample volumes were much lower when saliva was donated in 
just 30 s expectoration periods.  
2.5.2.2 Buffer Capacity 
A 200 μL saliva sample was allowed to warm to 37 °C in a 1 mL glass vial. Smaller 
apparatus and sample sizes were used compared to trial 1 due to practical reasons 
surrounding the smaller sample volume. Temperature was maintained using a 
polycarbonate water bath with temperature probe in which the glass vial for titration 
was placed. The water bath was placed on the above RCT basic hotplate stirrer. Initial 
pH was tested using the micro electrode above. The sample was then titrated as per 
section 2.5.1.2. Each sample was titrated only once, again due to the low saliva 
volume produced in 30 s intervals.  
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2.5.3 Characterisation of Simulated Salivary Fluids 
The SSFs characterised were obtained from commercial sources initially, and 
subsequently our own SSFs were developed in house as part of the PhD. The 
composition and origin of commercial SSFs was detailed earlier in this Chapter in 
section 2.1. The rationale for selection of commercial SSFs is discussed in detail in 
Chapter 3, whilst development and composition of our own SSFs is discussed in 
Chapter 5.  
A 4 mL sample of SSFs was allowed to warm to 37 °C in the test tube and the pH was 
measured as per section 2.5.1.1. This was also considered the initial pH for buffer 
capacity measurements, which were performed as per section 2.5.1.2. SSF buffer 
capacity was measured 5 times for each SSF, thus pH was also measured with 5 
replicates for all SSFs.  
2.6 Characterisation of Surface Tension 
2.6.1 Trial 1 and Characterisation of Simulated Salivary Fluids 
A DSA 100 Drop Shape Analyser with DSA 4 software (Kruss GmbH, Germany) using 
pendant drop method for surface tension analysis with Laplace-Young computational 
method was employed. Temperature was set to 37 °C using an MB-5 heat circulator 
(Julabo GmbH, Germany) with water bath. Measurements were taken immediately 
after droplet formation. Samples were measured with 5 replicates.  
A plunger in the syringe holding the sample is depressed and liquid is forced out of 
the needle causing a drop to be suspended from the needle tip. The shape of the 
drop depends on the surface tension and the effect of gravity. An image of the drop 
is recorded from the camera and transferred to the drop shape analysis software. A 
contour recognition is fitted to the drop, and a mathematical model is fitted to the 
contour line [191]. The software uses this to calculate the surface tension based on 
the equation below: 
γ =
∅𝑚𝑔
2𝜋𝑟
=  
∅𝑉𝜌𝑔
2𝜋𝑟
 
Equation 2.1: Calculation of surface tension [2].  
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Surface tension, γ is related to the acceleration due to gravity, g and mass of the 
droplet, m. The mass of the droplet is equal to the density of the liquid, ρ which is 
input into the software after experimental determination, multiplied by the volume 
of the drop, V. The radius of the needle tip, r is also measured and input into the 
software, which also uses a correction factor, Φ [2].  
This system was selected for practical reasons based on availability of apparatus at 
the University. It is particularly beneficial as it uses small sample volumes, provides 
quick, easy and simple measurement of surface tension and has the option for 
heating the system to physiological temperature. However, the sample is held in a 
syringe in the vertical position. This can be problematic since saliva is not a solution, 
but an inhomogeneous mixture of many components. When the sample is orientated 
vertically in the syringe for a long period of time, heavier components e.g. proteins or 
particles may drop to the bottom of the syringe and have higher abundance in the 
first few droplets, which can affect the surface tension measurements. Therefore, 
five replicates were taken and the surface tension averaged across the droplets to 
reduce this effect.  
In addition, other researchers investigating the surface tension of human saliva using 
the pendant drop method [192] found that the surface tension decreased as time 
after droplet formation increased. Therefore, the surface tension was always 
measured immediately after droplet formation to reduce this variability.  
2.6.2 Trials 2 and 3 
Surface tension was not measured in trials 2 and 3 since no significant difference 
between unstimulated and stimulated human saliva was found in trial 1.  
2.7 Characterisation of Viscosity 
2.7.1 Trial 1 and Characterisation of Simulated Salivary Fluids 
A Modular Compact Cone-Plate Rheometer MCR 302 (Anton Paar GmbH, Germany) 
was used. The cone used was a CP50-2-SN30270 with diameter 49.972 mm, angle 
2.016 °, truncation 211 μm. Analysis was carried out at 37 °C. 8 points per decade 
were used for 3 decades with shear rate increasing logarithmically from 1 - 1000 s-1. A 
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total of 25 points were made, 1 point per minute. Rheoplus analysis software (Anton 
Paar GmbH, Germany) was used. The sample volume was 1.2 mL. In a review of the 
biochemical and physical properties of saliva in 2007 [182], viscosity was measured 
across shear rates from 1 - 450 s-1. Some studies found that saliva exhibited non-
Newtonian behaviour. Therefore, a range of shear rates was used to confirm this. A 
shear rate of 4 s-1 corresponds to movement of particles across the tongue, 60 
corresponds to swallowing and 160 s-1 to speech, whilst shear rates of 10 - 500 s-1 
have been proposed to reflect the shear during eating. We therefore used 1 - 1000 s-1 
to encompass values that are likely to be present in the oral cavity [193]. The same 
method was used for all SSFs. Saliva was analysed in triplicate for each participant for 
US and SS. Each SSF was also analysed in triplicate. 
In the development of this method, water was used as a control since it is known to 
have Newtonian properties. Initially, the shear rate was increased from 0.1 – 1000 s-1 
over 5 minutes. However, this gave inconsistent results and indicated non-Newtonian 
behaviour for water. The shear rate was thus ramped more slowly, over 25 minutes 
which gave Newtonian results for water. In the low shear rate region, between 0.1 – 
1 s-1, the viscosity measurements remained inconsistent. This was thought to be due 
to the low torque for fluids of low viscosity such as water at low shear rates, thus 1 s-1 
was the lowest shear rate used. Only 8 points per decade were taken since increasing 
the number of points per decade allows less time for each measuring point, and less 
time for flow to equilibrate at each shear rate, giving unreliable results. These 
conditions showed a suitable rheological profile for water and were selected for 
further analysis.  
The cone-plate geometry was chosen due to its capability of even shear rate across 
the whole sample compared to the parallel plate geometry. Truncation of the cone 
was required due to the presence of particles in biological samples such as human 
saliva, which can cause friction if the cone tip is not truncated. A 50 mm diameter 
cone was deemed appropriate since it is mid-range of the available cone diameters, 
therefore can be used to measure all samples from the low viscosity water / 
phosphate buffer samples to higher viscosity Saliva Orthana® gel.  
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This method was found to be reproducible and versatile for analysis of a range of 
different materials. However, there are some limitations to this method. In the low 
shear rate region, a slight peak in apparent viscosity was observed for human saliva, 
perhaps due to inhomogeneous flow. Additionally, for water or phosphate buffer, the 
first few points were still in the low torque region and may not be considered. 
Furthermore, at the highest shear rates, turbulent flow caused an apparent increase 
in viscosity of some samples. The run time was quite long at 25 minutes and due to 
the absence of any hood around the cone-plate to control the ambient temperature, 
some evaporation of the fluid occurred from the heated peltier. Finally, the sample 
volume of 1.2 mL, (determined experimentally once the cone geometry was 
ascertained) was too high to allow this method to be used for trials 2 and 3 where 
very low sample volumes were available.  
2.7.2 Trials 2 and 3 
Viscosity was not characterised for trials 2 and 3 since insufficient volume of saliva 
was generated during the 30 s intervals for analysis.  
2.8 Statistical Analysis 
Prior to trial 1, the number of study participants was determined using a power 
calculation. This was performed using an online power calculator [194]. With 80 % 
power and a level of significance of p < 0.05, a sample size of 8 – 34 participants is 
sufficient to detect small to very large differences, with sample size being inversely 
proportional to the difference to be detected.  
Following the completion of the experiments, the normal distribution of the results in 
each group was tested using a D'Agostino & Pearson omnibus normality test. Where 
two normally distributed groups were compared, a t-test was used (either paired or 
unpaired). If one or both groups were not normally distributed, a Wilcoxon matched 
pairs test was used for paired samples, and a Mann Whitney test was used for 
unpaired samples. Where three or more groups were compared, ANOVA was used if 
the groups were all normally distributed. A Friedman’s test was used where normal 
distribution was not present for paired (repeated measures) samples, and Kruskal-
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Wallis for unpaired samples. p < 0.05 was considered significant in all cases. In all 
Figures, data represents mean +/- S.D.  
2.9 Analytical Methodology for Model API 
2.9.1 HPLC Methodology and Conditions 
A Waters (Milford, USA) 5695 separations module HPLC system with autosampler, 
quaternary pump and Waters 696 diode array UV detector was employed. A Waters 
Xterra C18 3.5 μm 2.1 x 100 mm column with guard column and pre-column filter 
including 0.5 µm stainless steel frit was used. The mobile phase consisted of 0.2 M 
ammonium acetate buffer pH 7.0 and acetonitrile in a ratio of 56:44, with a flow rate 
of 0.3 mL/min. This was modified from the methods of Daraghmeh et al. [195]  and 
Dinesh et al. [196]. The column and sample temperature were 40 °C and 10 °C 
respectfully and a wavelength of 290 nm was used for stock and biological samples, 
and 224 for simulated salivary fluids analysis. Injection volume was 20 μL. Run time 
was 20 minutes with API (sildenafil citrate) and internal standard (bifonazole) 
retention times of approximately 3.5 minutes and 9.6 minutes respectively. 
Representative chromatography is shown in Figure 2.1 below.  
 
Figure 2.1: Representative chromatography showing stock solution of API (sildenafil, 
1 μg/mL in MeOH) peak at 3.5 minutes and internal standard (bifonazole, 5 μg/mL in 
MeOH) peak at 9.6 minutes. Wavelength: 290 nm.  
 
2.9.2 Sample Preparation 
2.9.2.1 Stock Solutions 
A 100 mg/mL stock solution of API was made in DMSO. Serial dilution with MeOH, by 
50 % each time, was performed yielding 16 further stock concentrations for spiking 
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calibration samples, ranging from 100 mg/ml to 1525.8 ng/mL. A 1 mg/mL solution of 
bifonazole was made in MeOH and further diluted to 50,000 ng/mL with MeOH. This 
solution was used as the internal standard.  
2.9.2.2 Calibration Solutions 
Calibration solutions were generated using the same vehicle as the corresponding 
analytical samples. 90 μL of vehicle e.g. saliva was transferred to each glass test tube. 
These were spiked with 10 μL of the API stock solutions from section 2.9.2.1. Two 
separate calibration curves were generated – initially, the highest six concentrations 
(calibration concentrations 312,500 to 10,000,000 ng/mL), were diluted 100 times 
with the vehicle e.g. saliva before proceeding further. Subsequently the remaining 
(lower) concentrations were prepared without dilution.  
To all of these, 10 μL of 50,000 ng/mL bifonazole solution was added, followed by 
400 μL of cold 1:1 acetonitrile / MeOH. Finally, 3 mL of HPLC grade methyl-tert-butyl 
ether (MTBE) was added. Samples were vortexed at 1000 mot/min for 10 minutes 
and then centrifuged at 3000 rpm for 10 minutes. 2.7 mL of each supernatant was 
transferred to a second set of glass tubes and evaporated to dryness under a gentle 
stream of nitrogen. The residue was reconstituted with 100 μL of mobile phase, 
without buffer (44:56 acetonitrile : HPLC grade water). Samples were then vortexed 
for a further 10 minutes and centrifuged for a further 1 minute under the conditions 
previously described before transferring to a HPLC vial. The sample treatment 
method was modified from Tripathi et al. [197], who also added acetonitrile to 
precipitate proteins of a 100 μL sample of sildenafil citrate in plasma, followed by 
liquid–liquid extraction in diethyl ether, evaporation of the supernatant and 
reconstitution in mobile phase.  
2.9.2.3 Dissolution Samples 
Development of the dissolution method is described separately in Chapter 6 in more 
detail. Herein we discuss the sample treatment of dissolution samples for HPLC 
analysis only. For dissolution samples, the entire contents of each dissolution vial was 
transferred to a Costar® Spin-X 2 mL polypropylene centrifuge tube with 0.22 μm 
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cellulose acetate filter (Corning Inc., Tewksbury, USA) at a set time point and 
centrifuged for 1 minute at 13,000 rpm. The filtrate was diluted if necessary with 
plain dissolution media e.g. saliva. 100 μL was taken and underwent the same sample 
treatment as per section 2.9.2.2. In each case calibration solutions were made by 
spiking the same vehicle as the dissolution media.  
2.9.3 Validation 
The analytical method was validated for limit of quantification (LOQ), intra- and inter- 
day accuracy and precision and linearity in accordance with FDA guidance [198].  
Validation was performed for four different dissolution media: human US and SS, and 
SSF US and SS. In each media, LOQ and intra- day and inter- day accuracy and 
precision at three quality control (QC) levels was determined for the model API, 
sildenafil citrate. For LOQ samples, the acceptance limit was +/- 20 % for accuracy 
and precision, whereas this limit was 15 % for all QC samples. The validation results 
are detailed in Table 2.6. LOQ was determined to be within the limits of acceptance 
in all media at 100 ng/mL. The QC samples tested had concentrations of 312.5, 1,250 
and 5,000 μg for low, medium and high quality control samples respectively.  
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Table 2.6: Summary of validation data. LOQ = limit of quantification, RSD = relative 
standard deviation, RE = relative error, QC = quality control, US = unstimulated saliva, 
SS = stimulated saliva, SSF = simulated salivary fluid.  
 
2.9.4 Solubility Testing 
The solubility of the model API in water was determined from literature and found to 
be approximately 3.5 mg/mL, however this value is dependent on the pH of the 
solution [199, 200]. The solubility in stimulated human saliva was determined 
experimentally. 50 mg of API powder was stirred in 1 mL of stimulated human saliva 
from one volunteer for 30 minutes at 37 °C. This was performed in duplicate. This 
was considered to be far greater than the maximum anticipated solubility in human 
saliva. This also reflected the greatest possible concentration which could be 
observed in dissolution testing, since dissolution tests were also performed at 37 °C 
for 30 minutes. At 30 minutes, samples were diluted 100 times. 100 μL was taken and 
underwent sample treatment as detailed in section 2.9.2.2. Dissolution experiments 
in which powdered API was analysed in human US/SS were also indicative of the API 
powder solubility. However, this preliminary solubility testing was performed prior to 
these dissolution tests to ascertain expected values for the dissolution experiments 
and gauge the amount of dilution required such that dissolution samples fall within 
Media Sample RSD (%) RE (%) RSD (%) RE (%) RSD (%) RE (%) RSD (%) RE (%) RSD (%) RE (%) RSD (%) RE (%) RSD (%) RE (%)
1 17.35 1.41 11.31 1.95 -4.37 -1.19 -6.50
2 -1.77 -0.40 6.53 -6.56 1.71 -14.04 -10.87
3 0.12 8.39 7.57 5.81 -6.74 -9.08 -7.34
4 -8.59 -0.41 1.57 7.74 -3.60 1.86 -9.55
5 -3.97 -8.86 5.42 5.74 -2.93 -12.73 -9.17
1 -0.89 13.71 -2.48 5.29 -7.55 9.38 -10.86
2 5.55 12.70 -6.13 -12.02 -6.29 8.54 -10.69
3 -4.37 11.20 -4.26 1.39 -10.51 -2.42 -13.81
4 7.89 7.17 -9.19 -7.53 -2.76 -3.79 -13.99
5 7.83 -1.47 -1.45 2.61 -8.62 -6.88 -14.82
1 -5.70 -0.77 7.16 -8.08 -7.37 5.91 4.95
2 -17.86 -10.40 3.04 0.45 6.35 -7.41 5.43
3 -14.47 -4.55 6.16 -10.22 -5.66 -2.55 9.18
4 -9.06 0.21 7.14 -12.36 -0.06 6.84 8.58
5 -16.19 3.35 3.26 -9.65 4.32 5.38 11.94
1 0.90 -5.11 -1.91 -6.62 -7.00 13.76 -12.53
2 19.55 -13.26 -2.88 13.42 -7.49 10.06 -11.80
3 7.68 -14.57 -3.60 9.89 -7.22 0.76 -5.58
4 2.32 -14.96 -2.82 -5.46 -7.19 -9.73 -9.15
5 16.87 -13.10 -3.42 -14.50 -4.00 2.45 -5.96
Human US
LOQ
Intra-day Inter-day
Lower QC
4.14
Medium QC
Intra-day Inter-day
Higher QC
Inter-dayIntra-day
1.83
1.95
Human SS 5.74 5.24 4.92 3.17 5.73 2.21
6.78 7.51
3.38
3.97 3.38 5.03
SSF US
SSF SS
2.58
5.23 4.32 1.94 6.04 2.35 2.38 3.87
6.33 4.74 1.02 4.52 5.30
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the calibration range. The solubility of powdered API in human saliva can be found in 
Chapter 6.  
2.9.5 Method Development 
2.9.5.1 Development of Chromatographic Conditions 
HPLC System 
Method development initially took place on an Agilent (Santa Clara, USA) 1100 series 
HPLC machine with autosampler, quaternary pump, column heater and diode array 
detector. However, a hire fee was chargeable to the students using this system. The 
research group acquired the Waters system detailed in section 2.9.1 which was 
available free of charge and thus all subsequent work was carried out on this system. 
In addition, the Waters system has the advantage of a sample chiller and functioning 
diode array detector (which was not functional in the scanning mode on the Agilent 
system at the time). No method adjustment was required when switching between 
the two systems. 
Column 
Initial method development work was carried out using an ACE (Aberdeen, UK) 3 μm 
C18 PFP 2.1 x 150 mm column. This column showed slanting of the API peak, and the 
retention time moved slightly later after each injection causing a marked change in 
retention time across a long run in the order of minutes, despite prolonged periods of 
column equilibration with the mobile phase. Efforts were made to reduce this effect 
by increasing the temperature from room temperature to 50 °C and flow rate from 
0.2 mL/min to 0.4 mL/min to yield sharper peaks, but the same effect was still noted.  
Method development then continued using a similar column with the same 
dimensions, but non PFP, however, asymmetrical peaks were observed and changing 
retention time was still problematic despite prolonged equilibration time. At this 
point, the Agilent machine was no longer used and all further work continued on the 
Waters system. A “ghost peak” in the system became problematic with wavelength 
258 nm at the same retention time as the API and efforts were made to understand 
the origin of this peak by changing vial material and storage conditions. Zero volume 
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injections showed that this peak was to do with the injection system, and varying 
injection volumes confirmed this as the interfering peak area was proportional to the 
injection volume. The peak was also not seen on the Agilent system. The injector 
system was washed with various solvents and a service engineer cleaned the 
injection system. However, the initial problems of asymmetric peaks and changing 
retention time continued. 
Another column was tested: a Phenomenex (Macclesfield, UK) Luna C18, 3 μm, 2.0 x 
100 mm column was tested under the same conditions as the previous columns. The 
retention time was consistent and area was similar to previous for the API peak. 
However, the API peak eluted close to the solvent peak, thus different ratios of 
acetonitrile: water were trialled until 44:56 was found to be optimal. The 
Phenomenex column belonged to another member of the research group, and could 
not be used permanently for this research as students do not routinely share 
columns. Therefore, a column of similar dimensions was then used. This was a 
Waters Xterra C18 3.5 μm 2.1 x 100 mm column. This column was used for the rest of 
the analysis.  
On one occasion, the system stopped working mid-sample for reasons unknown, 
leaving a biological sample (human saliva) in the column. This happened whilst the 
system was operating overnight and the column did not undergo its usual automated 
washing procedure. When attempts were made to wash the column, the pressure 
elevated very quickly, probably due to precipitation of the sample in the column. 
Despite using multiple solvents to try to wash the column, it could not be rescued 
and the pressure remained very high. Therefore a second Waters Xterra column was 
used. The column washing cycle was also increased to five hours encompassing both 
high organic and high aqueous proportions before being stored in a high proportion 
of organic solvent, to avoid insufficient cleaning after biological samples causing 
pressure problems in future.  
Mobile Phase  
The mobile phase initially comprised acetonitrile and water in the ratio 48:52. This 
was taken from a paper by Dinesh et al. [196] who used this mobile phase in the 
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analysis of sildenafil citrate using reverse phase HPLC. Methanol/water was also 
tested in various ratios to see if this gave more suitable chromatography. A ratio of 
57:43 gave best results for methanol/water; however, chromatography was 
preferable using acetonitrile: water in the optimised ratio of 44:56.  
Peak area and retention time was still somewhat inconsistent for the API using this 
mobile phase ratio. Some trailing of the peak was also observed. The API, sildenafil 
citrate, can adopt 6 different ionisation states, ranging from +3 to -1 [201] and thus it 
was decided to introduce a buffer to eliminate variability in ionisation state. 
Daraghmeh et al. [195] used a 1:1 ratio of ammonium acetate pH 7.0, 0.2 M buffer : 
acetonitrile in the analysis of sildenafil citrate by HPLC, thus this buffer was used for 
our research. This largely solved the problem of variability in retention time and peak 
trailing.  
Injection Volume 
Injection volume was initially 2 μL. This was so that the minimum possible volume 
was injected to reduce the likelihood of contaminating the column or causing 
pressure issues when injecting biological samples. The sample treatment method was 
optimised, as described in section 2.9.5.2 below, and the injection volume was 
increased to 20 μL so that a suitable LOQ could be achieved. In addition, an injection 
volume of 2 μL was below the limit of the machine which is 5 μL and therefore, low 
injection volume introduced more variability.  
Column Temperature 
The column temperature was varied at multiple stages during analysis. It was 
observed that heating the column led to sharper peaks, however, little difference was 
observed between 40 °C and 50 °C, therefore, the lower of the two values was 
selected for further analysis.  
Sample Temperature 
Sample temperature was initially set to 5 °C to reduce the likelihood of any drug 
degradation during storage in the autosampler. However, the machine struggled to 
maintain sample temperature at 5 °C and stopped mid-run several times due to 
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sample temperature being out of range. A temperature of 10 °C +/- 5 °C was 
therefore selected and proved to be more suitable.  
Flow Rate 
Flow rate was varied between 0.2 – 0.4 mL/min. A flow rate of 0.3 mL/min was 
selected as this gave suitably sharp peaks without causing pressure to be too high. 
Wavelength 
The API, sildenafil citrate, showed two λmax values at 224 and 292 nm respectively. 
Analysis was initially carried out using stock solutions at 224 nm as this was the 
wavelength with the strongest UV absorption. However, when biological samples 
were tested, interference at 224 nm led us to use 290 nm to reduce noise. When our 
developed SSFs were tested, interference was observed at 290 nm, perhaps due to 
the presence of xanthan gum, thus the wavelength for analysis was switched back to 
224 nm which yielded a cleaner baseline.  
Guard Column and Pre-Column Filter 
After the first Waters Xterra column had to be discarded due to high pressure when 
the machine stopped mid-sample, it was decided to use a guard column to reduce 
contamination of the main column. Over prolonged periods of analytical testing, the 
peaks still became broader and had trailing or splitting in some cases. Removal of the 
guard column and testing of “clean” stocks on the main column revealed there were 
no problems with the main column and problems were a result of the guard column. 
This had to be changed approximately every 6 months when peaks began to broaden, 
split or trail. Exchanging for a new guard column resolved these problems every time. 
Despite sample treatment being optimised, this is still the case now and perhaps 
further sample treatment procedure development is necessary. A pre-column filter 
was also employed to add an additional step to reduce contamination of the guard 
column; however, the effect of this additional cleaning step is questionable.  
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2.9.5.2 Development of Sample Preparation and Treatment Procedure 
Selection of Internal Standard  
A number of internal standards were tested in the development of this method 
including testosterone, ibuprofen, dextromethorphan, simvastatin, THC 
(tetrahydrocannabinol), cannabidiol and bifonazole. Bifonazole was found to be the 
only one with retention time suitable for analysis since it does not elute too close to 
the solvent or API and does not have a retention time far greater than the API.  
Solvent Choice for Stock Solutions 
Stock solutions were generally prepared in methanol. The API was found to be more 
soluble in methanol than acetonitrile or water. In addition, it was hoped that less 
degradation would occur in methanol than in water. For the 100 mg/mL stock 
solution, DMSO was used as the solvent since the API was far more soluble in this 
than methanol.  
Protein Precipitation  
Protein precipitation alone was initially used as a sample treatment procedure. In this 
case, a cold solvent was added to precipitate the proteins in human saliva. Numerous 
solvents were chosen, however, a 1:1 mixture of acetonitrile and methanol yielded 
the cleanest chromatography. Initially, the solvent was added in a 2:1 ratio of 
precipitating solvent: saliva. However, this did not yield clean enough samples as over 
time, pressure began to rise and it was assumed this was due to unclean samples 
being injected. The ratio was increased to 4:1 precipitating solvent: saliva sample, 
which yielded better results, however, a continuing increase in pressure over several 
injections led to the use of liquid – liquid extraction in addition to protein 
precipitation.  
Liquid-Liquid Extraction  
Liquid-liquid extraction was employed as a result of rising pressure with simple 
protein precipitation techniques. A number of extraction solvents were tested 
including methanol, ethanol, ethyl acetate and methyl-tert-butyl-ether (MTBE) and 
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hexane. The API recovery was assessed for each one and was found to be greatest for 
MTBE. Therefore, this was used as the solvent for extraction.  
Reconstitution and Dilution  
Split peaks were occasionally observed for both the API and internal standard. It was 
thought that this could possibly be a result of injecting a highly organic sample into a 
mixed aqueous/organic mobile phase, predominantly aqueous (56 %). Therefore, 
samples were diluted with water so that the sample vehicle being injected was more 
consistent with the mobile phase. However, this did not help, and it was likely that 
the split peaks were due to guard column contamination instead. Samples were 
reconstituted with mobile phase after liquid-liquid extraction and evaporation so that 
they were introduced into the system in the same solvents and ratio.  
High concentration dissolution samples were diluted prior to sample treatment with 
fresh dissolution media e.g. saliva to reduce matrix effects and to ensure that they 
were within the calibration range, as described in section 2.9.2.2.  
Use of Two Calibration Curves  
It was necessary to use two calibration curves since a wide range of concentrations 
was expected in dissolution testing. For non-taste masked samples, such as pure API 
powder or non-coated pellets of API, dissolution values were expected to be very 
high, towards the solubility of the API. However, for taste masked samples, i.e. 
pellets coated with a reverse enteric coating to reduce release in saliva or simulated 
salivary fluids, release was expected to be minimal to zero. Therefore, a wide range 
of values had to be considered for calibration curves. It was not possible to use one 
calibration curve since higher values had a greater influence on the equation of the 
line of best fit, and the curve was found to be non-linear. Therefore, two calibration 
curves were used. Without dilution, concentrations in the upper calibration range 
were greater than the maximum limit of quantification and showed rectangular 
peaks with no correlation between peak area and concentration. The upper 
calibration curve was therefore diluted 100 fold to generate values within the 
measureable range of the HPLC-UV detector.  
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Chapter 3: Characterisation of Human Saliva and Simulated Salivary Fluids 
3.1 Introduction  
N.B. The content of this Chapter of the thesis is modified from the publication by 
Gittings et al., 2015 [202] in which I was the leading author. 
The oral cavity as a dissolution site is often overlooked due to rapid oral transit as 
conventional dosage forms are swallowed. However, conventional oral formulations 
such as tablets and capsules are of limited application in some populations such as 
paediatrics and geriatrics, and alternative oral dosage forms which may reside in the 
mouth for a significant time are increasing in popularity [8]. In addition, adult dosage 
forms which can be taken “on the move”, without the co-administration of water are 
also gaining interest [203]. Many alternative formulations, such as oral films, 
sublingual and buccal tablets and orally disintegrating tablets rely on dissolution or 
disintegration in saliva. On the contrary, taste masked oral dosage forms often aim to 
reduce drug dissolution in saliva in order to prevent contact between the unpleasant 
tasting active pharmaceutical ingredient (API) and the taste buds [1]. Saliva therefore 
plays a critical role in the dissolution and performance of these formulations. 
However, as highlighted in Chapter 1, there is no consensus on the composition of 
simulated salivary fluids to represent human saliva in dissolution testing, or the 
apparatus or model employed. Many of the examples observed in literature are not 
biorelevant. We therefore aim to develop a biorelevant dissolution methodology for 
drugs and dosage forms in the oral cavity. Our focus begins with the selection or 
development of a suitable biorelevant media representing human saliva.  
In Chapter 1, we discussed the dissolution media that have been employed in the 
dissolution assessment of taste masked oral dosage forms. These included water, 
phosphate buffer and electrolyte mixtures. However, other simulated salivary fluids 
(SSFs) exist. Five SSFs are proposed in a paper by Marquez, Loebenberg and 
Almukainzi in 2011 [157] which are simple electrolyte mixtures with or without 
addition of viscosity modifying mucins and amylase. Additionally, the British National 
Formulary details artificial saliva preparations used clinically in the treatment of 
xerostomia [204]. These include a mixture of sprays, gels and saliva stimulating 
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tablets. In other literature, largely from dental publications, many more SSF 
compositions can be found. In fact, one review paper from the year 2000 details over 
60 different artificial saliva compositions [205]. With such a vast array of simulated 
salivary fluids to choose from, it is challenging for one to select the most appropriate 
one for dissolution testing. For best correlation with human saliva, the in vitro media 
should represent the in vivo fluid as closely as possible. Thus the most biorelevant SSF 
should be selected. In order to select the media which mimics human saliva the 
closest, one first needs to understand the key characteristics of human saliva.  
A number of parameters can be considered as highly influential on dissolution. The 
pH, buffer capacity and surface tension have been identified as some of the most 
important factors [206]. Additionally, viscosity is considered in many cases [207]. 
Furthermore, Wang et al. described biorelevant dissolution and suggested 
consideration of pH, buffer capacity, surface tension and viscosity of the medium to 
be paramount for biorelevant dissolution testing (along with non-medium related 
hydrodynamic factors such as volume, flow, agitation and apparatus) [208]. The 
importance of these particular parameters is evident as similar approaches have 
been adopted in the characterisation of other gastrointestinal fluids, leading to the 
development of other simulated biological fluids [95, 189, 190, 209-212]. By 
investigating the same characteristics, one is also able to compare saliva to other 
biological or simulated biological fluids.  
A literature search was carried out to investigate the pH, buffer capacity, surface 
tension, viscosity, and, to aid model development in later stages, flow rate for human 
saliva and SSFs. This allows one to draw direct comparisons between the 
characteristics of human and artificial saliva, thus supporting the selection of the 
most appropriate SSF.  
The pH of a dissolution medium is important since it affects ionisation of the API, 
according to the Henderson-Hasslebalch equation, and ionisation is directly linked 
with the aqueous solubility of an API [2]. Of equal importance therefore is the ability 
of the medium to resist changes in pH as an acidic or basic drug begins to dissolve, 
i.e. the medium’s buffer capacity.  This was demonstrated by Tsume et al. [213] who 
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performed dissolution experiments in media of different buffer capacities with the 
acidic drug ibuprofen and found that when the buffer capacity was low, the pH 
decreased to a greater extent as dissolution proceeded, which hindered the rate and 
extent of further dissolution.  
The pH of human saliva has been described previously, with varying results in the 
wide range of 5.3 to 7.8, depending on the stimulation state [95, 192]. The findings of 
our preliminary literature search are shown in Table 3.1. As seen in this Table, in most 
studies, either unstimulated saliva (US) or stimulated saliva (SS) was investigated, but 
not both [90, 176]. We noted at this point that there may be significant differences in 
the characteristics of human saliva relevant to dissolution in different stimulation 
states. Additionally, the only study in which the pH of both types of saliva was 
investigated experimentally, by  Bardow et al. [173] had only a small number of 
participants, and focussed on just two salivary characteristics relevant to dissolution 
testing - the pH and buffer capacity. With so little consensus on the pH of human 
saliva, and limitations in methodology or study design employed, we decided to 
design and carry out our own characterisations of human saliva. We therefore aim to 
characterise the pH of both US and SS, as well as other key parameters within the 
same sample. 
Table 3.1: pH of human saliva from literature values. (US = unstimulated saliva, SS = 
stimulated saliva). 
Reference 
Type of 
Saliva 
Measure 
Quoted 
Value 
Standard 
deviation 
pH Range 
Aframian, Davidowitz 
and Benoliel [90] 
US 
Mean 
(N = 50) 
6.78 0.04 6.24 – 7.36 
Fenoll-Palomares et 
al. [89] 
US 
Mean 
(N = 159) 
6.79 0.29 5.86 - 7.54 
Shpitzer et al. [96] US 
Median 
(N = 25) 
6.4 - 5.5 – 7.3 
Kazakov et al. [192] US 
Mean 
(N = 142) 
6.77 0.33 6.13 – 7.53 
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Reference 
Type of 
Saliva 
Measure 
Quoted 
Value 
Standard 
deviation 
pH Range 
Emekli-Alturfan et al. 
[92] 
US 
Mean 
(N = 11) 
7.4 0.44 - 
Bardow et al. [173] 
US 
Mean 
(N = 20) 
6.8 0.3 - 
SS 
Mean 
(N = 20) 
7.2 0.2 - 
Whelton [168] 
US 
Mean 
(review) 
7.04 0.28 - 
SS 
Mean 
(review) 
7.61 0.17 - 
Madsen et al. [214] SS 
Mean 
(N = 12) 
6.83 0.4 - 
Christersson et al. 
[176] 
SS 
Mean 
(N = 3) 
7.4 - - 
Kalantzi et al. [95] All 
Mean 
(review) 
- - 5.45 – 7.8 
Patel, Liu and Brown 
[136] 
All 
- 
(review) 
- - 5.5 - 7.0 
Humphrey and 
Williamson [167] 
All 
- 
(review) 
- - 5.3 - 7.8 
 
Buffer capacity has been investigated in numerous studies. However, as discussed in 
Chapter 2, in most cases the experimental design employed does not allow one to 
draw conclusions about the actual buffer capacity value or range. Literature values 
are reported in different ways. Some research groups have simply quoted the buffer 
capacity to be high, medium or low, without providing any actual value [185]. Thus 
one cannot draw direct comparisons between studies. Some researchers simply state 
the bicarbonate concentration of saliva samples to infer buffer capacity [89]. 
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Furthermore, in some cases, buffer capacity is quoted in mmol L-1 pH-1 [173, 187]. 
The lack of similarity in experimental design has led to inconclusive findings regarding 
the buffer capacity of saliva. This research aims to address these issues by assessing 
the buffer capacity of saliva using similar experimental design to that used for other 
gastrointestinal fluids [159, 162, 189, 190] to allow for comparison.  
Viscosity is another key parameter affecting dissolution. A high viscosity medium 
would increase the thickness of the boundary layers (h) and decrease the diffusion 
coefficient (D) according to the Noyes – Witney dissolution model, thus reducing the 
drug dissolution rate compared with a medium of lower viscosity [215]. Despite 
viscosity of stimulated and unstimulated whole human saliva being evaluated by 
several research groups, no consensus has been reached on human saliva viscosity 
due to differences in experimental conditions. For example, in a review by Schipper 
et al. [182] viscosity of unstimulated whole saliva was found to be 1.5 - 1.6 mPa.s 
over a shear rate of 1 - 300 s-1 in one study [216]. However another study found it to 
range from 3.8 to 8.8 mPa.s at a single shear rate of 90 s-1 [172] and a viscosity of 100 
mPa.s was recorded at a shear rate of 0.02 s-1 in another study [217] within this 
review. Research groups used different shear rates, temperatures and types of 
rheometer and often small sample sizes. This research aims to address these issues 
by using physiological temperature and assessing viscosity across a wide range of 
shear rates.  
It is well known that the surface tension of the medium also affects the rate of 
dissolution [211]. A high interfacial tension reduces wetting of the drug particles and 
reduces the rate of dissolution. Wetting can be improved by the addition of 
surfactants, reducing interfacial tension and increasing the rate of dissolution, and it 
is a common practice to add surfactants to dissolution media [218]. Although many 
studies have investigated the film forming properties of saliva, as well as salivary 
pellicle thickness and composition [219], few studies have focussed on the surface 
tension of whole human saliva [192] and none have investigated the unstimulated vs. 
stimulated surface tension of whole saliva. Literature regarding the surface tension of 
saliva uses variable experimental designs including different temperatures and sites 
in the oral cavity, and often small or non-specified numbers of participants [171, 
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220]. Further clarification of this parameter is therefore required, using a sufficient 
number of samples and physiologically relevant temperature.  
Despite not directly affecting media choice and composition, salivary flow rate is an 
important factor when developing a biorelevant dissolution model [208]. The volume 
available for dissolution, or flow rate, should reflect physiological conditions since 
this affects the concentration gradient of solvated API molecules and saturation of 
the bulk fluid.  Salivary flow rate has been investigated; however, most groups 
investigated either US [90] or SS [221] as shown in Table 3.2. Since inter-individual 
variation is so vast in these studies, flow rate should be considered for US and SS in 
the same individual to allow accurate comparison of stimulation states.  
Table 3.2: Flow rate of human saliva from literature values. (US = unstimulated saliva, 
SS = stimulated saliva).  
 
 
Reference 
Type of 
Saliva 
Measure 
Quoted 
Value 
(mL/min) 
Standard 
deviation 
Range 
(mL/min) 
Aframian, 
Davidowitz and 
Benoliel [90] 
US 
Mean 
(N = 50) 
0.37 0.21 0.05 – 0.95 
Fenoll-
Palomares et al. 
[89] 
US 
Median 
(N = 159) 
0.48 - 0.1 – 2.0 
Rudney, Ji and 
Larson [91] 
US 
Mean, 
Median 
(N = 128) 
0.56, 
0.41 
0.41 0.10 – 2.87 
Emekli-Alturfan 
et al. [92] 
US 
Mean 
(N = 11) 
0.52 0.38 - 
Hershkovich 
and Nagler 
[166] 
US 
Mean, 
Median 
(N = 90) 
0.34, 
0.24 
- 0.04 – 1.5 
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Reference 
Type of 
Saliva 
Measure 
Quoted 
Value 
(mL/min) 
Standard 
deviation 
Range 
(mL/min) 
Del Vigna de 
Almeida et al. 
[165] 
US 
Range 
(review) 
- - 
0.1 – 0.35 
Hyposalivation 
if < 0.1 
SS 
Range 
(review) 
- - 
0.7 – 3.0 
Hyposalivation 
if < 0.7 
Bardow et al. 
[173] 
US 
Mean 
(N = 20) 
0.55 0.19 - 
SS 
Mean 
(N = 20) 
1.66 0.67 - 
Humphrey and 
Williamson 
[167] 
US 
Mean 
(review) 
0.3  
Hyposalivation 
if < 0.1 
SS 
Max. 
(review) 
7.0 - - 
Inoue et al. 
[175] 
US 
Mean 
(N = 51) 
0.43 0.23 - 
SS 
Mean 
(N = 51) 
1.71 0.87 - 
Whelton [168] 
US 
Mean 
(review) 
0.32 0.23 - 
SS 
Mean 
(review) 
2.08 0.84 - 
Rantonen [222] 
 
US 
Range of 
means 
(review) 
0.17 – 
0.39 
0.16 – 
0.23 
- 
SS 
Range of 
means 
(review) 
 
1.49 – 
1.87 
0.6 – 
0.92 
- 
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No single SSF has been evaluated for all of these parameters in the literature, with a 
single characteristic being reported for a specific SSF in many cases. Despite the wide 
range of artificial salivas (SSFs) available, these have generally been developed for 
different applications other than dissolution testing. For example, artificial salivas are 
used clinically for the treatment of xerostomia. Consequently, the film forming and 
lubricating properties of such formulations are of paramount importance, but 
perhaps the buffer capacity for example may have been overlooked. Electrolyte 
solutions are often used for dental applications such as erosion studies, and do not 
consider the viscosity or surface tension. Whilst it is possible that some of the 60 
compositions in the review article may be appropriate for dissolution studies, 
information regarding parameters key to dissolution testing is not available [205]. It is 
also difficult to select the single most appropriate SSF without a clear understanding 
of human salivary characteristics.  
The aim of this work was therefore to characterise stimulated and unstimulated 
human saliva for the key characteristics relevant to dissolution to provide a platform 
of reference for the future selection or development of oral dissolution media that 
would be representative of human saliva. The saliva flow rate was assessed in this 
work to aid development of oral dissolution models. Age and gender related 
differences were also investigated for each parameter. To the best of our knowledge, 
this is a first work in which the key parameters relevant to drug dissolution - pH, 
buffer capacity, viscosity, surface tension and flow rate - are assessed simultaneously 
Reference 
Type of 
Saliva 
Measure 
Quoted 
Value 
(mL/min) 
Standard 
deviation 
Range 
(mL/min) 
Delvadia et al. 
[133] 
SS 
Mean 
(review) 
0.9 0.094 - 
Erdem, Yildiz 
and Erdem 
[221] 
SS 
Mean 
(N = 40) 
1.41 0.50 - 
Schipper et al. 
[182] 
All 
Range 
(review) 
- - 0.2 – 7.0 
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for both stimulated and unstimulated whole human saliva with a sufficient number of 
participants to draw statistically meaningful conclusions.  
In addition, to aid selection or development of a suitable SSF to represent human 
saliva, we characterised SSFs under the same conditions as human saliva to allow for 
direct comparison. There is a vast array of SSFs available for analysis. However, they 
can broadly be categorised into three main types: simple electrolyte solutions, SSFs 
containing the viscosity modifying polymer carboxymethylcellulose, and SSFs 
containing viscosity modifying mucins. We selected one SSF from each class for 
characterisation: phosphate buffered saline from the British Pharmacopoeia [223], 
Glandosane® as a carboxymethylcellulose containing SSF, and Saliva Orthana® spray 
which contains mucin. These SSFs were selected to represent each category since 
their full quantitative composition was available to us. CCMed® supplied Saliva 
Orthana® spray free of charge and also requested that we characterise Saliva 
Orthana® gel, which has the same composition as the spray except for the addition of 
xanthan gum in the gel. This is also a first work in which SSFs have been compared to 
both unstimulated and stimulated human saliva for the four key characteristics 
relevant to drug dissolution.  
3.2 Aims 
The aims of this chapter are: 
 To characterise both stimulated and unstimulated human saliva from the 
same participants for key characteristics relevant to dissolution, with a 
sufficiently large sample to draw statistically meaningful conclusions 
 To understand how age and gender influence salivary characteristics 
 To evaluate the suitability of existing SSFs to represent human saliva 
 
3.3 Methods  
All methods relevant to this Chapter are detailed in Chapter 2. Refer to sections 2.1 
to 2.8 including specific sections regarding “Trial 1”.  
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3.4 Results  
3.4.1 pH 
3.4.1.1 Human Saliva 
SS had a higher pH than US (Figure 3.1) and a statistically significant difference was 
observed between the two groups according to a paired t-test (p < 0.0001). 
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Figure 3.1: pH of US and SS. Box represents median value, 25th and 75th percentile. 
Whiskers represent maximum and minimum values. N = 30, triplicate. (US = 
unstimulated saliva, SS = stimulated saliva). **** significant difference (p < 0.0001, 
paired t-test). The saliva of the investigator (relevant for Chapter 6) had mean pH 
values of 6.8 and 7.3 for US and SS respectively.  
 
No significant difference in pH was observed between males and females for either 
US or SS. Similarly, no significant difference in pH was observed between age groups 
for US or SS (Table 3.3). 
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Table 3.3: pH of Human Saliva. (US = unstimulated saliva, SS = stimulated saliva).  
 US pH Mean (S.D.) SS pH Mean (S.D.) 
All participants (N = 30) 6.97 (0.20)a 7.40 (0.21) 
Male (N = 13) 7.02 (0.23) 7.40 (0.16) 
Female (N = 17) 6.93 (0.17) 7.39 (0.25) 
Age 20 - 27 (N = 22) 6.97 (0.18) 7.40 (0.21) 
Age 28 - 35 (N = 8) 6.98 (0.25) 7.40 (0.20) 
All measurements are in triplicate. a significantly different to SS (p < 0.0001, paired t-
test).  
3.4.1.2 Simulated Salivary Fluids 
The pH of SSFs was measured and results are shown in Figure 3.2 below. Due to the 
limited number of batches, an ANOVA statistical test across all groups is not 
appropriate as results represent one batch of each SSF with the exception of PBS 
where N = 5. Therefore, each SSF was compared as a control group to human saliva in 
both the stimulation states.  
Figure 3.2: pH of SSFs and human saliva. Data represents mean +/- S.D. N = 30 for 
human saliva, triplicates, N = 5 for PBS, quintuplicate, otherwise N = 1, quintuplicate. 
(PBS = phosphate buffered saline, GLN = Glandosane®, SOS = Saliva Orthana® spray, 
SOG = Saliva Orthana® gel, US = unstimulated saliva, SS = stimulated saliva, SSF = 
simulated salivary fluid).  
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3.4.2 Buffer Capacity 
3.4.2.1 Human Saliva 
The buffer capacity was found to be significantly different for US and SS (paired t-
test, p < 0.0001), with SS having a much greater buffer capacity, as shown in Figure 
3.3.  
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Figure 3.3: Buffer capacity of US and SS. Box represents median value, 25th and 75th 
percentile. Whiskers represent maximum and minimum values. N = 30, duplicates. 
(US = unstimulated saliva, SS = stimulated saliva). **** significant difference (p < 
0.0001, paired t-test). The saliva of the investigator (relevant for Chapter 6) had 
mean buffer capacity values of 3.8 and 8.3 mmol H+/L for US and SS respectively. 
 
No significant difference in buffer capacity was observed for US between males and 
females. However, a significant difference in buffer capacity was observed for SS 
between males and females (unpaired t-test, p < 0.05). No significant difference in 
buffer capacity was observed between different age groups for US or SS (Table 3.4).  
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Table 3.4: Buffer Capacity of Human Saliva. (US = unstimulated saliva, SS = stimulated 
saliva).  
 US buffer capacity (mmol 
H+/L) Mean (S.D.) 
SS buffer capacity (mmol 
H+/L) Mean (S.D.) 
All participants (N = 30) 5.93 (1.78)a 8.41 (2.02) 
Male (N = 13) 6.60 (1.73) 9.39 (1.31)b 
Female (N = 17) 5.42 (1.72) 7.66 (2.18) 
Age 20 - 27 (N = 22) 5.83 (1.76) 8.44 (2.25) 
Age 28 - 35 (N = 8) 6.21 (1.99) 8.31 (1.32) 
All measurements are in duplicate. a significantly different to SS (p < 0.0001, paired t-
test) b significantly different to SS female (p < 0.05, unpaired t-test). 
 
3.4.2.2 Simulated Salivary Fluids 
The buffer capacity of the SSFs varied greatly, with PBS and SOG appearing the most 
similar to human saliva values according to characterisations on a limited number of 
batches, as shown in Figure 3.4 below. PBS did not have a statistically significant 
difference to SS but was found to be significantly different to US according to ANOVA 
(p < 0.05). As with other characterisations, statistical analysis could not be used to 
compare the other SSFs with human saliva at this stage since only one batch was 
analysed. However, Glandosane® and SOS showed distinct differences in buffering 
capability compared to human saliva. All of the SSFs are based on a phosphate buffer 
and not bicarbonate.  
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Figure 3.4: Buffer capacity of SSFs and human saliva. Data represents mean +/- S.D. N 
= 30 for human saliva, duplicate. N = 5 for PBS, quintuplicate, otherwise N = 1, 
quintuplicate. (PBS = phosphate buffered saline, GLN = Glandosane®, SOS = Saliva 
Orthana® spray, SOG = Saliva Orthana® gel, US = unstimulated saliva, SS = stimulated 
saliva, SSF = simulated salivary fluid).  
 
3.4.3 Surface Tension 
3.4.3.1 Human Saliva  
The surface tension for US and SS are shown in Figure 3.5. The surface tension of US 
was very similar to SS, with no significant difference observed between the two types 
of saliva (paired t-test). Note the variability between individuals in surface tension of 
saliva was very low.  
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Figure 3.5: Surface tension of US and SS. Box represents median value, 25th and 75th 
percentile. Whiskers represent maximum and minimum values. N = 30, quintuplicate. 
(US = unstimulated saliva, SS = stimulated saliva). No significant difference in surface 
tension between US and SS (paired t-test). The saliva of the investigator (relevant for 
Chapter 6) had mean surface tension values of 58.8 and 59.4 mN/m for US and SS 
respectively. 
 
The surface tension of human saliva (Table 3.5) showed no significant difference 
between males and females for US or SS. In addition, no significant difference in 
surface tension of human saliva was observed between different age groups for US or 
SS. 
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Table 3.5: Surface Tension of Human Saliva. (US = unstimulated saliva, SS = 
stimulated saliva).  
 US Surface Tension 
mN/m Mean (S.D.) 
SS Surface Tension mN/m 
Mean (S.D.) 
All participants (N = 30) 58.98 (2.18) 59.69 (2.71) 
Male (N = 13) 58.71 (2.06) 59.19 (3.43) 
Female (N = 17) 59.18 (2.30) 60.07 (2.03) 
Age 20 - 27 (N = 22) 58.86 (2.13) 59.49 (2.34) 
Age 28 - 35 (N = 8) 59.30 (2.40) 60.22 (3.67) 
All measurements are in quintuplicate. No significant difference between US and SS 
for all participants. No significant differences observed between males and females, 
or between age groups for US or SS.  
 
3.4.3.2 Simulated Salivary Fluids 
The SSFs were compared as a control group to human saliva. The results are shown in 
Figure 3.6 below. PBS was compared to US and SS using an analysis of variance 
(ANOVA) test. A statistically significant difference was observed for PBS compared to 
both US and SS (p < 0.05). However, at this time, we are unable to perform statistical 
tests for other SSFs due to the low number of batches assessed. Preliminary data 
suggests Saliva Orthana® gel was the most different to human saliva and no 
particular SSF was a clear closest match. 
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Figure 3.6: Surface tension of human saliva and SSFs. Data represents mean +/- S.D. 
N = 30 for human saliva, N = 5 for PBS, otherwise N = 1, all quintuplicate. (PBS = 
phosphate buffered saline, GLN = Glandosane®, SOS = Saliva Orthana® spray, SOG = 
Saliva Orthana® gel, US = unstimulated saliva, SS = stimulated saliva, SSF = simulated 
salivary fluid).  
 
3.4.4 Viscosity 
3.4.4.1 Human Saliva 
The viscosity of US and SS are described in Figure 3.7. SS was shown to have a lower 
viscosity, and a statistically significant difference in viscosity was observed between 
US and SS at every shear rate recorded with p < 0.0001 (Wilcoxon matched pairs 
test).  
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Figure 3.7: The viscosity of US and SS at different shear rates. Data represents mean 
+/- S.D. N = 30, triplicates. (US = unstimulated saliva, SS = stimulated saliva). A 
statistically significant difference in viscosity was observed between US and SS at 
every shear rate recorded (p < 0.0001, Wilcoxon matched pairs test). The saliva of the 
investigator (relevant for Chapter 6) had mean viscosity values within one standard 
deviation of the mean for both US and SS respectively.  
 
A statistically significant difference (Mann Whitney test, p < 0.05) in US viscosity was 
observed between males and females at 5 shear rates in the lower shear rate range, 
with male saliva showing higher viscosity (Figure 3.8 A). This trend appears to 
continue across the remainder of the viscosity profile. Practically no difference was 
observed for SS between male and female groups, with a statistically significant 
difference (Mann Whitney test, p < 0.01) observed at just one shear rate (Figure 3.8 
B).  
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Figure 3.8: The viscosity of US (panel A) and SS (panel B) for males (N = 13, triplicates) 
and females (N = 17, triplicates) at different shear rates. Data represents mean +/- 
S.D. (US = unstimulated saliva, SS = stimulated saliva). * significant difference 
between males and females (Mann Whitney test, p < 0.05).  
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The viscosity of US was significantly higher for the age group 28 - 35 compared to 20 
– 27 at 3 shear rates (Mann Whitney test, p < 0.05, Figure 3.9 A). This trend also 
appears to continue across the rest of the viscosity profile. For SS, no significant 
difference was observed between the two age groups (Figure 3.9 B). 
 
 
                                                                         
 
 
 
 
Figure 3.9: The viscosity of US (panel A) and SS (panel B) for participants age 20 - 27 
(N = 22, triplicates) and age 28 - 35 (N = 8, triplicates) at different shear rates. Data 
represents mean +/- S.D. (US = unstimulated saliva, SS = stimulated saliva). * 
significant differences between age groups (Mann Whitney test, p < 0.05).  
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3.4.4.2 Simulated Salivary Fluids 
The four SSFs were compared with US and SS under the same conditions. The SSFs 
demonstrated a variety of behaviours, some being Newtonian (PBS, SOS) and some 
being Non-Newtonian (SOG, Glandosane®) in which shear thinning is observed. 
Glandosane® results were not plotted due to the large variability in results, probably 
due to shearing when sprayed from its container. As seen in Figure 3.10 below, no 
particular SSF was a close match for human saliva, indicating the need for 
development of a novel biorelevant SSF. Water was also plotted as a control.  
 
 
 
 
 
 
 
Figure 3.10: SSF and human saliva viscosity. Data represents mean +/- S.D. N = 30 for 
human saliva, triplicates, N = 5 for PBS, triplicates, otherwise N = 1, quintuplicate. 
(PBS = phosphate buffered saline, SOS = Saliva Orthana® spray, SOG = Saliva 
Orthana® gel, US = unstimulated saliva, SS = stimulated saliva, SSF = simulated 
salivary fluid).  
 
3.4.5 Flow Rate 
As anticipated, the flow rate of SS was significantly greater than US, shown in Figure 
3.11 (paired t-test, p < 0.0001). 
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Figure 3.11: Flow rate of US and SS. Box represents median value, 25th and 75th 
percentile. Whiskers represent maximum and minimum values. N = 30, triplicates. 
(US = unstimulated saliva, SS = stimulated saliva). **** significant difference (p < 
0.0001, paired t-test). The saliva of the investigator (relevant for Chapter 6) had 
mean flow rate values of 0.5 and 1.4 mL/min for US and SS respectively. 
 
No significant difference in flow rate was observed between males and females for 
US or for SS. Similarly, no significant difference in flow rate was observed between 
age groups for US or SS (Table 3.6).  
Table 3.6: Flow Rate of Human Saliva. (US = unstimulated saliva, SS = stimulated 
saliva).  
 US flow rate (mL/min)  
Mean (S.D.) 
SS flow rate (mL/min)  
Mean (S.D.) 
All participants (N = 30) 0.58 (0.24)a 1.51 (0.72) 
Male (N = 13) 0.65 (0.20) 1.60 (0.63) 
Female (N = 17) 0.52 (0.26) 1.44 (0.79) 
Age 20 - 27 (N = 22) 0.57 (0.22) 1.46 (0.66) 
Age 28 - 35 (N = 8) 0.61 (0.28) 1.64 (0.88) 
All measurements are in triplicate. a significantly different to SS (p < 0.0001, paired t-
test). 
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3.5 Discussion 
3.5.1 pH 
The pH of SS was found to be significantly higher than US. This can be attributed to 
differences in electrolyte composition, including a greater bicarbonate concentration 
in SS [168]. The pH of saliva is modified as it moves through the duct system within 
salivary glands by the secretion and reabsorption of electrolytes, depicted in Figure 
3.12. Initially, an isotonic fluid is released in the secretory acinus. As fluid travels 
along the duct, reabsorption of some ions such as sodium and chloride, and secretion 
of others such as bicarbonate and potassium occurs, until a hypotonic solution is 
released from the duct [167]. 
 
Figure 3.12: Structure of a single salivary gland acinus and duct showing ion 
movement. Modified from Gibson and Beeley [97]. 
 
Each acinus may contain only serous cells, mucous cells or both. Serous secretions 
are rich in electrolytes and enzymes, whereas mucous secretions are rich in 
glycoproteins. The parotid gland has predominantly serous secretion. Upon 
stimulation of saliva, there is a greater parotid gland output, thus a greater release of 
bicarbonate rich serous secretion. This coincides with a lower mucin concentration 
for SS which also affects viscosity, as discussed in section 3.3.4 [167]. 
Literature stating the pH of human saliva reports variable values that range from 5.3 
to 7.8 depending on the stimulation state [90, 176, 192]. A detailed analysis of 
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literature values for the pH of human saliva was provided in Table 3.1 which can be 
used for comparison with our results. We found US and SS to be within the literature 
range, with mean values of 6.97 and 7.40 for US and SS respectively (range US: 6.49 – 
7.28, range SS: 6.96 – 7.69). It thus would be advisable to select or develop artificial 
salivas as a dissolution media with pH values to reflect these findings.  
The pH of phosphate buffer was unsurprisingly closest to that of human saliva. PBS 
was compared as a control group to US and SS using ANOVA. It was found only to be 
significantly different to SS (p < 0.05). This is because after reviewing the literature, 
pH 6.8 was chosen since this was within literature values for human saliva. PBS was 
made up in the laboratory to this pH. Saliva Orthana® Gel, being an unlicensed, 
unmarketed product at the moment does not have any literature in which the pH has 
been characterised. According to the manufacturers of Saliva Orthana® products 
(CCMed), both products should be in the pH range 6.5 - 7.5. However, we found the 
pH values to be lower than this, with the gel being the lowest at a mean pH of 5.12 
and spray at a mean pH of 5.91. Other research groups have characterised the pH of 
Saliva Orthana® Spray. Christersson et al. [88] found it to be 5.7, whilst Madsen et al. 
[87] found it to be 5.9. Thus it is reassuring to know that other research groups also 
found the pH to be outside the manufacturer’s specification. Characterisation of 
several batches of each SSF may help us to understand the variability in these 
commercial products. Finally, Glandosane® pH is reported to be 5.75 [63], however 
we reported the mean pH value to be 5.40. Difficulties in the analysis of Glandosane® 
were encountered due to it being contained in a pressurised vessel, and sprayed 
propelled by carbon dioxide, which may explain the slightly lower pH in our 
characterisation compared to manufacturers reports. This spraying of Glandosane® 
also caused difficulties in the rheological analysis as discussed in section 3.3.4.  
To the best of our knowledge, the pH of saliva is not known to directly affect 
reception or perception of bitter tastant molecules directly. However, it is reported 
to affect sourness perception. Sour tastant molecules are often weak acids, with the 
degree of acidity being proportional to the proton concentration. In stimulated saliva, 
a greater bicarbonate proportion is present, thus increasing the pH and buffer 
capacity of stimulated saliva. This counteracts the acidity of solutions containing sour, 
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acidic components. Therefore, an increasing salivary pH has been reported to 
correlate with a diminished sour taste perception [224].  
The data shows notable differences in pH for all SSFs when compared to US and SS. 
However, we were unable to confirm these statistically except for PBS which was not 
found to be significantly different to US, but was for SS. The Saliva Orthana® products 
were donated free of charge by the supplier, who were unable to provide sufficient 
batches to allow for statistical analysis.  Based on pH alone, PBS appeared to be the 
most suitable SSF to represent human saliva in dissolution testing. However, all other 
parameters should be considered together.  
3.5.2 Buffer Capacity 
The greater buffer capacity of SS can also be attributed to the higher bicarbonate 
concentration. Bicarbonate contributes approximately 80 % of the overall buffering 
capacity of human saliva [225], and is found in higher concentrations in SS due to the 
higher proportion of parotid gland secretions [185]. It should be noted that unlike pH 
which was measured immediately upon collection, buffer capacity was measured 
after flash freezing and short term storage at -80 °C. The bicarbonate buffer is a 
dynamic system and in liquid saliva samples, carbon dioxide may be lost from the 
system. Although we do not anticipate the buffer capacity to alter as a result of 
freezing, this could be considered a limitation of the study. However, as discussed in 
Chapter 2, no significant difference was observed in the same sample when the pH 
was compared before and after freezing, storage and defrosting.  
A direct comparison with other literature is challenging due to methodological 
differences. Nevertheless, the approach used here was also used by Bardow et al. 
[173] who found the buffer capacity to range from 3.1 to 6.0 mmol H+/L of saliva in 
US and 3.3 to 8.5 mmol H+/L of saliva in SS depending on the pH. This is comparable 
to our values, since we found mean values to be 5.93 and 8.41 mmol H+/L of saliva 
for US and SS respectively. In both cases, SS buffer capacity is higher than US. Despite 
methodological differences, this was also true for other literature [185]. However, we 
found buffer capacity to be highly variable for both US and SS, with relative standard 
deviation being 30.29 % and 24.08 % for US and SS respectively. This demonstrates a 
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high inter-individual variation, which should be taken into account when designing a 
dissolution medium.  
The buffer capacity of the SSFs varied greatly, with PBS and SOG appearing the most 
similar to human saliva values according to characterisations on a limited number of 
batches. PBS did not have a statistically significant difference to SS but was found to 
be significantly different to US according to ANOVA (p < 0.05). As with other 
characterisations, statistical analysis could not be used to compare the other SSFs 
with human saliva at this stage. However, Glandosane® and SOS showed distinct 
differences in buffering capability compared to human saliva. Interestingly, all of the 
SSFs are based on a phosphate buffer and not bicarbonate. Additionally, buffer 
capacity of SSFs does not appear to be well documented in literature.  
3.5.3 Surface Tension 
The mean value for US was 58.98 mN/m whilst SS was slightly higher at 59.69 mN/m. 
Literature reports variable values, however our results are similar to some other 
research groups. For example, Kazakov et al. [192] measured the surface tension of 
US at room temperature and found that it ranged from 68.7 to 44.9 mN/m depending 
on the time after surface formation, with highest values being obtained at 1 s after 
surface formation, and lowest values representing time infinity after surface 
formation. Kirkness et al. found US surface tension to have a more similar mean value 
to us at 57.4 mN/m in their year 2000 study [220], and 57.7 mN/m in 2005 [170]. 
However, these articles did not specify the number of samples or participants tested. 
Furthermore, for SS, Madsen et al. [214] found human saliva to have an equilibrium 
surface tension of 41.83 mN/m, whilst Christersson et al. [176] found it to range from 
56.2 mN/m at 30 s after surface formation to 48.5 mN/m at 600 s after surface 
formation.  
The exact composition of surface-active molecules responsible for the interfacial 
tension of saliva remains unclear. However, proteinaceous and glycoproteinaceous 
material has been attributed with surface activity according to numerous studies 
investigating the composition of salivary pellicle [226, 227] or salivary film formation 
[176, 228]. In particular, proline rich proteins are thought to be present at these 
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interfaces [229, 230]. There is also some suggestion of “surfactant associated 
proteins A, B, C and D” in saliva, which are not structurally or functionally described 
[231]. Moreover, lipidic material such as phospholipids, fatty acids and triglycerides 
are known to be present which may also play a role [192, 232]. Since we found no 
significant difference between US and SS, it is likely that the surface active 
components of human saliva remain approximately constant, regardless of the 
stimulation state. Therefore, SSFs representing US and SS should have the same 
surface tension as each other, and as human saliva.  
Characterisation of our chosen SSFs’ surface tension is not well documented in 
literature, with Saliva Orthana® spray receiving the most attention. Madsen et al. [87] 
also characterised the equilibrium surface tension of PBS and Saliva Orthana® spray 
and found them to be 69.7 and 31.3 mN/m respectively.  These values are slightly 
lower than those observed under our conditions, probably due to the time after 
surface formation. Meanwhile, Christersson et al. [88] characterised Saliva Orthana® 
spray and found at 30 s after surface formation, the surface tension was 41.9 mN/m, 
which is quite similar to our findings. Some researchers also characterised 
carboxymethylcellulose containing solutions, however, due to the differing 
electrolyte and carboxymethylcellulose content compared to Glandosane®, direct 
comparisons of the surface tension cannot be made [88, 89]. Based on surface 
tension alone, it is difficult to conclude which of the SSF best reflects the properties 
of human saliva, however, SOG appears to be the poorest match.  
3.5.4 Viscosity 
Human saliva was found to be non-Newtonian across the range of shear rates 
applied. As discussed in Chapter 2, the shear rates tested are likely to be in the range 
observed in the oral cavity since it has been suggested that a shear rate of 4 s-1 
corresponds to the movement of particles across the tongue whilst 60 s-1 and 160 s-1 
correspond to swallowing and speech respectively [193, 217]. Furthermore, shear 
rates between 10 and 500 s-1 have been proposed to mimic the range of shear rates 
in the mouth during eating [233]. US was shown to have a higher variability, with a 
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greater relative standard deviation observed for US than SS at all shear rates 
measured, with the exception of the very lowest shear rate.  
SS’s lower viscosity is proportional to its higher flow rate, leading to an increased 
aqueous content, and a lower concentration of mucins - glycoproteins with a 
polypeptide backbone and oligosaccharide side chains which are thought to be 
responsible for the viscosity of saliva [234]. It has been suggested that this is due to 
SS originating predominantly from different salivary glands compared to US [172]. SS 
has been suggested to have a larger proportion of parotid secretions. However, 
mucins are mainly secreted from the sublingual, submandibular and palatal glands 
[172]. Indeed, it is well documented that secretions from the main salivary glands 
have differing mucin proportions and thus differing viscosities. In some cases, parotid 
saliva has actually been shown to demonstrate Newtonian behaviour, further 
reinforcing the link between mucin presence and shear thinning behaviour [182, 
235]. 
In human saliva, there are two main types of mucin present: a high molecular weight 
(MW) mucin, MUC5B (MW 2 - 40 MDa), and a low molecular weight mucin, MUC7 
(MW approx. 150 kDa). The molecular structure of mucin is discussed in detail 
elsewhere by Haward et al. [20] One study investigated which of these types of 
mucin is responsible for modifying the viscosity of saliva. They established that 
MUC5B concentration increased linearly with viscosity, but MUC7 did not, thus it is 
likely that MUC5B is responsible for the viscosity of saliva [22].  
The results obtained in this study correspond well with other reports regarding the 
viscosity of US and SS since other research groups found SS to be of lower viscosity 
[175, 235]. The actual viscosity values for US and SS in literature vary depending on 
the type of viscometer, shear rates and temperature used. However, similar to other 
reports [234-236], we also observed non-Newtonian behaviour for human saliva. This 
is thought to be attributed to the destruction of the mucin networks within the 
samples which undergo breakdown upon shearing [182].  
It is clear from the graph that, as expected, PBS behaved similarly to water. The 
closest matches to human saliva were the Saliva Orthana® products. The gel also 
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contains xanthan gum, but is otherwise identical to the spray. This alters the viscosity 
profile from one demonstrating Newtonian behaviour to one of non-Newtonian 
nature. This indicates that xanthan gum is the component responsible for the shear 
thinning behaviour of the gel, although literature clearly describes the shear thinning 
properties of mucins [69, 74, 78, 82], which are present in both formulations. 
However, the rheological properties of mucins largely depend on the origin and type 
of mucin used. The mucin used in Saliva Orthana® products is porcine gastric mucin 
(PGM), 3.5 % (35 mg/mL). This has been shown to demonstrate a linear viscosity at all 
concentrations tested in one study (2, 4 and 8 % w/v), exerting Newtonian behaviour 
over a range of shear rates. On the other hand, in the same study, bovine 
submandibular mucin (BSM) (2 %) and 1:1 mixtures of PGM/BSM (2 %/2 %) showed 
clear shear thinning behaviour with a similar profile to whole human saliva [74]. In 
accordance with our findings, another study showed that Saliva Orthana® spray is 
Newtonian with approximately the same viscosity as observed under our conditions 
[69]. However, the authors of this paper also found both BSM and PGM solutions to 
demonstrate some degree of shear thinning behaviour at 5 mg/mL or less. 
Interestingly, the vehicle in which the mucins were dispersed made a difference to 
their results and may explain differences between this research and others.  
The differential effect on viscosity described earlier between MUC5B and MUC7 [78], 
coupled with the origin of the mucin effecting its rheological behaviour further 
reinforces the concept that mucins of different types have different effects on 
viscosity and should be selected very carefully in the design of a novel SSF.  
Glandosane® showed a huge variation in viscosity profiles, particularly below a shear 
rate of 100 s-1. Above this shear rate, viscosity became more constant, showing a 
linear profile with approximate viscosity of 4 mPa.s. This may be due to spraying 
before analysis, which is a high shear procedure and may cause some breakdown of 
the carboxymethylcellulose (CMC) polymer chains. Carboxymethylcellulose sodium is 
responsible for the viscosity of Glandosane® and is known to be non-Newtonian with 
viscosity being proportional to the concentration of CMC and temperature [83]. 
Glandosane® and other SSFs containing 1 % CMC were analysed by Vissink et al. [74] 
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and were found to be slightly shear thinning and therefore non-Newtonian with 
viscosity decreasing from 48 mPa.s to 25 mPa.s over the range 0.0175 - 94.5 s-1. 
None of the SSFs investigated were found to be suitable to represent human saliva 
based on their viscosity. In the development of a biorelevant SSF which better 
represents human saliva, it may be prudent to investigate combinations of mucin 
(perhaps of differing origins), xanthan gum or carboxymethylcellulose at different 
concentrations.  
3.5.5 Flow Rate 
The increased flow rate for SS results from the parasympathetic response to 
Parafilm® chewing which increases saliva output from the salivary glands, in 
particular the parotid gland. Inter-individual variability was high, with relative 
standard deviation being 41.0 and 47.5 % for US and SS respectively. In this study, US 
flow rate ranged from 0.23 – 1.10 mL/min with a mean value of 0.58 mL/min whilst 
SS flow rate ranged from 0.43 – 3.45 mL/min with a mean value of 1.51 mL/min.  
Literature is also highly variable, with one study finding a maximum US flow rate of 
2.87 mL/min [91], whilst mean SS flow rate was quoted to be just 0.9 mL/min in 
another study [133]. Across literature, salivary flow rate has been quoted to range 
from 0.05 to 7.0 mL/min [90, 222]. Literature values were previously detailed in Table 
3.2 and can be used for comparison with our findings.  
It is known that saliva undergoes diurnal changes in flow rate [222], and since a 
higher flow rate was associated with a higher pH, higher buffer capacity and lower 
viscosity in our study, the time at which saliva is collected may affect many of the 
other salivary parameters investigated. Thus, the time of collection was controlled 
and 3pm was chosen for practical reasons.  
There are three main mechanisms of salivary stimulation: mechanical, gustatory and 
olfactory [167].  Dissolution testers should consider whether the dosage form may 
stimulate saliva. Crucially, the presence of a dosage form in the oral cavity such as an 
orally disintegrating tablet or oromucosal formulation may stimulate the release of 
saliva and therefore it may be prudent to consider both US and SS when modelling 
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the oral cavity. Given that the flow rate and many other parameters are so variable 
for human saliva, this reinforces the requirement to model both the US and SS state 
since a single set of test conditions is unlikely to represent the range of salivary 
scenarios observed.  
Decreased salivary flow and dry mouth rate have been reported to be associated 
with taste abnormalities and taste dissatisfaction [237-239]. This is probably related 
to saliva’s action as a solvent for the dissolution of tastant molecules, and a carrier of 
such molecules to taste bud sites. Low salivary flow rates may provide less solvent for 
dissolution, and less mobility to the taste buds, therefore reducing the ability to taste 
the substance [224]. Low salivary flow rate is also sometimes associated with the 
sensation of a burning mouth – something which is occasionally attributed to 
treatment with certain APIs, thus it may not always be an iatrogenic phenomenon 
[239].  However, many other factors can result in taste abnormalities, such as iron 
deficiency, oral candidiasis, psychiatric stress, depression, presence of dentures 
covering entire hard palate, inadequacy in chewing, certain diseases and a number of 
medications, which should also be taken into account [237, 238, 240]. 
3.5.6 Effect of Age and Gender on Salivary Parameters  
We observed significant gender and age related differences in viscosity of US in the 
low shear rate region wherein viscosity was found to be higher for males and the 
older age group (even with the relatively narrow age range of volunteers). This low 
shear rate region may require further investigation as key differences between 
demographic groups are only seen in this region. Furthermore, when designing 
biorelevant dissolution media, this low shear rate region should be modelled 
accurately.  Little is understood about the effect of age and gender on saliva viscosity. 
Humphrey and Williamson [167] claim that mucin concentrations decrease with age, 
but also state that secretory hypofunction is not a normal age related phenomenon.  
No differences were observed in surface tension for any demographic group. 
Similarly to viscosity, little research has been carried out in this area. Kazakov et al. 
[192] found that equilibrium surface tension decreased with age, whereby age 5 - 9 > 
10 - 15 > 40 - 55 years. However, surface tension in the over 55 years group began to 
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increase so a linear relationship with age was not established. The effect of gender 
was also not considered in that study.  
Conversely, extensive literature exists detailing the influence of age or gender on 
flow rate. Despite this, age and gender related effects remain unclear due to 
conflicting reports [165]. In this study, no significant differences in flow rate were 
observed between males and females, or between the two age groups. Accordingly, 
other researchers also found flow rate was not affected by age [241] or gender [173]. 
However, some literature suggests that female gender correlates with lower flow 
rate [89, 242] which may be attributed to smaller salivary glands and a lower body 
mass index (BMI) [243, 244]. If this is true, it could be extrapolated from this that 
paediatrics or elderly people of low BMI may also have a smaller body mass and 
therefore smaller salivary glands and a lower flow rate. However, this is not proven 
by literature. Additionally, increased age has been reported to correspond with lower 
flow rates in some cases [89, 245]. In a review by Whelton [168], decreased salivary 
flow in older patients is described as being secondary to disease or medication rather 
than directly due to aging, and total flow is considered to be independent of age.  
No significant differences in pH or buffer capacity were found for any demographic 
group in this study except for SS buffer capacity, which was found to be higher for 
males than females. This is in agreement with Wikner and Soder [246] who found 
females had a lower SS buffer capacity. Fenoll-Palomares et al. [89] also found no 
significant differences in pH, and higher bicarbonate concentration in men than 
women. However, their findings were based on US only. Conversely, another report 
states gender had no effect on buffer capacity [173]. pH has been described as higher 
for males in some studies [242]. Additionally, literature describing the effect of age 
on pH [242] and buffer capacity [247] reaches no consensus. A review of paediatric 
gastrointestinal physiology data relevant to oral drug delivery [248] states the pH of 
human saliva across different age groups to be 7 for neonates (0 - 27 days), 7.1 for 
children (2 - 11 years), 7.4 for adolescents (12 - 18 years) and 6 - 7.4 for adults. This 
does not show any particular trend in saliva pH values across different ages. 
Additionally, the wider range stated for the adult population could perhaps be due to 
this population receiving the most extensive characterisation of salivary pH values.  
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In this research, for the first time the effect of both age and gender on salivary key 
parameters for dissolution testing was investigated. The age and gender related 
differences observed were not as distinct as the differences between US and SS. 
Therefore, the development of two different biorelevant dissolution media 
representing US and SS is strongly recommended, whilst age and gender related 
differences should be kept in mind and may require further investigation. This is 
particularly prudent since taste masked and alternative oral formulations are most 
commonly used in the paediatric and geriatric population. To note, a limitation of this 
study is the relatively narrow age range employed. This is a result of recruiting unpaid 
volunteers from within the University. Further investigations of these key parameters 
in human saliva in a wider age range would be necessary in order to confirm trends 
seen in the data. However, it is worthy to note that should the paediatric and 
geriatric population be investigated, it would be inappropriate to make conclusions 
about each of those populations as a single group compared to the adult population. 
For example, a single “paediatric dissolution media” or “paediatric model” is 
unadvisable since a neonate differs greatly in physiology, body mass and 
pharmacokinetics to an infant or teenager, and salivary parameters may vary greatly 
too. 
3.6 Conclusions 
US and SS were found to be significantly different to each other for pH, buffer 
capacity and flow rate, with SS being higher for these characteristics.  No significant 
difference was seen between US and SS for surface tension. SS had lower viscosity 
with significant differences between US and SS observed across all shear rates 
measured. US and SS were both found to be non-Newtonian. Significant age and 
gender related differences were observed in some parameters but were not as 
distinct as differences between US and SS and may require further investigation. 
None of the four simulated salivary fluids characterised in this study were found to 
represent human saliva adequately based on key parameters relevant to dissolution. 
These SSFs represent the three main types of artificial saliva available. Therefore the 
development of a novel, biorelevant SSF is indicated.  
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These findings can be used as a platform of reference for the development of future 
dissolution media representing human saliva. Since SS was found to be significantly 
different to US for all of the assessed characteristics except surface tension, this 
suggests the potential requirement for the development of two different biorelevant 
dissolution media: one representing US with a lower pH and buffer capacity but 
higher viscosity, and one representing SS with a higher pH and buffer capacity, but 
lower viscosity.  
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Chapter 4: Conversion from Unstimulated Saliva to Stimulated Saliva in Human 
Volunteers 
4.1 Introduction 
Biorelevant dissolution tests simulating the oral cavity can be used to assess the taste 
masking efficacy or dissolution of alternative oral dosage forms such as 
microparticulates or ODTs as discussed in Chapter 1.  
If the amount of API released in a simulated oral environment is below its bitterness 
threshold, taste masking is achieved. This provides a robust, reproducible, analytical 
approach which circumvents issues associated with in vivo taste testing such as cost 
and ethical considerations. However, there are no pharmacopoeial recommendations 
for dissolution testing methodology or choice of media for the assessment of taste 
masked formulations [116]. 
For optimal predictability, the dissolution media should resemble human saliva as 
closely as possible. Until recently, no consensus had been reached on the key 
properties of human saliva that are likely to affect dissolution. We recently observed 
significant differences between US and SS for pH, buffer capacity, viscosity and flow 
rate. This suggested the requirement for SSFs representing both stimulation states. 
However, despite an array of SSFs being available, to our knowledge, no SSFs 
currently represent the US and SS states for parameters likely to influence dissolution 
such as pH, buffer capacity, surface tension and viscosity.  
It could be argued that the presence of a dosage form in the oral cavity may 
immediately stimulate saliva, and that saliva may remain in the stimulated state for 
the likely duration in which particles reside in the oral cavity. However, to our 
knowledge, the effect of placing a dosage form in the oral cavity on the stimulation of 
saliva has never been reported in literature. Thus testing in only SS could be 
appropriate. Consequently, to confirm the requirement for development of 
dissolution media representing both US and SS, the conversion from the 
unstimulated state to the stimulated state with respect to time was investigated.  
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Two different types of stimulation were evaluated: prolonged mechanical stimulation 
using Parafilm®, in line with previous research [202], and a single gustatory stimulant 
in the form of an ascorbic acid ODT in order to better represent the presence of a 
dosage form in the oral cavity. The rationale for the selection and type of ODT is 
described in Chapter 2, section 2.4.3. Rationale for experimental design is also 
discussed in Chapter 2.  
The parameters assessed were similar to those characterised in our previous 
research. Surface tension was not assessed in line with previous results as this was 
shown to remain constant irrespective of the stimulation state. Assessment of 
viscosity required a greater volume than the microliter amounts available at short 
time intervals after stimulation. Therefore, the pH, buffer capacity and flow rate were 
assessed in the unstimulated state, and with respect to time after stimulation 
commenced.  
4.2 Aims 
The aims of this chapter are: 
 To investigate the effect of mechanical and dosage form (ODT) stimulant 
exposure on the characteristics and stimulation state of human saliva with 
respect to time 
 To evaluate if development of biorelevant SSFs representing both stimulation 
states is necessary 
 
4.3 Methods 
All methods relevant to this Chapter are detailed in Chapter 2. See sections 2.1 to 2.8 
including specific sections regarding “Trials 2 and 3”.  
4.4 Results 
4.4.1 Characterisation of Unstimulated and Parafilm® Stimulated Saliva over 
Time (Trial 2) 
4.4.1.1 pH 
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The pH of unstimulated human saliva was compared with Parafilm® stimulated saliva 
collected over a 30 minute period of continuous masticatory stimulation. The pH of 
SS was consistently raised compared to US values, and continued to increase over the 
30 minute stimulation period (Figure 4.1). Each SS point was compared to US as a 
control group. Significant differences between US and SS were observed from 5 
minutes (Friedman’s test with Dunn’s multiple comparisons test).  
U
S 1 2 3 4 5 6 7 8 9 1
0
1
4
1
8
2
2
2
6
3
0
6 .0
6 .5
7 .0
7 .5
8 .0
T im e  (m in u te s )
p
H
B
A
B B
B C
C C B B
C
C
D
C
C D D
D
 
Figure 4.1: The pH of unstimulated human saliva and Parafilm® stimulated human 
saliva over 30 minutes of continuous masticatory stimulation. Data represents mean 
+/- S.D. N = 10 participants, US saliva triplicates, SS saliva single measurements. 
Friedman’s test compared each SS point to US control, with Dunn’s multiple 
comparisons test. A: p < 0.05, B: p < 0.01, C: p < 0.001, D: p < 0.0001. (US = 
unstimulated saliva, SS = stimulated saliva).  
 
In order to more clearly see the variability and difference between the US value and 
each SS value, this is also presented as an X-Y plot as shown in Figure 4.2.  Variability 
appears quite consistent across all SS time points. Some SS points show error bars in 
the negative range, indicating that for initial SS time points, the pH was sometimes 
lower than US mean value.  
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Figure 4.2: The difference in pH between US (time zero) and each time point of 
Parafilm® stimulated human saliva over 30 minutes of continuous masticatory 
stimulation. Data represents mean +/- S.D. N = 10 participants, US saliva triplicates, 
SS saliva single measurements. (US = unstimulated saliva, SS = stimulated saliva).  
 
4.4.1.2 Buffer Capacity 
The buffer capacity of unstimulated human saliva was compared with Parafilm® 
stimulated saliva collected over a 30 minute period of continuous masticatory 
stimulation. The buffer capacity of SS was consistently raised compared to US values. 
An initial peak in buffer capacity was seen in the first 2.5 minutes of stimulation, 
followed by a steady decrease toward but not returning to US values over 30 minutes 
(Figure 4.3).  Each SS point was compared to US as a control group. Significant 
differences between US and SS were observed within the first 2.5 minutes of 
stimulation (ANOVA with Dunnetts’s multiple comparisons test).  
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Figure 4.3: The buffer capacity of unstimulated human saliva and Parafilm® 
stimulated human saliva over 30 minutes of continuous stimulation. Data represents 
mean +/- S.D. N = 10 participants, US saliva triplicates, SS saliva single measurements. 
ANOVA compared each SS point to US control, with Dunnetts’s multiple comparisons 
test. A: p < 0.05. (US = unstimulated saliva, SS = stimulated saliva).  
 
Similarly to pH, in order to more clearly see the variability and difference between 
the US value and each SS value, this is also presented as an X-Y plot as shown in 
Figure 4.4 below.  Variability appeared greatest for SS samples taken in the first 10 
minutes after stimulation commenced. Many error bars indicate negative values, 
showing that buffer capacity was below the US value in some individuals, particularly 
from 12 – 30 minutes. However, mean values remained elevated compared to US 
values across the 30 minute period.  
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Figure 4.4: The difference in buffer capacity between US (time zero) and each time 
point of Parafilm® stimulated human saliva over 30 minutes of continuous 
masticatory stimulation. Data represents mean +/- S.D. N = 10 participants, US saliva 
triplicates, SS saliva single measurements. (US = unstimulated saliva, SS = stimulated 
saliva).  
 
4.4.1.3 Flow Rate 
The flow rate of unstimulated human saliva was compared with Parafilm® stimulated 
human saliva collected over a 30 minute period of continuous masticatory 
stimulation. The flow rate of SS was consistently raised compared to US values. 
Highest flow rate values were observed within the first 10 minutes, with some SS 
points showing statistical significance compared to US values (Friedman’s test with 
Dunn’s multiple comparisons test). From 10 – 30 minutes, flow rate remained 
elevated compared to US values, however no significant differences were observed 
(Figure 4.5).  
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Figure 4.5: The flow rate of unstimulated human saliva and Parafilm® stimulated 
human saliva over 30 minutes of continuous stimulation. Data represents mean +/- 
S.D. N = 10 participants, US saliva triplicates, SS saliva single measurements. 
Friedman’s test compared each SS point to US control, with Dunn’s multiple 
comparisons test. A: p < 0.05, B: p < 0.01, C: p < 0.001, D: p < 0.0001. (US = 
unstimulated saliva, SS = stimulated saliva).  
 
In line with previous parameters, in order to more clearly see the variability and 
difference between the US value and each SS value, this is also presented as an X-Y 
plot as shown in Figure 4.6 below.   
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Figure 4.6: The difference in flow rate between US (time zero) and each time point of 
Parafilm® stimulated human saliva over 30 minutes of continuous masticatory 
stimulation. Data represents mean +/- S.D. N = 10 participants, US saliva triplicates, 
SS saliva single measurements. (US = unstimulated saliva, SS = stimulated saliva).  
 
4.4.2 Characterisation of Unstimulated and ODT Stimulated Saliva over Time 
(Trial 3) 
4.4.2.1 pH 
The pH of unstimulated human saliva was compared with ODT stimulated human 
saliva collected over a 30 minute period. Stimulation was provided by a single short 
stimulus as the mean ODT disintegration time was 59.1 s. The pH of SS was initially 
raised compared to US values, however continued to decrease toward but not 
reaching US values over the 30 minute experiment (Figure 4.7). Each SS point was 
compared to US as a control group. Significant differences between US and SS were 
observed within the first 10 minutes. (Friedman’s test with Dunn’s multiple 
comparisons test).  
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Figure 4.7: The pH of unstimulated human saliva and orally disintegrating tablet 
stimulated human saliva. Data represents mean +/- S.D. N = 10 participants, US saliva 
triplicates, SS saliva single measurements. Friedman’s test compared each SS point to 
US control, with Dunn’s multiple comparisons test. B: p < 0.01, C: p < 0.001, D: p < 
0.0001. (US = unstimulated saliva, SS = stimulated saliva).  
 
In order to more clearly see the variability and difference between the US value and 
each SS value, this is also presented as an X-Y plot as shown in Figure 4.8. Variability 
appears quite consistent across all SS time points. The data points on this graph are 
not connected between time zero (US value) and the first SS time point, during which 
time, the ODT was administered. Participants allowed the ODT to disintegrate then 
swallowed their saliva three times to ensure all acidic components of the ODT were 
removed from saliva by swallowing. Thus one cannot extrapolate the pH in the 
intervening period.   
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Figure 4.8: The difference in pH between US (time zero) and each time point of orally 
disintegrating tablet stimulated human saliva over 30 minutes after stimulation. Data 
represents mean +/- S.D. N = 10 participants, US saliva triplicates, SS saliva single 
measurements. (US = unstimulated saliva, SS = stimulated saliva).  
 
4.4.2.2 Buffer Capacity 
The buffer capacity of unstimulated human saliva was compared with ODT stimulated 
human saliva collected over a 30 minute period. The buffer capacity of SS was initially 
raised compared to US values, however it continued to decrease toward but not 
reaching US values over the 30 minute stimulation period (Figure 4.9). Each SS point 
was compared to US as a control group. Significant differences between US and SS 
were observed within the first 9.5 minutes. (ANOVA with Dunnett’s multiple 
comparisons test).  
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Figure 4.9: The buffer capacity of unstimulated human saliva and orally disintegrating 
tablet stimulated human saliva. Data represents mean +/- S.D. N = 10 participants, US 
saliva triplicates, SS saliva single measurements. ANOVA test compared each SS point 
to US control, with Dunnett’s multiple comparisons test. A: p < 0.05, B: p < 0.01, C: p 
< 0.001. (US = unstimulated saliva, SS = stimulated saliva).  
 
This data was also presented as an X–Y plot (Figure 4.10) for reasons detailed above. 
Similarly to Figure 4.8, the time points were not connected as discussed earlier. 
Variability appears greater at earlier SS time points compared to later ones in the 
profile. Error bars show negative values for some SS time points, indicating that some 
individual values were lower than the US mean value at these data points. 
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Figure 4.10: The difference in buffer capacity between US (time zero) and each time 
point of orally disintegrating tablet stimulated human saliva over 30 minutes after 
stimulation. Data represents mean +/- S.D. N = 10 participants, US saliva triplicates, 
SS saliva single measurements. (US = unstimulated saliva, SS = stimulated saliva).   
 
4.4.2.3 Flow Rate 
The flow rate of unstimulated human saliva was compared with ODT stimulated 
human saliva collected over a 30 minute period. The flow rate of SS was initially 
raised compared to US values, with significant differences between SS and the US 
control group in the first 3 minutes (Friedman’s with Dunn’s multiple comparisons 
test). From 3.5 to 30 minutes, SS flow rate remained elevated compared to US, 
however, significant differences between US and SS were only seen at 5 points during 
this time period (Figure 4.11).  
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Figure 4.11: The pH of unstimulated human saliva and orally disintegrating tablet 
stimulated human saliva. Data represents mean +/- S.D. N = 10 participants, US saliva 
triplicates, SS saliva single measurements. Friedman’s test compared each SS point to 
US control, with Dunn’s multiple comparisons test. A: p < 0.05, B: p < 0.01, D: p < 
0.0001. (US = unstimulated saliva, SS = stimulated saliva).  
 
As with previous Figures, this data is now presented as an X–Y plot (Figure 4.12). 
Similarly to Figure 4.10, variability appears greater at earlier SS time points compared 
to later in the profile. Error bars show negative values for some SS time points, as 
they did for Figure 4.10, indicating that some individual values were lower than the 
US mean value at these data points.  
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Figure 4.12: The difference in flow rate between US (time zero) and each time point 
of orally disintegrating tablet stimulated human saliva over 30 minutes after 
stimulation. Data represents mean +/- S.D. N = 10 participants, US saliva triplicates, 
SS saliva single measurements. (US = unstimulated saliva, SS = stimulated saliva).  
 
4.5 Discussion 
4.5.1 Characterisation of Unstimulated and Parafilm® Stimulated Saliva over 
Time 
It could be argued that when a dosage form is placed in the mouth, saliva is 
immediately stimulated and may remain in the stimulated state for the likely 
duration that taste masked particles would reside in the oral cavity. Thus dissolution 
testing in SS alone would be indicated. To this end, the rate of conversion of saliva 
from US to SS was investigated, and properties were monitored for a 30 minute 
period of stimulation to assess whether they returned to US during this time. It is 
common practice to achieve stimulation of saliva by asking participants to chew on 
Parafilm®, an inert material, and to control this stimulation using a set sized piece of 
Parafilm® [173-175]. Thus, participants were asked to donate a US sample and SS 
samples collected over 30 minutes of continuous masticatory stimulation. Samples 
were characterised for pH, buffer capacity and flow rate.  
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The pH of SS was consistently greater than US and continued to rise over the 30 
minute experiment. Significant differences between the US control group and SS 
appeared after 5 minutes of stimulation and the level of significance increased as 
stimulation continued. In previous research (Chapter 3) [202], the pH of SS was found 
to be significantly greater than US. This was attributed to the different glandular 
composition of SS, originating largely from the parotid gland, which releases a 
bicarbonate rich secretion, leading to higher pH values in this stimulation state.  
Numerous other researchers have investigated the effect of masticatory stimulation 
on the pH of saliva. A mixture of flavoured chewing gums and unflavoured chewing 
gum bases have been used as the stimulant [180, 249-251]. It must be noted that 
those using flavoured gums involve both gustatory and mechanical stimulation, and 
therefore cannot be compared directly to Parafilm® (mechanical) stimulation alone. 
Other researchers have reported pH showing an initial peak in the first few minutes, 
then decreasing slightly over time toward, but not returning to US state. In these 
cases, SS pH remained significantly higher than US throughout the experiment [180, 
249, 251]. Dawes and Kubeineic [180] compared unstimulated saliva with chewing 
gum stimulated saliva using peppermint and fruit gum. SS pH was found to be 
significantly higher from 2 minutes to 2 hours compared to US for both gums. For 
peppermint gum, an initial peak and gradual decrease was observed, whereas with 
fruit gum, an initial decrease due to release of acids was observed followed by a 
steady increase throughout the 120 minute experiment.  Polland, Higgins and 
Orchardson [249] used mint flavoured chewing gum and found that pH showed peak 
levels in the first 6 minutes, then remained statistically greater than US  during the 90 
minute experiment. They also administered a fresh piece of chewing gum every 30 
minutes for 90 minutes. Similarly, peak pH values were observed within the first 6 
minutes of administration of each new piece of gum, with peak values rising a little 
every time a new piece was given. SS pH remained significantly greater than US at all 
time points in this research.  
In our case, pH continued to rise throughout the whole 30 minute stimulation period. 
These findings are in accordance with literature since pH remained elevated above 
US values for the whole experiment. However literature reports an initial peak, which 
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was not observed in our experiments. It is unclear why this increasing trend was 
observed in our study and not others, but this could possibly be related to the release 
of some components from the Parafilm®. Despite the manufacturers describing it as 
odourless and colourless [252], the exact composition is not divulged and may have 
affected the study.  
The buffer capacity showed a similar initial peak and slightly reducing trend to that 
described in literature which was discussed previously surrounding the pH. Buffer 
capacity of SS showed an initial increase, with significant differences observed 
between the US control group and SS in the first 3 minutes of stimulation. The buffer 
capacity then decreased toward, but did not return to US values over the 30 minute 
stimulation period. In previous research (Chapter 3) [202], the buffer capacity of SS 
was significantly greater than US. Again, this is attributed to the presence of higher 
amounts of bicarbonate. The buffer capacity of SS was consistently greater than that 
of US, but only significantly different in the first 3 minutes. The changing buffer 
capacity over time as saliva becomes stimulated is not described in literature. 
However, it would be expected to follow a similar pattern to pH. Literature describing 
the pH is in accordance with the trend observed for buffer capacity data [249, 251].  
Flow rate was found to be a highly variable parameter with significant differences 
between the US control group and SS in the first 10 minutes of stimulation. It then 
remained elevated above US values and did not return to US values over the 30 
minute experiment, although no significant differences were observed between US 
and SS from 10 - 30 minutes. Many studies of the effect of mechanical stimulation on 
saliva investigated flow rate as an outcome. In all cases, the flow rate demonstrated 
an initial peak [180, 181, 249, 251, 253-255], occurring in the first minute in many 
cases [181, 253-255], followed by a gradual decrease to levels higher than US flow 
rate over the length of the experiment (up to 120 minutes), or to a plateau above US 
values [180]. Rosenhek, Macpherson and Dawes [255] also compared unflavoured 
chewing gum base with flavoured chewing gum and found the same flow rate profile 
was observed for both types of stimulant, whereby an initial increase in the first two 
minutes was followed by a decrease to a plateau above US values for the remainder 
of the 20 minute experiment.  
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Interestingly, in two cases, a fresh piece of gum was provided at set times. One study 
gave a fresh piece of gum at 30 and 60 minutes and found flow rate showed a further 
peak within the first two minutes of each new piece of gum [249]. In another study, a 
second piece of gum was administered at 90 minutes and flow rate also increased 
further above the already stimulated flow rate [180].  
After the initial peak and raised phase, the subsequent reduction in buffer capacity 
and flow rate over time compared to US could possibly be explained by a reduction in 
the size of the piece of Parafilm® and it becoming less “chewy” over time, reducing 
the size of the stimulus.  It has been reported by Kjeilen et al. [177] that increasing 
the frequency, force and number of teeth involved in chewing increased parotid 
secretions, therefore a redution in the salivary output would be expected if the size 
of the Parafilm® decreased. Additionally, Rosenhek, Macpherson and Dawes [255] 
reported that flow rate increased as weight of gum increased, thus if the Parafilm® 
decreased in size, salivary output would also be expected to. It may also be possible 
that under prolonged and continuous mechanical stimulation, the response to the 
stimulant becomes desensitised.  
4.5.2 Characterisation of Unstimulated and ODT Stimulated Saliva over Time 
It was considered that continuous masticatory stimulation over 30 minutes could be 
not representative of the stimulation of saliva provided when an oral dosage form is 
administered e.g. an orally disintegrating tablet. In this case, short term stimulation 
of saliva occurs. Thus, an orally disintegrating tablet was administered as the 
stimulant, and the trial was repeated as before, with characterisation of US, and SS at 
set times after stimulation. Citric and ascorbic acid are often excipients in ODT 
formulations, included to stimulate the production of saliva and to provide a pleasant 
taste [256]. Thus an ascorbic acid ODT with no active pharmaceutical ingredient was 
used as a placebo ODT.  
The release of ascorbic acid from the ODT results in a decrease of salivary pH, and 
inability to accurately titrate saliva to assess buffer capacity. In another study, citric 
acid was used as a stimulant and the decrease and recovery of pH was measured 
over time [257]. However, in this study, participants were asked to swallow their 
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saliva three times after disintegration of the ODT to ensure that particles of the ODT 
were swallowed and would not affect subsequent analysis.  
In this trial, all parameters showed an initial increase with significant differences 
between the US control group in the first 10 and 9.5 minutes for pH and buffer 
capacity respectively. Flow rate showed an initial increase with significant differences 
in the first 6 minutes. Then values remained at an elevated plateau for flow rate, with 
some further significant differences observed between US control group and SS at 
later time points. However, for pH and buffer capacity, values reduced towards 
without reaching US values over the 30 minute experiment.  
To our knowledge, this is the first time in which stimulation of saliva with respect to 
time has been investigated with a realistic method of stimulation representing 
dosage form administration, thus we cannot compare this data to literature. 
However, short term gustatory stimulation has been used in the literature, commonly 
using citric acid application to the tongue. The changes in pH and buffer capacity with 
respect to time after gustatory stimulation are not well documented in literature; 
however a number of studies investigated changes in the flow rate after short-term 
gustatory stimulation with citric acid.  
In general, the flow rate increased in the first minute after stimulation, but returned 
to US values and demonstrated a rapid recovery compared to continuous masticatory 
stimulation. Morimoto et al. [178] investigated the effect of citric acid stimulation on 
parotid gland size. The parotid gland is known to be responsible for the majority of 
stimulated saliva secretions [202]. They found that mean time to maximum duct area 
was 69 s +/- 29 s after stimulus application, and time taken to return to 50 % of pre-
stimulation size was 156 s +/- 61 s. Therefore, flow rate and parotid output was 
shown to be quickly induced and demonstrated a rapid recovery to pre-stimulation 
conditions. Tanaka et al. [258] performed a similar experiment on both the parotid 
and submandibular glands and found that parotid gland maximum duct area was 
observed within 60 s and submandibular within 120 s, confirming the rapid induction 
of salivary flow. Millward et al. [257] observed peak parotid flow 1 minute after citric 
acid stimulation, with full recovery to baseline US levels within 6 minutes, whilst 
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Duran et al. [259] observed peak salivary flow within 30 s of citric acid stimulation, 
and recovery to US levels within two minutes. Additionally, de Mata et al. [260] 
compared two acid containing lozenges and found peak flow rates within 5 minutes 
of administration, with flow rates returning to baseline within 20 minutes. The time 
taken for lozenge dissolution could be responsible for slightly longer flow induction 
and recovery times in this study compared to other literature.  
In all cases, the results of this trial are in agreement with literature with respect to 
the initial peak in each parameter and subsequent reduction. However, unlike 
literature, a return to US values was not seen for any parameter during the 30 minute 
time period. The slight prolonged elevation of each parameter above US levels 
(although not always significantly different to US values) may possibly be explained 
by prolonged stimulation of, and desensitisation of taste receptors. Despite 
participants being asked to swallow saliva to ensure all particles of the ODT are 
removed from the oral cavity, it is possible that some particles remained in the oral 
cavity at very low concentrations at taste bud sites. This may have caused prolonged 
stimulation of the taste receptors, resulting in a response over time that slowly 
declines, which would describe the pattern observed in this study [261]. 
The observation of significant differences between US and SS at different times for 
each parameter with Parafilm® stimulation and with perhaps the more realistic ODT 
stimulation confirms that dissolution testing in SS alone is not sufficient as saliva does 
not remain in the stimulated state throughout these experiments. Thus dissolution 
testing of taste masked formulations is recommended in simulated salivary fluids 
representing both the US and SS states.  
4.6 Conclusions 
The requirement for development of a simulated salivary fluid representing both US 
and SS was investigated. Salivary parameters were characterised with respect to time 
after Parafilm® and ODT stimulation. Significant differences between the US and SS 
states appeared at different times after stimulation for different parameters. Saliva 
did not remain in the stimulated state for the whole duration of the two experiments 
as significant differences between US and SS disappeared over time for most 
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parameters. Thus, it is recommended to perform dissolution testing of taste masked 
oral dosage forms in simulated salivary fluids representing both the unstimulated and 
stimulated states to confirm taste masking is achieved.  
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Chapter 5: Development and Proposal of Biorelevant Simulated Salivary Fluids 
5.1 Introduction  
The choice of media to represent human saliva in dissolution tests has been a matter 
of great interest. The media should represent human saliva as closely as possible in 
order to best predict the dissolution behaviour of drugs or dosage forms in the oral 
cavity. Our previous research also confirmed that dissolution media should be 
developed representing both the unstimulated and stimulated states.  
There are a number of simulated salivary fluids (SSFs) available for dissolution testing, 
as discussed in Chapter 3. Crucially, to our knowledge, there are no SSFs in existence 
representing both the salivary stimulation states. Existing SSFs can be categorised 
into three main groups: 1 - simple electrolyte mixtures such as phosphate buffered 
saline, 2 - those containing the viscosity modifying polymer carboxymethylcellulose, 
such as Glandosane®, and 3 - those containing viscosity modifying mucins such as 
Saliva Orthana® products. In Chapter 3, these were characterised using the same 
methodology as human saliva to allow for a direct comparison. Unfortunately, none 
of the three classes were found to be suitable to represent human saliva based on 
key parameters relevant to dissolution. There is therefore a requirement for novel, 
more biorelevant SSFs representing both the unstimulated and stimulated human 
salivary states to be developed.  
In the present research, for the first time, biorelevant SSFs representing both the 
unstimulated and stimulated states of human saliva are proposed for use as 
dissolution media. 
5.2 Aims 
The aims of this Chapter are: 
 To develop novel biorelevant simulated salivary fluids representing both the 
unstimulated and stimulated states for application in dissolution testing 
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 To evaluate the suitability of these to represent human saliva by direct 
comparison with human saliva based on key characteristics relevant to 
dissolution 
 
5.3 Methods 
All methods relevant to this Chapter are detailed in Chapter 2. In particular, refer to 
section 2.1 for materials and 2.5 – 2.7 for characterisation of pH, buffer capacity, 
viscosity, and surface tension. These were characterised according to methodology 
for “Trial 1”. Human saliva data is described in Chapter 3, and methods can be found 
in Chapter 2 for human saliva characterisation. Refer also to Chapter 2, section 2.8 
for statistical analysis.  
5.4 Results 
5.4.1 Development of Simulated Salivary Fluids 
5.4.1.1 Comparison of Glandosane® made up from its component parts to 
Human Saliva and PBS, and Analysis of the Effect of 
Carboxymethylcellulose on SSF Characteristics.  
In Chapter 3, Glandosane® was characterised and compared to human saliva. 
However, measurements were found to be erratic due to it being a spray, propelled 
by carbon dioxide from a pressurised container. This may have influenced the pH 
measurements as CO2 left the sample, and made measurements of viscosity 
incomprehensible due to the high shear exerted on the sample during its removal 
from the container prior to rheological analysis. The development of a biorelevant 
SSF therefore began with the manufacture and characterisation of Glandosane® in 
our laboratory from its component parts to assess its similarity to human saliva. The 
quantitative composition of Glandosane® is publicly available [164] and is listed in 
Chapter 2, Table 2.2.  
Glandosane® contains 1 % w/w of the viscosity modifier carboxymethylcellulose 
sodium (CMC). In order to assess the suitability of CMC as a viscosity modifier, and its 
effect on the pH, buffer capacity and surface tension of a potential SSF solution, 
concentrations between 0 – 5 % w/w CMC were assessed. These varying 
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concentrations of CMC were characterised in Glandosane® made from its component 
parts in our laboratory and also in phosphate buffered saline (PBS) from the British 
Pharmacopoeia [223] as vehicles. These solutions were compared to each other and 
to human saliva. Characterisation of each parameter followed the same methodology 
as for human saliva, detailed in Chapter 2, section 2.5.1 to allow for a direct 
comparison.  
The pH of PBS / CMC solutions was found to be approximately the same (pH 6.8) 
irrespective of CMC concentration. This was slightly lower compared to human US 
values and substantially lower than human SS values. The pH of Glandosane® made 
up from its component parts (GLN) increased as the concentration of CMC increased. 
However, pH values were all lower than that of PBS / CMC solutions and therefore 
less suitable to represent human saliva than PBS / CMC solutions as shown in Figure 
5.1.  
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Figure 5.1: The pH of potential SSFs containing differing carboxymethylcellulose 
(CMC) concentrations expressed as % w/w compared to unstimulated and stimulated 
human saliva. Data represents mean +/- S.D. N = 30, quintuplicate for US and SS, N = 
5, quintuplicate for PBS and GLN. (PBS = phosphate buffered saline, GLN = 
Glandosane® made up from its component parts, US = unstimulated human saliva, SS 
= stimulated human saliva (data from Chapter 3)).  
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The buffer capacity of PBS / CMC solutions was found to increase slightly as CMC 
concentration increased. These values were slightly higher than human US values but 
similar to human SS values. The buffer capacity of Glandosane® made up from its 
component parts (GLN) also increased as the concentration of CMC increased. 
However, these buffer capacity values were all much lower than that of human US, 
except for 5 % CMC, and thus less suitable to represent human saliva than PBS / CMC 
solutions as shown in Figure 5.2.  
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Figure 5.2: The buffer capacity of potential SSFs containing differing 
carboxymethylcellulose (CMC) concentrations expressed as % w/w compared to 
unstimulated and stimulated human saliva. Data represents mean +/- S.D. N = 30, 
duplicate for US and SS, N = 5, triplicate for PBS and GLN. (PBS = phosphate buffered 
saline, GLN = Glandosane® made up from its component parts, US = unstimulated 
human saliva, SS = stimulated human saliva (data from Chapter 3)).  
 
The surface tension of both the PBS / CMC and GLN / CMC solutions changed very 
little as CMC concentration increased as shown in Figure 5.3. Additionally, all values 
were found to be much higher than human US and SS values and neither would be 
suitable to represent human saliva without the addition of a surfactant.  
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Figure 5.3: The surface tension of potential SSFs containing differing 
carboxymethylcellulose (CMC) concentrations expressed as % w/w compared to 
unstimulated and stimulated human saliva. Data represents mean +/- S.D. N = 30, 
quintuplicate for US and SS, N = 5, quintuplicate for PBS and GLN. (PBS = phosphate 
buffered saline, GLN = Glandosane® made up from its component parts, US = 
unstimulated human saliva, SS = stimulated human saliva (data from Chapter 3)).  
 
The viscosity of PBS / CMC solutions was found to be very similar to that of GLN / 
CMC at each CMC concentration, and the rheological profiles almost overlap. 
However, none of the solutions were found to be a good match to human saliva. 
Human saliva shows considerable shear thinning behaviour; whereas the CMC 
solutions showed very little shear thinning except at the higher 5 % concentration. 
However, even at this concentration, it was not found to exhibit suitable rheological 
behaviour to represent human saliva as shown in Figure 5.4.  
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Figure 5.4: The viscosity at different shear rates of potential SSFs containing differing 
carboxymethylcellulose (CMC) concentrations expressed as % w/w compared to 
unstimulated and stimulated human saliva. Data represents mean +/- S.D. N = 30, 
triplicates for US and SS, N = 5, triplicates for PBS and GLN. (PBS = phosphate 
buffered saline, GLN = Glandosane® made up from its component parts, US = 
unstimulated human saliva, SS = stimulated human saliva (data from Chapter 3)).  
 
5.4.1.2 Choice of Viscosity Modifier 
It was clear from the rheological analysis of carboxymethylcellulose solutions that 
CMC is not an appropriate viscosity modifying agent since it did not exhibit the 
required extent of shear thinning necessary to represent the highly shear thinning 
human saliva. Other viscosity modifiers were therefore investigated.  
Acacia is a component of one of the commercially available artificial saliva 
formulations detailed in the British National Formulary [204] used clinically for the 
treatment of xerostomia. It has also been reported to have shear thinning properties 
[262, 263]. The viscosity of PBS with differing concentrations of acacia was therefore 
evaluated. Unfortunately, the solutions did not demonstrate shear thinning 
behaviour and thus acacia is not a suitable choice of viscosity modifier to use in 
simulated salivary fluids, as shown in Figure 5.5.  
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Figure 5.5: The viscosity at different shear rates of potential SSFs containing differing 
acacia concentrations expressed as % w/v compared to unstimulated and stimulated 
human saliva. Data represents mean +/- S.D. N = 30, triplicates for US and SS, N = 5, 
triplicates for acacia samples. (PBS = phosphate buffered saline, US = unstimulated 
human saliva, SS = stimulated human saliva (data from Chapter 3)).  
 
Bovine submandibular mucin (BSM) has also been reported to have shear thinning 
properties in some literature as discussed in more detail in Chapter 3, section 3.3.4. 
We therefore evaluated the viscosity of two concentrations of BSM in PBS. However, 
as seen in Figure 5.6, shear thinning was not demonstrated under our conditions and 
this was also not found to be a suitable viscosity modifier for SSF solutions.  
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Figure 5.6: The viscosity at different shear rates of potential SSFs containing differing 
bovine submandibular mucin concentrations expressed as % w/v compared to 
unstimulated and stimulated human saliva. Data represents mean +/- S.D. N = 30, 
triplicates for US and SS. N = 1, triplicates for BSM samples. (PBS = phosphate 
buffered saline, BSM = bovine submandibular mucin, US = unstimulated human 
saliva, SS = stimulated human saliva (data from Chapter 3)).  
 
Xanthan gum is a viscosity modifying component of the Saliva Orthana® gel 
characterised in Chapter 3. We observed clear shear thinning behaviour for Saliva 
Orthana® gel. This was attributed solely to the presence of xanthan gum, since the 
Saliva Orthana® spray did not exhibit shear thinning behaviour, and the only 
difference in composition between the two formulations is the presence of xanthan 
in the gel. However, the viscosity of the gel, which contains 0.5 % w/v xanthan gum 
was much higher than that of human saliva. Xanthan was therefore investigated in 
more depth as a viscosity modifier at concentrations of 0.05 – 0.15 % w/v.  
All concentrations of xanthan gum in PBS showed distinct shear thinning behaviour 
comparable to that of human saliva, as seen in Figure 5.7. A concentration of 1 % was 
found to be within the range of values seen for human saliva since it sits inside the 
error bars, which represent standard deviation. Although the gradient of the viscosity 
profile is not an exact match, xanthan gum was found to be the most suitable 
viscosity modifier for use in SSFs to represent human saliva out of all options tested. 
Therefore, further work continued with xanthan gum.  
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Figure 5.7: The viscosity at different shear rates of potential SSFs containing differing 
xanthan gum concentrations expressed as % w/v compared to unstimulated and 
stimulated human saliva. Data represents mean +/- S.D. N = 30, triplicates for US and 
SS. N = 5, triplicates for xanthan samples. (PBS = phosphate buffered saline, US = 
unstimulated human saliva, SS = stimulated human saliva (data from Chapter 3)).  
 
5.4.1.3 Choice of Buffer 
Human saliva is made up of three buffering systems: bicarbonate, phosphate and 
protein buffers [182]. The prevalence of each buffer changes with respect to the 
stimulation state. Bicarbonate is present in greater quantities in stimulated saliva, as 
discussed in Chapter 3, and is the predominant buffer in stimulated saliva. However 
unstimulated saliva is predominantly buffered by the phosphate buffering system.  
Bicarbonate buffers have not been used in any of the SSFs detailed in literature or 
commercially available. Due to the escape of carbon dioxide from the system, which 
constantly changes the pH unless measures are taken to avoid this, it is a challenging 
buffer to use from practical considerations. Phosphate buffer was therefore selected 
for all future experimentation. Additionally, where a buffering system is employed in 
SSFs from commercial sources or literature, phosphate buffer is also the buffer of 
choice.  
Until now, our characterisations have focussed on the use of phosphate buffered 
saline BP pH 6.8 as this appears in many of the SSFs from the literature (see Chapter 
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1). However a number of other phosphate buffers are detailed in both British 
Pharmacopoeia (BP) [264] and United States Pharmacopoeia (USP) [265] without the 
high, non biorelevant concentrations of sodium chloride. British Pharmacopoeial 
phosphate buffer [264] is manufactured from a disodium hydrogen phosphate 
solution and a citric acid solution, mixed in differing proportions to generate buffers 
of different pH, as seen in Table 5.1.  In this case, the pH is varied by changing the 
ratio of salt present. 
Table 5.1: Phosphate buffer solutions modified from British pharmacopoeia. 
Quantities provided for 100 mL buffer.  
pH of Buffer Volume Na2HPO4 solution, mL 
(28.36 g/L Na2HPO4) 
Volume citric acid 
monohydrate solution, mL 
(21 g/L C6H8O7.H2O) 
7.0 82.4 17.6 
7.4 91.3 8.7 
 
However, USP phosphate buffer [265] is made by placing 50 mL of a 0.2 M monobasic 
potassium phosphate solution into a 200 mL volumetric flask, adding the specified 
volume of the sodium hydroxide solution from Table 5.2, and then adding water to 
volume. In this case, the pH is varied by changing the amount of NaOH added in the 
final step.  
Table 5.2: Amount of NaOH required to make 200 mL of phosphate buffer with the 
pH specified in the Table. Modified from the United States Pharmacopoeia.  
 
The buffer capacity of both BP and both USP buffers was determined with and 
without the addition of 0.1 % xanthan. The pH values of 7.0 and 7.4 were based on 
our previous findings from Chapter 3 which state that the mean pH of unstimulated 
and stimulated human saliva was found to be 7.0 and 7.4 to one decimal place 
respectively.  
pH of Buffer 7.0 7.4 
mL 0.2 M NaOH 29.1 39.1 
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The addition of xanthan did not affect the pH during the manufacture of the buffers, 
nor did it appear to have any effect on the buffer capacity of the solution, as seen in 
Table 5.3. BP buffers were found to have approximately 10 times the buffer capacity 
of human saliva, and USP buffers approximately 4 times the buffer capacity of saliva 
since values for human saliva were 5.9 and 8.4 mmol H+/L respectively. Buffer 
capacity was also much greater for BP phosphate buffers than USP buffers. These 
would therefore require dilution before they could be considered sufficient to 
represent human saliva in SSFs. 
Table 5.3: Buffer capacity of BP and USP buffers with or without the addition of 0.1 % 
xanthan gum. (BP = British pharmacopoeia, USP = United States pharmacopoeia).  
Buffer pH Xanthan (Y/N) Run 
Buffer capacity 
(mmol H+/L) 
Mean buffer 
capacity (mmol 
H+/L) 
BP 
7.0 
Y 
1 85.00 
86.25 
2 87.50 
N 
1 82.50 
80.00 
2 77.50 
7.4 
Y 
1 75.00 
77.50 
2 77.50 
N 
1 77.50 
76.25 
2 82.50 
USP 
7.0 
Y 
1 22.50 
21.88 
2 21.25 
N 
1 22.50 
21.88 
2 21.25 
7.4 
Y 
1 25.00 
25.25 
2 25.50 
N 
1 25.00 
21.38 
2 23.75 
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5.4.1.4 Modifying the Rheological Properties 
The rheological profile of phosphate buffered saline with 0.1 % xanthan gum is a 
reasonable match for human saliva as seen previously in Figure 5.7. However, a 
steeper gradient of the profile would be ideal since it currently encompasses viscosity 
values across both human US and SS, and does not closely represent either of the 
stimulation states. We investigated the effect of changing the pH and salt 
composition of the buffer on the gradient of the rheological profile, with a view to 
obtaining a steeper gradient for the xanthan containing buffer solution such that it 
can represent US or SS individually.  
USP buffers of varying pH within the range of human saliva were used to ascertain 
the effect of pH on the rheological profile of xanthan gum containing buffer 
solutions. This is because the pH of USP buffers can be altered by simply adding more 
NaOH without affecting the phosphate concentration. Very little difference was 
observed between profiles as seen in Figure 5.8, thus pH did not appear to affect 
viscosity.  
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Figure 5.8: The viscosity at different shear rates of potential SSFs containing 0.1 % 
w/v xanthan gum in USP phosphate buffer solutions. Data represents mean +/- S.D. N 
= 5, triplicates. (USP = United States pharmacopoeia).  
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BP buffers of varying pH within the range of human saliva were used to ascertain the 
effect of salt concentration on the rheological profile of xanthan gum containing 
buffer solutions. This is because the pH of BP buffers is altered by changing the 
phosphate and citrate concentrations. Very little difference was observed between 
profiles as seen in Figure 5.9, thus salt concentration did not appear to affect 
viscosity.  
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Figure 5.9: The viscosity at different shear rates of potential SSFs containing 0.1 % 
w/v xanthan gum in BP phosphate buffer solutions. Data represents mean +/- S.D. N 
= 5, triplicates. (BP = British pharmacopoeia).  
 
These two data sets were then overlaid with human saliva data from Chapter 3 in 
order to assess how well these solutions represent human saliva, and the differences 
between them, as seen in Figure 5.10 for BP buffer solutions and USP buffer solutions 
respectively. BP buffer / xanthan solutions had a very slightly lower viscosity 
compared to USP buffer / xanthan solutions. This meant the BP solutions were 
always within the error bars of at least one subtype of human saliva, whereby error 
bars represent standard deviation. However, USP solutions were a good match for 
human US, but were of very slightly higher viscosity than SS in the high shear range, 
making BP solutions marginally more suitable when 0.1 % xanthan is used.  
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Figure 5.10: The viscosity at different shear rates of potential SSFs containing 0.1 % 
w/v xanthan gum in USP phosphate buffer solutions (Panel A) and in BP phosphate 
buffer solutions (Panel B).  Data represents mean +/- S.D. N = 5, triplicates for 
potential SSFs. N = 30, triplicates for US and SS. (BP = British pharmacopoeia, USP = 
United States pharmacopoeia, US = unstimulated human saliva, SS = stimulated 
human saliva (data from Chapter 3)). 
 
5.4.1.5 Choice of Surfactant 
We observed in Table 5.3 that the addition of xanthan did not appear to affect the 
buffer capacity of phosphate buffer solutions. It was also observed during 
manufacture that no change to the pH was observed upon addition of xanthan gum. 
We therefore investigated the surface tension of xanthan-containing solutions based 
B 
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on both BP and USP phosphate buffers to assess their suitability to represent human 
saliva based on surface tension. No significant difference was observed between the 
surface tension of the four samples (ANOVA and Holm-Sidak’s multiple comparisons 
test). All samples had a higher surface tension than human saliva which was 58.98 
mN/m and 59.69 mN/m for US and SS respectively. Therefore a surfactant is required 
regardless of which type of buffer is selected. However, BP values were slightly lower 
and thus slightly closer to human saliva values (Figure 5.11).  
 
 
 
 
 
 
 
 
Figure 5.11: Surface tension of phosphate buffers of different pH containing 0.1 % 
xanthan gum. Data represents mean +/- S.D. N = 5, quintuplicate. (BP = British 
pharmacopoeia, USP = Unites States pharmacopoeia).  
 
Neither type of buffer was found to be a suitable match for human salivary buffer 
capacity without dilution. Additionally, neither buffer affected the rheological profile 
or the surface tension of xanthan solutions. BP buffers were a very slightly better 
match to human salivary values for viscosity as BP buffer values were within the error 
bars at both extremes of shear rate for US and SS. BP buffers also exhibited slightly 
closer surface tension values to human values without surfactants. Therefore, BP 
buffers were chosen for further work. The amount of dilution required for each 
buffer to have a similar buffer capacity to human saliva was determined 
experimentally by dilution of the buffer with deionised water and analysis of buffer 
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capacity. The exact composition of the final buffer solution is given shortly in the 
summary of SSF composition. All further work in this Chapter now relates to diluted 
BP buffers as the base component of developed SSFs.  
Since the surface tension of all xanthan containing phosphate buffers was greater 
than that of human saliva, (Figure 5.11), it was identified that a surfactant is required 
to reduce surface tension to physiological values. Two surfactants were tested which 
are used in other biorelevant media: lecithin and Tween 20® [218, 266-268]. To 
solutions of diluted BP phosphate buffer pH 7.2 plus 0.1 % xanthan was added 
varying concentrations of Tween 20® or lecithin, and the surface tension was 
assessed. Tween 20® demonstrated a more linear, predictable relationship between 
concentration and surface tension as shown in Figure 5.12 than lecithin in Figure 
5.13, and thus Tween 20® was used for further development of biorelevant simulated 
salivary fluids.  
 
 
 
 
 
 
 
Figure 5.12: Surface tension of diluted phosphate buffer pH 7.2 containing 0.1 % 
xanthan gum and varying concentrations of Tween 20®. Data represents mean +/- 
S.D. N = 2, quintuplicate. Linear regression line indicated.  
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Figure 5.13: Surface tension of diluted phosphate buffer pH 7.2 containing 0.1 % 
xanthan gum and varying concentrations of lecithin. Data represents mean +/- S.D. N 
= 2, quintuplicate. Linear regression line indicated.  
 
The surface tension of human saliva was found to be 58.98 and 59.69 mN/m for 
human US and SS respectively, with no significant difference in surface tension 
between the two stimulation states. Thus a concentration of 0.01 mM was employed 
since this concentration provided the closest surface tension compared to human 
salivary values.  
5.4.1.6 Evaluation of the Effect of Tween 20® on Viscosity 
The addition of Tween 20® did not affect the pH of the solutions. Being a non-ionic 
surfactant, it was also not expected to affect buffer capacity. However, it is a viscous 
solution and may affect the viscosity of the solution of buffer and xanthan. Therefore 
the viscosity was re-assessed after the addition of Tween 20®. The viscosity of buffer 
solutions containing 0.1 % xanthan gum and 0.01 mM Tween 20®, as shown in Figure 
5.14, Panel A, was slightly raised compared to Figure 5.10, Panel B, which shows BP 
buffer solutions containing 0.1 % xanthan gum without Tween 20®. It was therefore 
decided to reduce the concentration of xanthan gum from 0.1 % to 0.09 % (Figure 
5.14, Panel B) and 0.08 % (Figure 5.14, Panel C). The xanthan concentration of 0.08 % 
appeared to give the closest results compared to those of human saliva, thus this 
concentration was used for future work.  
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Figure 5.14: The viscosity at different shear rates of potential SSFs containing 0.1 % 
w/v (Panel A), 0.09 % (Panel B) and 0.08 % (Panel C) xanthan gum in diluted BP 
phosphate buffer solution plus 0.01 mM Tween 20®, compared to human US and SS. 
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Data represents mean +/- S.D. N = 30, triplicates for US and SS. N = 3, triplicates for 
potential SSFs. (US = unstimulated human saliva, SS = stimulated human saliva (data 
from Chapter 3), SSF = simulated salivary fluid). 
 
5.4.1.7 Summary of Developed Simulated Salivary Fluids’ Composition 
The most suitable composition to represent human saliva based on pH, buffer 
capacity, surface tension and viscosity was found to be BP phosphate buffer, diluted 
with deionised water as determined experimentally, with 0.08 % xanthan gum and 
0.01 mM Tween 20®. The final composition of the developed SSFs is summarised in 
Table 5.4.  
Table 5.4: US and SS composition for 100 mL of SSF. (US = unstimulated saliva, SS = 
stimulated saliva, BP = British pharmacopoeia).  
* Tween 20® from Sigma Aldrich, MW 1228, density 1.095 g/mL ** Xanthan gum 
from Sigma Aldrich, viscosity 800 - 1200 mPa.s for 1 % solution 
 
5.4.2 Characterisation of Developed Simulated Salivary Fluids and 
Comparison to Human Saliva 
5.4.2.1 pH 
Five batches of US and SS SSF were made and characterised for pH, buffer capacity, 
surface tension and viscosity, and compared to human saliva characteristics from 
Chapter 3.  
The pH of unstimulated and stimulated human saliva was compared to developed 
simulated salivary fluids (Figure 5.15). As described in Chapter 3, significant 
Component US SS 
BP pH 7.0 buffer (Table 5.1) 7.692 mL - 
BP pH 7.4 buffer (Table 5.1) - 9.009 mL 
HCl (1 M) To pH 7.0 To pH 7.4 
Tween 20®* 5.6 μL 5.6 μL 
Xanthan gum** 80 mg 80 mg 
Deionised water To 100 mL To 100 mL 
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differences were observed between human US and SS. No significant difference was 
observed between human saliva and SSF for either stimulation state. However, 
significant differences were observed between US SSF and SS human saliva, and 
between US human saliva and SS SSF (Kruskal-Wallis and Dunn’s multiple 
comparisons test).  
U
S
 H
S
U
S
 S
S
F
S
S
 H
S
S
S
 S
S
F
0
2
4
6
8
S a m p le
p
H
*
****
**
 
Figure 5.15: The pH of unstimulated and stimulated human saliva and simulated 
salivary fluids. Data represents mean +/- S.D. N = 30 for human saliva, triplicates. N = 
5 for SSFs, triplicates. (US = unstimulated saliva, SS = stimulated saliva, SSF = 
simulated salivary fluids, HS = human saliva). * significant difference (Kruskal-Wallis 
and Dunn’s multiple comparisons test, p < 0.05) ** significant difference (Kruskal-
Wallis and Dunn’s multiple comparisons test, p < 0.01) **** significant difference 
(Kruskal-Wallis and Dunn’s multiple comparisons test, p < 0.0001). 
 
5.4.2.2 Buffer Capacity 
The buffer capacity of unstimulated and stimulated human saliva was compared to 
developed simulated salivary fluids (Figure 5.16). As described in Chapter 3, 
significant differences were observed between human US and SS. No significant 
difference was observed between human saliva and SSF for either stimulation state. 
However, significant differences were observed between US SSF and SS human saliva, 
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and between US human saliva and SS SSF (ANOVA and Holm-Sidak’s multiple 
comparisons test).  
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Figure 5.16: The buffer capacity of unstimulated and stimulated human saliva and 
simulated salivary fluids. Data represents mean +/- S.D. N = 30 for human saliva, 
triplicates. N = 5 for SSFs, triplicates. (US = unstimulated saliva, SS = stimulated saliva, 
SSF = simulated salivary fluids, HS = human saliva). * significant difference (ANOVA 
and Holm-Sidak’s multiple comparisons test, p < 0.05) **** significant difference 
(ANOVA and Holm-Sidak’s multiple comparisons test, p < 0.0001). 
 
5.4.2.3 Surface Tension 
In our previous research, no significant difference was observed between US and SS 
human saliva (Chapter 3) [202]. In the present work, no significant differences were 
observed between human saliva and SSFs for either stimulation state (ANOVA and 
Holm-Sidak’s multiple comparisons test), (Figure 5.17). 
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Figure 5.17: The surface tension of unstimulated and stimulated human saliva and 
simulated salivary fluids. Data represents mean +/- S.D. N = 30 for human saliva, 
triplicates. N = 5 for SSFs, triplicates. (US = unstimulated saliva, SS = stimulated saliva, 
SSF = simulated salivary fluids, HS = human saliva). 
 
5.4.2.4 Viscosity 
Human saliva demonstrated a shear thinning pattern with unstimulated saliva 
showing significantly higher viscosity at every shear rate as described in Chapter 3. 
The viscosity of human saliva was compared to simulated salivary fluids (Figure 5.18). 
SSFs also demonstrated a shear thinning rheological profile similar to that of human 
saliva. The amount of xanthan in both SSFs was constant since minor increases or 
decreases in xanthan concentration resulted in SSF viscosity outside of the standard 
deviation of human saliva, indicated by error bars on the graph, in either the high or 
very low shear rate regions. 
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Figure 5.18: The viscosity of unstimulated and stimulated human saliva and simulated 
salivary fluids. Data represents mean +/- S.D. N = 30 for human saliva, triplicates. N = 
5 for SSFs, triplicates. (US = unstimulated saliva, SS = stimulated saliva, SSF = 
simulated salivary fluid).  
 
5.5 Discussion 
In our previous research (Chapter 3) [202], we identified significant differences 
between human US and SS for salivary characteristics likely to affect dissolution. 
Many SSFs are available including over 60 in literature [205], plus several clinical 
formulations for treatment of xerostomia [204]. Broadly, these can be classified into 
3 main groups, as discussed in Chapter 3. Previously, we took one example from each 
group and characterised these under the same conditions as human saliva to allow 
for a direct comparison. Unfortunately, none were found to be suitable to represent 
human saliva based on key characteristics for dissolution (Chapter 3). This is likely to 
be because they were developed for other reasons e.g. to relieve xerostomia, in 
which case the film forming properties are very important, or for dental applications 
whereby characteristics relevant to dissolution are perhaps less important. 
Additionally, none of the SSFs available were found to represent the two salivary 
states (US and SS) which have significantly different parameters. In this work, we 
developed SSFs representing both the US and SS states based on characteristics 
relevant to dissolution testing.  
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SSF development began with the characterisation of Glandosane® made up from its 
component parts, and of phosphate buffered saline plus CMC, both with varying 
concentrations of CMC. This is because it had previously not been possible to reliably 
characterise Glandosane® due to it being a spray, propelled by CO2 under high shear 
from a pressurised container. Despite this, CMC-containing SSFs represent one of the 
three main categories of SSF and therefore should be considered in more detail.  
Interesting trends were observed when Glandosane® made from its component parts 
was compared to PBS/CMC containing solutions, both with varying CMC 
concentrations. The pH of PBS did not change, and the buffer capacity changed only a 
little, regardless of the CMC concentration. However, for Glandosane® the pH and 
buffer capacity demonstrated a profound increase as the concentration of CMC 
increased.  
An explanation for this could be because PBS has a greater buffer capacity than 
Glandosane® at all concentrations, as seen by Figure 5.2 Therefore, the addition of 
CMC (as the sodium salt, carboxymethylcellulose sodium) was well buffered in PBS 
and thus did not change the pH. However in Glandosane®, the buffer capacity is less 
and the addition of CMC sodium increased the pH. Carboxymethylcellulose sodium 
contains sodium ions to neutralise the charge of the ionised carboxylic acid groups 
(COO-Na+). In solution this can dissociate to become COO- and Na+. The pH of the 
solution may increase as the COO- groups accept a proton, and as the Na+ groups 
form NaOH. The buffer capacity of both types of solutions increased as CMC sodium 
concentration increased, possibly due to the increase in ionisable species present.  
PBS/CMC solutions were found to be more suitable than Glandosane® solutions to 
represent human saliva for pH. Little difference was observed between the two in 
their suitability to represent human saliva based on buffer capacity as neither was 
found to be a close match to human values. CMC was not found to alter surface 
tension considerably with similar results from both PBS and Glandosane® containing 
CMC solutions. This suggests that the CMC is not a surface active molecule. PBS 
solutions demonstrated a slightly closer surface tension to human salivary values. 
Crucially, CMC did not demonstrate sufficient shear thinning to represent human 
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saliva, and therefore further work with CMC-containing solutions was ceased, and 
the search for a more suitable viscosity modifier began. 
PBS gave more promising results than Glandosane® made up from its component 
parts, based on pH and surface tension, and no clear preference between the two 
was observed for buffer capacity and viscosity. Therefore the analysis of other 
viscosity modifiers took place in PBS.  
Acacia, bovine submandibular mucin and xanthan were investigated since these have 
been used as viscosity modifiers in other SSF formulations [204, 240, 243]. 
Unfortunately, the rheological profiles of acacia and BSM demonstrated Newtonian 
behaviour under our conditions and thus were not found to be suitable. However, 
only one batch of BSM was analysed at two concentrations, in triplicate, in this study 
due to the high costs associated with working with ex vivo products. Ideally, further 
batches should be evaluated to fully confirm this rheological behaviour.  
Xanthan gum showed promising results, demonstrating clear shear thinning similar to 
the extent observed for human saliva, and was therefore selected for further 
research as it was the most suitable candidate. Xanthan gum is a naturally occurring, 
biodegradable, anionic polysaccharide containing glucose, mannose, potassium 
glucuronate, acetate and pyruvate with a molecular weight of 2 – 20 MDa [269]. It is 
known to have non-Newtonian, shear thinning rheology. This is thought to be due to 
changes in conformational status of the polymer due to shear flow. In aqueous 
solution, xanthan gum may be regarded as highly extended worm like chains 
interacting by non-covalent association, such as hydrogen bonding, to develop a 
weak gel network. In times of shear flow, disentanglement of the polymer chains 
occurs, accompanied by alignment of the chains in the direction of flow, leading to a 
lower viscosity [270, 271]. Additionally, in preliminary testing, shear thinning was 
found to be reversible with xanthan gum solutions exhibiting complete and rapid 
recovery.  
Our attention then focussed on the selection of a suitable buffer. Phosphate buffered 
saline contains higher concentrations of sodium chloride than those present in 
human saliva [168, 223] and is thus not the most suitable choice of buffer solution. 
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Bicarbonate is one of the major buffers present in saliva, and is the most prevalent 
buffer in stimulated saliva. However loss of carbon dioxide from the buffer solution 
results in changes in pH unless measures are taken to prevent this. This is due to the 
equilibria shown in equation 5.1.  
𝐶𝑂2 + 𝐻2𝑂 ↔  𝐻2𝐶𝑂3  ↔ 𝐻𝐶𝑂3
−  + 𝐻+ 
Equation 5.1: Bicarbonate buffer system equation 
In order to prevent this escape of CO2 from the system, the system can be sealed. 
However, this would mean not only that the buffer should be made in a sealed 
environment and kept in a sealed container, but dissolution vessels would also need 
to be sealed. A certain amount of CO2 could escape into any airspace in the vessel, 
therefore ideally, the vessel should be hermetically sealed with no airspace in the 
vessel, or air removed to create a vacuum. An alternative approach is to use a pH 
stat. This is a system in which CO2 is sparged into the system in order to maintain a 
pre-determined pH, and can be automated or controlled manually [272-274]. Due to 
the complexity of working with bicarbonate buffers, phosphate buffers were selected 
for further investigation instead.  
Two types of phosphate buffer were compared for their buffer capacity: USP and BP 
buffers. Interestingly, both were found to have a far greater buffer capacity than 
human saliva, with BP buffers being approximately ten times, and USP buffers being 
approximately four times the buffer capacity of human saliva. To our knowledge, this 
finding has not been reported previously. This is highly impactful, since a number of 
research groups have used phosphate buffers without dilution to represent human 
saliva [10, 11, 15, 17, 75, 79, 118-120, 122], perhaps leading to inaccurate dissolution 
profiles not representative of in vivo dissolution.  BP buffers were selected for further 
research for reasons detailed in the results section. However, these were diluted with 
deionised water such that the buffer capacity reduced to values in line with human 
salivary values.  
We have now identified that BP buffers, diluted with deionised water provide 
suitable pH and buffer capacity to represent both the unstimulated and stimulated 
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human salivary states. We had previously found that addition of 0.1 % xanthan gum 
yielded a rheological profile reasonably similar to human saliva. However, a steeper 
gradient of this profile would allow us to tailor this to both stimulation states. 
According to literature [269, 270], the viscosity of xanthan solutions depends on the 
pH and concentration of salts. Attempts were made to alter the gradient of the SSF 
viscosity profile to better match that of human saliva by altering the electrolyte 
concentration and pH using different BP and USP buffers. However these were 
unsuccessful. Thus the concentration of xanthan gum remained constant for both US 
and SS states. This was because minor adjustments in xanthan concentration resulted 
in SSF viscosity values outside of the standard deviation range of human saliva in 
either the high or very low shear rate regions.  
The surface tension of diluted BP buffers with 0.1 % xanthan was found to be 
elevated compared to human saliva. Thus Tween 20® was added, at a concentration 
of 0.01 mM. This is well below the critical micelle concentration (0.06 mM) and 
achieved the desired reduction in surface tension to values representing human 
saliva. Since the surface tension of human saliva was found to remain constant 
irrespective of stimulation state in Chapter 3, the same amount of Tween 20® was 
added to both US and SS SSFs. Tween 20® is a non-ionic surfactant composed of 
polyethylene glycol sorbitan monolaurate. It has a molecular weight of approximately 
1228 Da and takes the form of a viscous liquid [275]. Consequently, after the addition 
of Tween 20®, a minor reduction in the concentration of xanthan was made, with 
0.08 % xanthan gum found to be most suitable to represent human saliva rheology.  
Five batches of the final composition of developed US and SS SSF were made, 
containing diluted BP buffers with the addition of xanthan gum and Tween 20®. 
These were characterised for key parameters likely to affect dissolution: pH, buffer 
capacity, viscosity and surface tension. These SSFs were found to have no significant 
difference to human saliva for any parameter for US and SS respectively. This 
confirms their suitability to represent human saliva in dissolution testing, and is the 
first time whereby SSFs representing both US and SS are proposed.  
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5.6 Conclusions 
To address the lack of appropriate dissolution media for evaluation of taste masked 
formulations, two simulated salivary fluids were developed. Previous research 
demonstrated significant differences between unstimulated and stimulated human 
saliva. In this work, for the first time, SSFs representing human saliva in both the US 
and SS states are proposed. No significant difference was observed between the SSF 
and human saliva for each stimulation state. This confirms the potential of these SSFs 
to represent human saliva in dissolution testing.  
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Chapter 6: Dissolution methodology of model API in human saliva and novel 
simulated salivary fluids 
6.1 Introduction 
In previous research, we identified significant differences between US and SS human 
salivary characteristics. Due to the lack of biorelevance of currently available SSFs and 
the absence of SSFs representing both stimulation states independently, we 
developed novel simulated salivary fluids representing both unstimulated and 
stimulated human saliva. These were characterised under the same conditions as 
human saliva and were found to be suitable to represent human saliva based on 
parameters relevant to drug dissolution.  
However, it is important to assess how well dissolution of drugs and dosage forms in 
the developed, novel SSFs corresponds to the same drugs and dosage forms in 
human saliva. Only then can one truly understand the suitability of the developed 
novel media to represent human saliva in dissolution testing.  
Many dissolution tests have been carried out in simulated salivary fluids as discussed 
in Chapter 1, section 1.7.4. However, the majority of these works did not use 
biorelevant apparatus, with a suitably low media volume to represent human saliva. 
Additionally, we have already discussed the limitations of current media choices, 
highlighting the inadequacy of current dissolution methodologies. Furthermore, 
there are no clear pharmacopoeial recommendations for dissolution tests 
representing the oral cavity. 
We therefore designed and employed a simple, biorelevant dissolution methodology 
in the assessment of drug and dosage form dissolution in both human and simulated 
saliva. To our knowledge, this is a first work in which human saliva itself has been 
used as a dissolution media, since all other researchers employed simulated salivary 
fluids, as discussed in Chapter 1. It is therefore also a first work in which dissolution in 
human saliva is directly compared with simulated salivary fluids, in both the 
unstimulated and stimulated states.  
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6.2 Aims 
The aims of this Chapter are: 
 To evaluate the dissolution of a model API in human saliva in both the US and 
SS states using a biorelevant methodology 
 To evaluate dissolution of the same model API in the novel, developed SSFs 
representing the US and SS states 
 To evaluate the suitability of the novel, developed SSFs by comparison of 
dissolution performance with human saliva 
 
6.3 Methods 
Materials 
Sildenafil citrate was used as a model API due to its bitter characteristic. Sildenafil 
citrate powder and pellets were kindly manufactured and donated by Pfizer® 
(Sandwich, UK). Uncoated sildenafil citrate pellets consisted of sildenafil citrate, 
microcrystalline cellulose and polyplasdone in the ratio 60 : 30 : 10. The pellets had a 
size range of 180 – 425 μm and a sphericity value of > 90 % according to in house 
testing at Pfizer®.  
The pellets were manufactured using Glatt® controlled pelletisation system (CPS) 
technology. During this process, powdered API, microcrystalline cellulose and 
polyplasdone are loaded into the CPS chamber by spraying in at the side. Then 
rotation of the base plate rotor begins to blend the powders. Water is then sprayed 
from the central rotating spray rotor nozzle.  The droplets travel in a horizontal 
direction into the wall of powder bed created by rotation of the angled base plate (45 
degree angle) and baffles direct particles back into the central zone. Once the pellets 
are formed and the process is complete, they are subsequently removed from the 
CPS chamber and dried using either a tray drier or fluid bed drier system.  
A taste masking coating can then be added to the particles using a fluid bed coating 
process - this is a separate machine and not also a function of the Glatt® CPS system. 
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Methods 
Some methods for this Chapter are described in Chapter 2 - specifically, refer to 
section 2.8 for statistical analysis and 2.9 for analytical method development, sample 
preparation development and final analytical methodology for sildenafil citrate.  
With the exception of Figure 6.7 and 6.8 whereby N = 3, all dissolution tests were 
performed such that N = 5 (five separate dissolution tests) with results analysed by 
HPLC in triplicate. Human saliva was obtained from a single volunteer (the 
investigator) according to the methods detailed in Chapter 2, section 2.4.1. 
Composition of novel SSFs is detailed in Chapter 5, section 5.3.1.7, Table 5.4.  
Dissolution methodology used is detailed below. 
Development of dissolution methodology 
In the literature, as discussed in Chapter 1, section 1.7.4, various apparatus have 
been employed to represent the oral cavity; however none were found to accurately 
represent the volume of saliva available in the oral cavity. Examples included use of 
900 mL of water in a paddle dissolution apparatus [51], a beaker of 50 mL of 
electrolyte solution as an SSF [23], a beaker of 20 mL phosphate buffer [22], and 
beakers with 5 mL phosphate buffer [31, 58]. Some perhaps more biorelevant 
attempts included placing a dosage form into a 10 mL syringe with 10 mL of water 
and either inverting or revolving the syringe by hand for 30 seconds before analysis 
of the concentration of API [34, 35, 132]. All of these methods used far greater 
volumes than the volume of saliva present in the oral cavity and were not 
appropriate.  
An early-stage, simple biorelevant dissolution methodology was developed. A mid-
range dose of the API (sildenafil citrate, SC) was selected for dissolution studies, 
which was 50 mg [204]. In one study, the volume of saliva in the oral cavity available 
for dissolution was found to be a mean of 1.19 mL and 0.96 mL for males and females 
respectively before swallowing, reducing to a mean value of 0.82 and 0.60 mL after 
swallowing for males and females respectively [93]. In another study, saliva volume 
was determined in 128 healthy young adults of mixed genders and was found to have 
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a mean value and standard deviation of 0.46 +/- 0.31 mL [91]. Therefore a value of 1 
mL of saliva as a dissolution medium was deemed appropriate. When 50 mg SC was 
placed into 1 mL of human saliva in a glass vial, this resulted in a wet mass of API with 
no distinct liquid phase from which to take samples at different time points. This 
simple approach was thus not suitable. 
It was therefore decided to perform multiple small scale dissolution tests inside 1.5 
mL Waters® glass HPLC vials placed in a water bath, held by a plastic rack within the 
water bath, on a magnetic stirrer at 37 °C, using a biorelevant volume of media i.e. 50 
mg API in 1 mL media, which equates to 10 mg API in 200 μL media. The stirring 
speed was set such that adequate mixing of the contents of the vial was observed 
visually, without the formation of mounding of particles or vortexes of the liquid 
phase. Due to the inability to sample from the liquid phase when this ratio of 
API/media is used as discussed above, dissolution was carried out in several 
individual vials, with each vial allowing dissolution to proceed for a set time. At the 
set time point, the entire contents of the dissolution vial was transferred to a filtered 
centrifuge tube and centrifuged for 1 minute at 13,000 rpm. This separated the 
undissolved API, which was retained in the filter from the dissolved API in the filtrate. 
The filtrate was then treated and analysed by HPLC to determine the API 
concentration at each time point, as described in Chapter 2, section 2.9.  
A limitation of our chosen methodology is that it does not represent the flow of saliva 
and the removal of particles by swallowing. Two research groups [37, 134] employed 
a mini column apparatus whereby the sample was placed into a column with 
phosphate buffer passed through the column and dissolution assessed over time. 
However, this method does not accurately represent swallowing where the majority 
of particles and a large proportion of the volume of saliva would be removed from 
the oral cavity in the first few seconds by swallowing. Another option is to use a USP 
4 apparatus, which is a flow through cell with similar principle to the mini column 
apparatus. This was available to us; however the minimum flow rate achievable was 2 
mL/min which is higher than the stimulated flow rate as seen in Chapter 3. This 
system, as well as the mini column systems, requires the cell to be wetted with 
dissolution media, and the system to be primed before use by passing media through 
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the cell. With a highly soluble drug, this priming sequence may allow substantial 
dissolution and the test results could be invalid. If these “flow-through” methods are 
used in future, this disadvantage must be taken into account in the experimental 
design.  
Additionally, a limitation of the analytical methodology employed in the analysis of 
human saliva dissolution samples was observed. The guard column required regular 
changing, after just a few months of use. Despite employing protein precipitation and 
liquid-liquid extraction in the sample treatment, over time the peaks became broader 
and/or split. This was resolved by changing the guard column indicating an 
accumulation of contaminants over time. Further investigation into the sample 
treatment is required to overcome this.   
Evaluation of the effect of varying pH and buffer capacity on dissolution 
The pH was varied within the range of human saliva by 0.4 pH units above and below 
the usual value for each type of SSF by the addition of citric acid or sodium hydroxide 
to the SSF. The value of 0.4 units was chosen since this represents the difference in 
mean pH between human US and SS.  
The buffer capacity was varied by doubling or halving the amount of the BP 
“concentrated” buffers used in the manufacture of each SSF (Table 5.4). This yielded 
“high, medium and low” buffer capacity SSFs likely to be within the maximum range 
of buffer capacity values observed in human saliva.  
6.4 Results 
Initially, the dissolution of sildenafil citrate powder, a model bitter API, was assessed 
in human saliva. The rationale for selection of sildenafil citrate as a model API is 
discussed later. The dissolution of sildenafil citrate (SC) powder was evaluated in 
unstimulated and stimulated human saliva. A significant difference in SC dissolution 
in unstimulated saliva compared to stimulated saliva was observed at every time 
point as seen in Figure 6.1 (unpaired t-test, p < 0.01).  
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Figure 6.1: Dissolution of sildenafil citrate (SC) powder in human saliva. Data 
represents mean +/- S.D. N = 5, triplicate. (US = unstimulated saliva, SS = stimulated 
saliva). Significant difference between US and SS at every time point, unpaired t-test, 
B: p < 0.01, C: p < 0.001, D: p < 0.0001.  
 
The powdered API has to be manufactured into a dosage form before administration. 
In our case, the dosage form we are evaluating is pellets of sildenafil citrate. The 
dissolution of sildenafil citrate (SC) pellets was evaluated in unstimulated and 
stimulated human saliva. A significant difference in SC dissolution in unstimulated 
saliva compared to stimulated saliva was observed at every time point as seen in 
Figure 6.2 (unpaired t-test, p < 0.01).  
 
 
 
 
 
 
0 1 0 2 0 3 0
0
5
1 0
1 5
2 0
T im e  (m in u te s )
S
C
 C
o
n
c
e
n
tr
a
ti
o
n
 (
m
g
/m
L
)
S C  p o w d e r d is s o lu t io n  in  U S S C  p o w d e r d is s o lu tio n  in  S S
D D
D
C
B
B
   
151 
 
Figure 6.2: Dissolution of sildenafil citrate (SC) pellets in human saliva. Data 
represents mean +/- S.D. N = 5, triplicate. (US = unstimulated saliva, SS = stimulated 
saliva). Significant difference between US and SS at every time point, unpaired t-test, 
B: p < 0.01, C: p < 0.001, D: p < 0.0001.  
 
The above two Figures were overlaid to allow the reader to observe the similarity 
between the dissolution profiles of SC powder and pellets (Figure 6.3). No significant 
difference was observed between powder and pellets within each stimulation state 
(ANOVA and Holm-Sidak’s multiple comparisons test). Further work therefore 
continued with the pellets as a formulation.  
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Figure 6.3: Dissolution of sildenafil citrate (SC) powder compared to pellets in human 
saliva. Data represents mean +/- S.D. N = 5, triplicate. (US = unstimulated saliva, SS = 
stimulated saliva).  
 
The dissolution of SC pellets was then investigated in the developed, novel SSFs from 
Chapter 5 representing both the unstimulated and stimulated states as shown in 
Figure 6.4. No significant difference was observed in dissolution of pellets in 
unstimulated SSF compared to stimulated SSF (unpaired t-test).  
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Figure 6.4: Dissolution of sildenafil citrate (SC) pellets in simulated salivary fluids. 
Data represents mean +/- S.D. N = 5, triplicate. (US = unstimulated saliva, SS = 
stimulated saliva, SSF = simulated salivary fluid).  
 
Figure 6.4 was then combined with Figure 6.2 to allow the reader to observe the 
similarity between the dissolution profiles of SC pellets in human saliva and SC pellets 
in the developed, novel SSFs (Figure 6.5). ANOVA and Holm-Sidak’s multiple 
comparisons test was carried out which showed no significant difference between 
human US and SSF US, confirming the suitability of the developed novel SSF US to 
represent human US in dissolution testing, at least for sildenafil. However, a 
significant difference was observed at every time point between human SS and SSF 
SS (p < 0.001), indicating the developed novel SSF SS is not suitable to represent 
human SS, at least for sildenafil. No significant difference was observed between SSF 
SS and either SSF US or human US, thus the developed, novel SSF SS is more similar to 
human US.  
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Figure 6.5: Dissolution of sildenafil citrate (SC) pellets in human saliva and simulated 
salivary fluids. Data represents mean +/- S.D. N = 5, triplicate. (US = unstimulated 
saliva, SS = stimulated saliva, HS = Human Saliva, SSF = simulated salivary fluid). SS 
human saliva significantly different to all other dissolution profiles at every time point 
(ANOVA and Holm-Sidak’s multiple comparisons test, p < 0.001).  
 
Since the developed, novel SSF stimulated saliva (SSF SS) was found not to be suitable 
to represent human SS, we investigated which parameters were most influential on 
dissolution of SC pellets in SSF SS. Firstly, the effect of viscosity on dissolution was 
evaluated by performing dissolution tests in SSF SS with and without the addition of 
xanthan gum, as seen in Figure 6.6. No significant difference was observed between 
dissolution in SSF SS with vs. without xanthan gum, at four of the six time points. Only 
the samples taken at 1 minute and 10 minutes were found to be significantly 
different (unpaired t-test, p < 0.05).  
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Figure 6.6: Dissolution of sildenafil citrate (SC) pellets in SSF SS with and without 
xanthan. Data represents mean +/- S.D. N = 5, triplicate. (SS = stimulated saliva, SSF = 
simulated salivary fluid). * significant difference observed between profiles at time 
points 1 and 10 minutes only (unpaired t-test, p < 0.05).  
 
The effect of pH on dissolution of SC pellets was investigated. pH was varied within 
the range of human saliva and the effect of changing pH was evaluated in both US 
and SS SSFs. In Chapter 3, human US was found to have a mean pH of 7.0, and human 
SS of 7.4 to one decimal place. The developed SSFs were thus designed to have a pH 
of 7.0 and 7.4 for US and SS SSF respectively, whereby the difference between the 
two is 0.4 pH units. For each SSF, the pH was raised and lowered by 0.4 pH units 
compared to the usual value by the addition of citric acid or sodium hydroxide. The 
effect of this change in pH on the dissolution of SC pellets was determined. Although 
some significant differences were observed as shown in Figure 6.7 (ANOVA and 
Holm-Sidak’s multiple comparisons test, p < 0.05), no clear trend was apparent and 
the effect of pH within this narrow range on dissolution remains unclear.  
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Figure 6.7: Dissolution of sildenafil citrate (SC) pellets in simulated salivary fluids of 
varying pH. Box represents median value, 25th and 75th percentile. Whiskers 
represent maximum and minimum values. Data represents samples taken after 30 
minutes of dissolution. N = 3, triplicate. (US = unstimulated saliva, SS = stimulated 
saliva). * significant difference (ANOVA and Holm-Sidak’s multiple comparisons test, 
p < 0.05), ** significant difference (ANOVA and Holm-Sidak’s multiple comparisons 
test, p < 0.01), *** significant difference (ANOVA and Holm-Sidak’s multiple 
comparisons test, p < 0.001).  
 
The effect of buffer capacity on dissolution of SC pellets was also investigated. SSFs 
are made using British pharmacopoeial phosphate buffers of pH 7.0 and 7.4, diluted 
with deionised water to reduce the buffer capacity. The amount of “concentrated” 
BP buffer used was doubled (high buffer capacity), and halved (low buffer capacity) 
as well as being tested at the usual value (medium buffer capacity) in each type of 
SSF. Buffer capacity was thus varied and the effect was evaluated in both US and SS 
SSFs. No significant difference was observed between high and medium buffer 
capacity, however, low buffer capacity SSF had significantly higher dissolution than 
high or medium, in both SSFs as seen in Figure 6.8 (ANOVA and Holm-Sidak’s multiple 
comparisons test, p < 0.001).  
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Figure 6.8: Dissolution of sildenafil citrate (SC) pellets in simulated salivary fluids of 
varying buffer capacity. Box represents median value, 25th and 75th percentile. 
Whiskers represent maximum and minimum values. Data represents samples taken 
after 30 minutes of dissolution. N = 3, triplicate. (US = unstimulated saliva, SS = 
stimulated saliva). *** significant difference (ANOVA and Holm-Sidak’s multiple 
comparisons test, p < 0.001), **** significant difference (ANOVA and Holm-Sidak’s 
multiple comparisons test, p < 0.0001).  
 
6.5 Discussion 
In this research, for the first time, the dissolution of a drug and dosage form was 
evaluated in both US and SS human saliva and in novel simulated salivary fluids 
representing US and SS human saliva. This was in order to understand how 
demonstrative the novel SSFs are in terms of dissolution performance compared to 
the biological fluids they represent.  
Sildenafil citrate is a typically bitter substance and was selected as a model API for 
this reason. Taste masking of sildenafil citrate formulations has been reported in 
literature [51, 276, 277] and therefore dissolution testing representing the oral cavity 
can be employed to evaluate taste masking efficiency in vitro. In our case, we aimed 
to use reverse enteric coatings applied directly to sildenafil pellets to achieve taste 
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masking. These are designed not to release the API at oral pH but to allow complete 
release of the API at gastric pH. Dissolution testing representing the oral cavity is 
therefore required to ensure that release of the sildenafil citrate is minimal and 
below the bitterness threshold of the API in the oral cavity.  
The bitterness threshold of sildenafil citrate is not documented in published 
literature currently. However, unpublished research [278] from the PhD of Jessica 
Soto at University College London investigated sildenafil citrate taste using both 
human taste testing panels and the brief access taste aversion (BATA) model [71] in 
rats. It was observed that the bitterness threshold was 1.99 mM in rats and 1.58 mM 
in humans. Release of sildenafil citrate in the oral cavity from taste masked 
microparticulates should thus be less than 1.58 mM (2.37 μg/L) for taste masking to 
be achieved. Additionally in Soto’s research [279],  sildenafil citrate bitterness was 
compared in both humans and rats to that of quinine and was found to be only 
slightly less bitter than the characteristically bitter quinine which has a bitterness 
threshold of between 0.873 – 1.052 mM [280-282]. When non-taste masked pellets 
of sildenafil citrate were evaluated for their dissolution in human saliva, the 
concentration of sildenafil was much greater than the bitterness threshold from 
Soto’s work in both unstimulated and stimulated conditions. This confirms that taste 
masking is required for compliance.  
Although sildenafil citrate is most commonly used for treatment of erectile 
dysfunction, it is also indicated in pulmonary hypertension [204]. For this application, 
it can be prescribed to the paediatric and geriatric population. These populations 
often cannot tolerate oral tablets and require alternative formulations, which are 
generally taste masked to increase compliance. We aimed to evaluate dissolution of 
taste masked and non-taste masked microparticulates (pellets) of this API, however 
the taste masked dissolution tests find their place in the future work section.   
Once the dissolution methodology had been determined, dissolution testing 
commenced with evaluation of powdered SC and a microparticulate (pellet) 
formulation of SC in human saliva. Pellets can be uncoated or taste-masked reverse 
enteric coated pellets. These can then be incorporated into an ODT, sprinkle 
   
159 
 
formulation or suspension. It is most likely that an ODT would be the final 
formulation. However, we evaluated the dissolution of the pellets alone. 
Unfortunately, dissolution of coated pellets was not possible and is a consideration 
for future work.  No significant difference between the powdered API and pellet 
formulation was found in either human US or SS, indicating the pellets formulation 
could be used for future dissolution testing. Drug loading of the pellets was taken 
into account.  
Significant differences were observed in the dissolution of both powder and pellets 
between unstimulated and stimulated human saliva. This finding is as expected since 
significant differences in many characteristics relevant to dissolution – pH, buffer 
capacity, viscosity and flow rate were observed in Chapter 3. This confirms that these 
characteristics are highly likely to be influential on dissolution and that there is 
indeed a requirement to develop novel SSFs representing both types of human saliva.  
The dissolution of SC pellets was then evaluated in the novel SSFs. Unfortunately 
dissolution was not found to be significantly different between the two novel SSFs, 
and when compared to human saliva, both SSFs were similar to human US with no 
significant difference between either novel SSF and US, but both being significantly 
different to SS. Thus the novel US SSF was found to be suitable to represent human 
US, but the novel SS SSF was not found to be suitable to represent human SS in 
dissolution testing.  
It is worthy to note that a limitation of this work is that human data was obtained 
from the saliva of a single individual. The single individual demonstrated salivary 
parameters close to the mean for each parameter in Chapter 3 and was not an outlier 
or extreme result in the earlier trial. The mean values for this individual are stated in 
each corresponding Figure legend to allow for comparison to whole sample results. In 
most cases, with the exception of US buffer capacity (whereby the value is within 2 
standard deviations of the mean), the mean values of the individual’s saliva used in 
this Chapter are within one standard deviation of the mean for all parameters. 
Nevertheless, dissolution testing in human saliva should be repeated to ensure the 
same results are observed in multiple people’s pooled saliva. Five separate 
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dissolution tests were carried out for each dissolution profile thus N = 5, and results 
were analysed by HPLC in triplicate. An additional limitation of this work is that only a 
single API was evaluated due to time restrictions. In order to make robust conclusions 
about the suitability of developed SSFs to represent human saliva, this work should 
be repeated with multiple APIs.  
In Chapter 3, four factors were found to be significantly different between human US 
and SS – pH, buffer capacity, viscosity and flow rate. Flow rate was not a factor for 
the dissolution methodology we employed. However, the novel SSFs were of 
different pH and buffer capacity. They also had a viscosity modifier, xanthan gum. 
The effect of pH, buffer capacity and viscosity was therefore assessed in order to 
understand which factor is most influential on dissolution, and how to develop the 
novel SS SSF such that it is more representative of human saliva.  
The effect of viscosity was assessed by performing dissolution tests in the standard 
novel SS SSF, and in SS SSF without the addition of xanthan gum. Dissolution of the 
pellets was only found to be significantly different at 2 of the 6 time points and the 
presence or absence of xanthan gum did not have a significant effect on dissolution 
across the whole profile. Thus viscosity was not thought to be a highly influential 
parameter on dissolution in this case.  
When the pH was varied by +/- 0.4 units from the usual value for each SSF, although 
some significant differences were observed in dissolution of pellets at different pH 
values, no clear trend was observed indicating how the SSFs could be modified to 
improve dissolution. Therefore small changes in pH were not considered to be a 
major contributor to dissolution performance. 
The effect of varying the buffer capacity of SSFs was also evaluated for its influence 
on dissolution. Buffer capacity was found to have a clear effect on the dissolution of 
pellets, with similar results being observed for US and SS SSF. As the buffer capacity 
decreased, dissolution increased significantly. This was contrary to expectations as it 
was thought that the higher the buffer capacity, the more of the basic sildenafil could 
dissolve without changing the pH and hindering further dissolution, as described in 
Chapter 3, section 3.1.  This interesting result may be caused by the combination of 
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using a phosphate – citrate buffer and dissolving a citrate salt of the API, meaning 
that the lower the buffer capacity, the less citrate is present and the less dissolution 
is hindered by the presence of a common ion. This theory should be evaluated in 
future work for example by using a different salt of the API or a different type of 
buffer. This is discussed in more detail in Chapter 7.  
6.6 Conclusions 
Dissolution testing of sildenafil citrate was carried out for the first time in both US 
and SS human saliva. Dissolution was found to be significantly different between US 
and SS human saliva as predicted by differences in key characteristics for dissolution 
in Chapter 3. To investigate the suitability of novel SSFs to represent human saliva, 
dissolution testing was also carried out in SSFs representing US and SS. The novel SSF 
representing US was found to be a good match to human US with no significant 
differences between these two, at least for sildenafil citrate. However, the novel SSF 
representing SS was not found to be suitable as it was significantly different to 
human SS. The most influential parameter on dissolution testing in this case appears 
to be buffer capacity. The presence of a citrate salt of the API and citric acid in buffer 
may have hindered dissolution. Further work is required to address these issues and 
develop a more biorelevant SSF SS.   
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Chapter 7: Conclusions and Future work  
7.1 Conclusions and Implications 
A number of findings presented in this PhD thesis are of great significance and have 
been reported here for the first time. In Chapter 1 [1], we highlighted the 
requirement for a biorelevant oral dissolution model, using a biorelevant media 
choice and volume to represent human saliva that can be coupled to gastrointestinal 
models for assessment of taste masked or alternative dosage forms. No such model is 
currently in existence.  
In Chapter 3 [202], we demonstrated the inadequacy of current literature 
surrounding the properties of human saliva. For the first time, human saliva was 
characterised for pH, buffer capacity, surface tension, viscosity and flow rate in both 
the unstimulated and stimulated states with a sufficient number of participants to 
generate statistically meaningful results. 
In addition, we characterised an example from the three main types of SSF and 
compared these under the same conditions to human saliva. This comparison had not 
previously been carried out based on all four parameters for each SSF. None of the 
SSFs were found to be suitable to represent human saliva. This implies that a novel 
SSF should be developed and existing ones should not be considered as biorelevant 
SSFs.  
Our research showed significant differences in pH, buffer capacity, viscosity and flow 
rate between the unstimulated and stimulated salivary states, based on the same 
sample of participants. This has not been reported elsewhere. The implications of this 
finding are that dissolution media representing human saliva (SSFs) should represent 
both the unstimulated and stimulated salivary states. However, no SSFs are currently 
in existence representing both stimulation states.  
The characterisation of human saliva for parameters key to dissolution [202] also 
provides a platform of reference for other research groups working with human 
saliva as a dissolution medium, or developing or selecting an SSF for use in dissolution 
testing.  
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In Chapter 4, we stimulated human saliva with Parafilm® and with an orally 
disintegrating tablet and assessed the conversion between stimulation states with 
respect to time. Although this had been performed before with unflavoured chewing 
gums and citric acid solutions as discussed in Chapter 4, it was a first work in which 
an ODT itself had been used to stimulate saliva.  
With both methods of stimulation, human saliva did not remain in the stimulated 
state (significantly different to US) for the whole test period for all parameters. The 
implications of this finding reinforce the requirement to perform dissolution tests for 
dosage forms in the oral cavity in media representing both US and SS human saliva.  
As mentioned previously, no SSFs are in existence representing both stimulation 
states. Therefore in Chapter 5, for the first time, SSFs representing both unstimulated 
and stimulated human saliva were developed. These were characterised under the 
same conditions as human saliva for key parameters relevant to dissolution and 
found not to show any significant differences between the novel SSF and human 
saliva for each parameter, in each stimulation state. This implies their suitability to 
represent human saliva in dissolution testing based on key parameters.  
In Chapter 6, dissolution testing was carried out in US and SS human saliva and 
significant differences were seen in dissolution between the two stimulation states. 
This further reinforces that dissolution testing should be carried out in SSFs 
representing both stimulation states. To the best of our knowledge, no dissolution 
tests have been performed in human saliva, particularly in both the stimulation 
states.  
Dissolution testing of the same formulation was also carried out in the developed, 
novel SSFs. The novel SSF US was found to be suitable to represent human saliva with 
no significant difference in dissolution between the SSF US and human US. However, 
significant differences were observed between SSF SS and human SS, thus SSF SS was 
not found to be suitable. The implications of this are that whilst further dissolution 
testing can now be carried out in SSF US, further work is necessary to improve the 
biorelevance of SSF SS before it can be proposed as suitable to represent human SS.  
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An additional interesting finding involved the discovery that BP and USP phosphate 
buffers have approximately 10 and 4 times the buffer capacity of human saliva as 
described in Chapter 5. This implies that other research groups should think carefully 
before simply choosing a compendial phosphate buffer to represent human saliva, 
and should consider a more biorelevant alternative. Many research groups have used 
compendial buffers and may have overestimated drug dissolution compared to that 
in human saliva.  
Finally, we also found that saliva as a matrix for dissolution required meticulous 
sample treatment prior to HPLC analysis with both protein precipitation and liquid-
liquid extraction. However this was not sufficient and the guard column became 
contaminated after a few months of use. This has not been reported before by other 
research groups using similar extraction methods for saliva. This implies that human 
saliva is a particularly complex matrix and additional steps may be required in the 
sample treatment process. It is surprising that saliva appears to be a more 
challenging matrix than plasma, which should be taken into consideration when 
future analytical methods are being developed for determination of drugs in saliva by 
our and other research groups.  
When considering the original aims of the PhD (Chapter 1), we can conclude that our 
first aim – the selection or development of biorelevant simulated salivary fluid(s) for 
use as dissolution media - has largely been met. We have developed biorelevant 
media representing the two stimulation states of human saliva and found them to 
compare well with human saliva based on key characteristics relevant to dissolution. 
However, dissolution experiments whereby these artificial media were directly 
compared to human saliva has revealed opportunities for future development.  
Our second aim - the development of a biorelevant dissolution methodology 
representing the oral cavity for the in vitro assessment of taste masking efficiency - 
has also partially been met. We have a very early stage model encompassing (aside 
from media parameters) biorelevant volume, temperature and residence time. 
However, further developmental work may be required to improve the model.  
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7.2 Future Work 
7.2.1 Short term 
In Chapter 6, the dissolution of sildenafil citrate powder and pellets was assessed in 
human saliva. Although each dissolution test was performed five times, this was from 
the saliva of a single individual. Therefore all dissolution testing in human saliva 
should be performed in the saliva of several other people, or in pooled saliva from a 
number of volunteers to ensure that the same trend is observed.  
The novel SSF SS was found not to be representative of human saliva, at least for 
sildenafil citrate. Repeating the human saliva experiments in pooled saliva from 
multiple volunteers may affect this. However, evaluation of the effect of pH and 
buffer capacity of the SSF on dissolution was repeated only three times and should be 
repeated at least two more times such that N = 5 for more meaningful statistical 
comparisons. This will help to confirm what steps to take next.  
If the same trend in results is still observed when N = 5 as above, future work should 
focus on improving the biorelevance of the SSF SS. In Chapter 6, a lower buffer 
capacity was found to result in greater SC dissolution, possibly due to the presence of 
less common ion (citrate).  To confirm if this theory is true, the same experiment 
could be performed using a different salt of the API, sildenafil. In addition, the 
phosphate – citrate buffer could be changed to a simple phosphate buffer without 
the citrate component. Alternatively, a different API could be evaluated instead.  
Unfortunately, it was only possible to perform dissolution testing using a non-taste 
masked pellet formulation in this research. It is highly important to evaluate the taste 
masked, reverse enteric coated formulation in addition, since the dissolution 
methodology was developed to support in vitro determination of taste masking 
efficiency by quantifying drug release from taste masked formulations in simulated 
salivary fluids. Where a taste masked formulation is evaluated, drug release is 
anticipated to be minimal in the oral cavity and the limit of detection may need to be 
reviewed. Analysis of very low concentrations may require the use of mass 
spectroscopy since this is a more sensitive technique than HPLC-UV.  
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The bitterness threshold of each API should be determined experimentally in vivo, if 
unknown. This result should be related back to the amount of drug released from the 
taste masked microparticulates. This will ascertain how in vitro release compares to 
the bitterness threshold, in order to understand the taste of the formulation and 
efficiency of taste masking. In vivo testing could be carried out using the BATA model 
[279] in rodents or using human taste testing panels [69].  
7.2.2 Medium term 
In order to ensure the dissolution methodology is robust and consistent, multiple 
APIs should be investigated, and all dissolution tests performed with sildenafil citrate 
in both human saliva and simulated salivary fluids should be repeated with additional 
APIs to validate the methodology.  
In addition, full validation of the HPLC methodology should be performed for each 
API in each media according to FDA guidance [198].  We also described in Chapter 6 a 
limitation of the HPLC methodology being that the guard column requires 
replacement after a few months of use as peaks become broader and show 
shoulders. This indicates a need for further development of the sample treatment 
procedure to improve the purity of the samples, which should also be investigated.  
In Chapter 3, we characterised SSFs from the three main classes and concluded that 
they were unsuitable to represent human saliva based on key parameters likely to 
affect dissolution. For completeness, dissolution testing of at least one API should be 
carried out in these and compared to human saliva and the novel SSFs to confirm 
that they do indeed demonstrate differences in dissolution and are unsuitable to 
represent human saliva, and that novel biorelevant SSFs are more suitable.  
In Chapter 6, the limitations of using a flow through cell (USP 4) or mini column 
apparatus were described, such as the need to prime the system and wet the 
contents of the cell before analysis. The methodology for using these systems could 
be investigated in more detail to understand how much effect this priming has on 
overall drug dissolution and whether this can be circumvented or accounted for in 
some way.  
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7.2.3 Long term 
A limitation of the human clinical trial in which characteristics of human saliva were 
evaluated (Chapter 3) is the relatively narrow age range of the population (aged 20 – 
35). The most likely recipients of taste masked, multiparticulate formulations are 
those with swallowing difficulties and a requirement for tailored dosage forms to 
meet individual needs such as the paediatric and geriatric population. All work in this 
thesis is based on the salivary characteristics of a healthy, young adult population and 
such salivary characteristics may change greatly in paediatrics or geriatrics. The trial 
should therefore be repeated in people of the target age range.  
One of the key issues highlighted in Chapter 1 is that there are currently no models in 
existence that combine an oral cavity (to assess taste masking efficiency) with a full 
sequential gastrointestinal model (to ensure that the taste masking technique does 
not affect the pharmacokinetic profile or bioavailability). Therefore, once the oral 
cavity dissolution methodology is established and validated, with biorelevant media 
representative of both human saliva stimulation states, the oral dissolution model 
should be coupled to a gastrointestinal model. A number of options were discussed 
in more detail in Chapter 1, section 1.8 for combining methodologies, such as using a 
flow through cell and passing different media through the cell, or transferring the 
contents of an individual dissolution vessel representing oral dissolution into an 
artificial stomach duodenum (ASD) model or TNO intestinal model (TIM) gradually to 
simulate swallowing. Ideally this process should be automated for convenience. Any 
model that is developed demonstrating a full sequential dissolution process 
simulating the multiple compartments of the gastrointestinal tract should be fully 
validated using in vitro–in vivo correlation to confirm its predictability, using multiple 
APIs.  
Once a fully validated model is developed, this could be used to evaluate the effect of 
different reverse enteric coating materials, thicknesses and porosities. The effect of 
particle sphericity on dissolution of taste masked microparticulates could also be 
assessed.  
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7.3 Final Remarks 
The key aspects of this research are the comprehensive characterisation of human 
saliva, leading to the discovery that human saliva exists in two distinct and 
significantly different stimulation states. Additionally, the discovery of the 
unsuitability of existing SSFs to represent human saliva for dissolution testing based 
on key characteristics relevant to dissolution, and the lack of SSFs representing the 
two stimulation states.  Finally, the first steps in the development and evaluation of 
novel SSFs representing unstimulated and stimulated human saliva. 
This research provides a platform of information regarding the properties of human 
saliva, and the commencement of research working towards development of a more 
biorelevant dissolution media representing human saliva. This research may be 
continued to develop SSFs fully representative of human saliva in both stimulation 
states for dissolution testing. Should such media have proven in vitro–in vivo 
correlation (IVIVC) in dissolution performance, this may vastly reduce the use of 
expensive and ethically challenging in vivo taste evaluation using BATA models or 
subjective human taste testing panels.  
In addition, the use of SSFs representing US and SS with proven IVIVC could reduce 
variability in media used to evaluate taste masked or alternative formulations. Such a 
reduction in variability of methodology would allow for comparison between 
different formulations or APIs in the same media. Dissolution testing in these media 
could provide a robust, analytical approach to taste evaluation via quantitative 
analysis of the concentration of API in simulated salivary fluids and may become an 
industry standard dissolution methodology or pharmacopoeial recommendation in 
future.  
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